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Chapter 1 
Introduction 
Introduction 
Diagnostic and therapeutic choice in neurology can fortunately be made without formal 
decision support in the majority of cases. in many patients a diagnosis and treatment choice 
are relatively easy to establish. This study however, concerns the application of a decision 
support methodology - clinical decision analysis - to several problems in the clinical neu-
rosdences where diagnosis, prognosis and therapeutic choice are not obvious. 
Sometimes decision making in clinical medicine can be extremely difficult There may be 
large interests atstake,and theamount of information that has to beprocessed can be enormous. 
Data from the patient's history, physical examination, diagnostic procedures, clinical knowl-
edge and the scientific information have to be combined in order to arrive at a prognosis and 
to develop a diagnostic and therapeutic strategy. Add to this that most diagnostic tests are not 
completely accurate, that therapy is not always and entirely effective, that diagnostic and 
therapeutic procedures may be risky, unpleasant, expensive and time-<:onsuming, and that 
prognosis is most of the times uncertain. 
The decision process itself is limited by time and by budgetary constraints. The clinician 
has to recognize situations where the patient's preferences are important, and he has to know 
when the clinical situation needs a doctor - patient relationship characterized by activity -
passivity, guidance - cooperation or mutual participation. 39'.2 Moreover, physicians and their 
patients (as any human being) find it difficult to handle uncertainty.'" Oinicians often discuss 
the pro' s and con' sof altemativemanagementstrategies with their senior and junior colleagues, 
but a language that effectively and explicitly addresses uncertainty and preferences for health 
outcomes is not part of the physician's standard equipment. Several other factors influence the 
decision process as welL It has been demonstrated that patient characteristics, (such as social 
class), physician's personal characteristics (such as age, type of specialty), and the physician's 
interaction with his profession (for example whether he is in a solo- of group-practice) all may 
be of influence.67,68,l06,392 
Is there a need for clinical decision analysis, or more in general, for formal decision support 
in neurology? This question is best answered by introducing a clinical situation from one of 
our own studies (Chapter 4): 
A 69-year-old man presents with a history of transient weakness of the left 
arm and face. Carotid angiography' revealeda50% stenosis of the right internal 
carotid artery: and surprisingly, a 5 mm saccular aneurysm' of the right 
posterior communicating artery.d What should be done now? 
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The transient ischaemic attacks (ITA)' are probably related to the carotid stenosis, but it is 
possible that the aneurysm is the source of thrombo-embolism' causing the TIA. Carotid 
endarterectomy" bas a risk of surgical complications, and its effectiveness in preventing strokeh 
has not been proven for patients with moderate carotid stenosis.284,110 The aneurysm poses a 
problem in itself. It may rupture, causing subarachnoid haemorrhage (SAH),' with grave 
consequences.2CB,169 On the other hand, an intracranial operation to 'clip' the aneurysm may 
lead to immediate morbidity and even mortality. Should this patient receive acetyl-salicylic 
add (ASA)?; This drug decreases the risk of stroke and of myocardial infarction, but increases 
the risk of complications from SAH. 
The clinical problem is quite complex and there are several therapeutic options with 
uncertain consequences. It illustrates that there isa need for refined treatment and management 
advice, based on all the available information, taking into account the attitude of the patient 
towards the possible consequences of treatment. Inevitably, clinidans will be increasingly 
confronted by choice situations that are characterized by complexity and uncertainty. Theneed 
for support will grow, because of the expansion of medical knowledge, the increase in diag-
nostic and therapeutic possibilities, the increasing quality demands by the public, and the 
increasing pressure towards cost-<=ontainment. 
Decision analysis can be used to produce a treatment advice for the management of indi-
vidual patients, but also to derive more general guide-lines for similar patients, based on a 
rational and explidt assessment of risks and benefits of different management strategies. The 
methodology consists of an intriguing mixture of mathematics and decision theory. Decision 
analysis is rational in the sense that it attempts to describe a course of action that is consistent 
with the decision maker's goals and expectations and maximizes the decision maker's expected 
satisfaction.'" Several applied sciences such as biostatistics and clinical epidemiology come 
together here, applied to real clinical problems. Decision analysis is a normative theory, used 
for prescriptive purposes, with foundations in probability theory and the theory of subjective 
expected utility.315 It should be stressed that clinical decision analysis should not be seen as the 
panacea to the ailments of human decision making, but merely as a tool, that can be used when 
decisions are difficult'''' 
1.1 The present study 
This study describes the results of research in the application of decision analysis in the 
clinical neurosciences. The aim of each of our studies is the synthesis of general clinical 
knowledge and preferences for health outcomes to derive guide-lines for the clinical man-
agement of individual patients, using a normative model of rational choice, using the subjective 
expected utility model. In Chapter 2 the methodology of clinical decision analysis is described 
12 
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and discussed, followed by a brief survey of related methods for formal decision support. The 
introduction and first section of Chapter2 are written in such a way that a basic understanding 
of the methodology is attained, and that the succeeding sections can be skipped when desired. 
In Chapter 3 published applications of decision analysis in the clinical neurosciences will 
be reviewed. The following three chapters concern the management of intracranial aneurysms. 
Chapter 4 concerns patients like the one descn"bed in the first paragraph of this chapter, a man 
with transient ischaemic attacks, carotid stenosis and an intracranial aneurysm. Chapter 5 
concerns patients with a familial intracranial aneurysm, detected after screening of a large 
family in which several subarachnoid haemorrhages had occurred. Chapter 6 discusses 
whether asymptomatic members of such a family should be advised to undergo angiography. 
Chapter 7 considers the neurosurgical management of patients with unruptured 
arteriovenous malfonnationsk and hereditary haemorrhagic telangiectasia} with a generalizw 
ation to patients with nonwsyndromal arteriovenous malformations. 
In Chapter 8 the diagnostic management of patients with dementia is analysed, with 
emphasis on the diagnosis and treatment of normal pressure hydrocephalus. m 
Chapter 10 contains a decision analysis of the management of patients with subarachnoid 
haemorrhage that compares the options of early and delayed surgery, and the use of antifi-
brinolytics." Mostof thedata for the decision analysis are based on a re-analysis of a randomized 
clinical trial of antifibrinolytics against placebo, which is described in Chapter 9. 
A general discussion of this work is presented in Chapter 11. It is followed by a summary 
in English and in Dutch. Statistical terms and techniques are explained in the text Some 
explanatory notes and, for the convenience of the reader without a medical background, 
explanations of medical terms can be found at the end of each chapter. 
Notes 
a. Angiography is an invasive procedure where contrast·fIuid is injected via a catheter through an artery in the 
leg (the Seldinger technique) and the lumen of the arteries is visualized by X-rays. 
b. A stenosis or narrowing of the lumen of the carotid artery, which is one of the two main arteries in the neck that 
eech supply a hemisphere, via the circle of Willis, is mostly caused by afhero-sclerosis and aggregations of 
platelets (thrombus). It is associated with the occurrence of transient ischaemic attacks (see below) and stroke. 
c. An aneurysm is an abnormal saccular distension of an artery, mostly located at an arterial bifurcation, near the 
circle of Willis. Sizes range from seoeral millimetres to centimetres. Aneurysms mtly rupture, and cause 
subarachnoid haemorrhage. 
d. The posterior communicating arteries connect the posterior cerebral arteries, that arise from the basilar artery 
with the carotid arteries. Together with these vessels, and with the anterior cerebral arteries they form the 
circle of Willis, at the base of the brain. Most aneurysms are located here. 
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e. Transient ischaemic attacks are episodes of sudden neurologic deficit with undisturbed wnsciousness, with 
symptoms resolving within one day, due to (partly) reversible focal brain ischemia. They are associated with 
an increased risk of stroke, and can be considered as a warning sign. Examples are transient loss of vision of 
one eye, transient weakness of an arm, leg or face. 
f. Thrombrrembolism refers here to the process where parts of a thrombus (a mass platelets, fibrin<, and sometimes 
atheromatous material, of plate/et-aggregation and formation of fibrine, are released into the bloodstream, 
and will plug distant arteries, leading to insufficient fWw, and hence to ischaemia and necrosis of part of the 
brain. 
g. Carotid endarterectomy is the surgical procedure where the carotid artery is clamped, and the lumen and its 
endothelial corJering is cleaned from atherosclerotic material. 
h. Stroke is a general term for a sudden focal deficit, due to haemorrhage or (in this case) ischaemia of parts of the 
brain. 
i. In subarachnoid hemorrhage blood (from trauma, ruptured arteriorJenous malformations or aneurysms) is located 
between the meninges of the brain. 
j. Acetyl-saIicylic acid (and derivatives, such as carbasalate calcium) decreases platelet aggregation and thrombus 
formation, and thus has a preventive effect on stroke and myocardial infarction, in patients at risk. The drug 
is also known by it brand name Aspirin". 
k. An arteril:roenous malformation amsists of abnormal connections between arterial (afferent) and venous (efferent) 
vessels, without the usual capillary network. When located in the head, it can cause seizures, headache, focal 
neurological deficits and intracranial haemmrhage. 
1. An autosomal dominant disease named after Reruiu, Osler and Weber, with arteriovenous mo.lformations and 
fistulae that may involve numerous organs in the body. The brain may be compromised through hypoxia, 
and (septic) emboli, or by an intracranial localization of the vascular malformations. 
m. Normal pressure hydrocephalus is a con.dition characterized by gait disturbances~ dementia, and urinary 
incontinence. Some only consider the gait disturbances obligatory for the diagnosis. The ventricles of the 
brain are enlarged, but the cerebrospinal fluid pressure seems normal. The syndrome is one of the causes of 
dementia that are amendable to treatment. 
n. Antifibrinolytics such as tranexamic acid inhibit the conversion of plasminogen into plasmine, and therefore, 
the natural breakdown of fibrine an important constituent of a blood-clot or thrombus. 
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Methods 
Methods 
Decision analysisis a normative theoryofdecision making under conditions of uncertainty, 
used for prescriptive purposes." It distinguishes a decision maker, who is usually the expert 
who acknowledges the decision problem, and wants help in structuring the choice situation 
and making the decision.' The decision analyst helps with explicitly formulating and struc-
turing the problem. This is the first, crucial and often the most difficult step in the analysis. In 
the structuring process, the choices that are perceived by the decision maker are laid down in 
a decision tree. The decision tree provides a scenario of possible events that may occur after a 
decision is made; it is used to avoid misunderstandi)lg and promote uniformity in representing 
a decision problem. 
After the construction of a decision tree, the phases of a decision analysis consist of: 
• assessment of relevant probabilities and utilities, 
• the necessary calculations, 
• presentation of the results of the analysis in a useful way.l48 
In reality, this is a process with many jumps back and forth again. 
A clinical decision analysis differs from decision analysis in general because of a confusing 
number of interested parties and potential decision makers. Apart from the treating physician 
and the patient as reasonable candidates for the position of "decision maker", there are ~ on a 
more aggregate level- the third party payers and insurance companies, the hospital board and 
the general public. Although a decision analysis can have any perspective, the perspective of 
the individual patient is adopted throughout this study. That is, approximations of patients' 
preferences for health outcomes are used. Estimates of the likelihood of events in a decision 
tree are based on general medical knowledge available in the clinical literature, clinicaI-epi-
demiological research, and expert opinion. 
2.1 Decision tree 
Through the remainder of this introduction we will use parts of the decision analysis of the 
management of a patient with symptomatic carotid stenosis and TINs (see also Chapter 4) to 
illustrate the methodology, and to establish a basis for discussion. 
Forthepatient in the example, there are four main strategies: wait, clipping of the aneurysm, 
endarterectomy and both clipping of the aneurysm and endarterectomy. For each strategy, 
acetyl-salicylic acid (aspirin) can be given as welL Figure 1 shows the root of the decision tree, 
depicting the four main strategies. In Figures 2, 3 and 4 the four strategies are visualized. 
15 
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Wait subtree I 
eli in subtree II 
69-year-old man with 
transient ischemic attacks. 
carotid lesion and 
intracranial aneurysm Endarterectomy subtree III 
eli in and endarterectomy subtree IV 
Figure 1. Root of the decision tree for the management of a patient with TfA's and ipsilateral carotid stenosis. 
In the example, a major stroke may occur, resulting in death or permanent disability, or the 
aneurysm may rupture, resulting in death, disability or recovery. When the patient is operated, 
surgery may be successful, or may be complicated by mortality or morbidity, resulting in 
permanent disability. 
A decision tree consists of interconnected decision nodes (quadrangles), chance nodes 
(clrcles) and terminal or outcome nodes (rectangles). Time flows from left to right. The decision 
node represents the point where the first choice must be made by the decision maker. The 
outcomes that result from previous events and decisions are represented. by a teoninal node. 
Chance nodes represent points where events take place that cannot be influenced directly by 
the decision maker, although their occurrence or likelihood may depend on previous decisions. 
Probabilities of mutually exclusive events are inserted at each branch of a chance node and 
should sum to unity, see also section 2.2. A quantitative measure of the patient's preferences 
for each health outcome (utility) relative to the worst and best outcome is inserted at each 
terminal node, see also section 2.3. The expected utility of each strategy is computed by 
multiplying the probabilities along each path in the tree with their associated utility,andadding 
the results for each strategy. The strategy with the highest expected utility is advised. Sensitivity 
analysesareused to assess the influence of uncertainty about the exact values of the probabilities 
by varying them over a plausible range, and examining the effect on the expected utility of 
each strategy. In this way, an impression of the stability, or robustness of the results of the 
analysis is obtained, see also section 2.4. 
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A decision tree is constructed by breaking down the problem and possible actions into 
smaller and smaller units. The structure of the decision tree must accommodate the rules of 
probability calculus and logic. It should contain a context and case description, be complete 
and pruned from unrealistic subtrees and it should be symmetrical. Branches should contain 
single~ not complex actions. For a discussion of the construction and assessment of a decision 
tree, see Wellman.'" In the course of the process of decision tree construction there is a lot of 
switching back between too complex and too simple decision trees. In discussions with the 
decision analyst interesting alternatives that were first not thought of or were (prematurely) 
discarded as "unusual" sometimes emerge. 
subrroo I 
subrroo U 
I I II 
Figure 2. Decision tree for the management of a patient with TlA's and ipsilateral carotid stenosis: Wait and clipping strat-
egies. 
Decision analysis requires that uncertain factors in a clinical problem be made explicit and 
quantifiable. Most if not all of the estimates will be based on the literature, as usual in clinical 
practice. This type of analysis can be found in the Chapters 4-8. Many times however, a decision 
analysis is not merely directed at a unique patient problem, but can be used as a deci-
sion-support tool for similar patients. Probability estimates that are crucial to the analysis are 
then not merely inserted in the tree, but a disgnostic or prognostic prediction model is created. 
This has been done in Chapter 8, and in the Chapters 9 and 10. Thus, the decision analysis has 
become a natural extension of decision oriented data acquisition and analysis. 
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subtree IV 
Clipping and 
endarterectomy 
Success 
Morbidity 
Mortality 
Endarter-
ectom 
Success 
Morbidity 
Mortality 
WeH 
isability 
isability 
oath 
Death 
isability 
Disability 
Disability 
Death 
Death 
Death 
No Stroke Disability 
No Stroke isability 
Stroke isability 
Mortaflty 
Death 
oath 
Agure 3. DeciSion tree for the management of a patient with TlA's and ipsilateral carotid stenosis: Endarterectomy. 
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Agure 4. Decision lIee for the management of a patient with TlA's and ipsilateral carotid stenosis: Clipping and Endarterec-
tomy. 
2.2 Probabilities 
In choosIng between the clinically relevant strategies one may want to consider the 
attractiveness of each outcome, and the chance that it occurs. In this section we will first go 
Into the application of probability theory to decision making in medicine, and then return to 
the patient example. Probability is defined as the personal degree of belief of a decision maker 
in the truth of a statement, on a scale of O~ 1. This implies that the subjective, Bayesian view of 
probability is adopted throughout this study.348 This is inevitable, as we cannot consider the 
practical use of decision theory without choosing this point of view.415 A probability of 0 means 
that the statement is certainly not true, and a probability of 1 means the exact opposite. A 
probability of 0.5 implies that the statement is equally likely to be true as not true, according 
to the decision maker. The probabilities of an exhaustive set of mutually exclusive events sum 
to 1. Likewise, the probabilities that are inserted at the branches of a chance node should sum 
to unity. 
In order to get a firm idea of the likelihood of a certain event, one might try to gather as 
much information as possible. This is where clinical epidemiology and biostatistics come in. 
Perhaps the decision maker has some experience with the clinical situa tion, and he thinks that 
the statement "the T1A is caused by thrombo-embolism from the intracranial aneurysm" is ten 
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times less likely to be true than not, implying a probability P(I'} = 0.09.' However, he is not 
certain about his own estimate. According to him, this probability might be as low as 0.05, or 
as high as 0.15. This is called 'secondary uncertainty'. Secondary uncertainty in decision 
analyses is sometimes represented by a 'plausible range', as has been done in some chapters 
of this book. Many authors regard the plaUSible range as an informal confidence range, spec-
ifying a range that encompasses the "true value" with 95% certainty. The former statement 
about the most likely cause of the TlA is not verifiable, and the uncertainty cannot be resolved ... 
m the other extreme situation the decision maker has carefully searched the literature 
instead of relying on personal experience and finds that in a consecutive series of 175 similar 
patients with an unruptured aneurysm 7 patients suffered peri-operative complications 
resulting in serious permanent disability. When the decision maker thinks that this represents 
all the available information, the most likely value for P(Mb) is 7/175 = 0.04. Ninety-five percent 
confidence limits can then be specified by taking for example the normal approximation to the 
binomial distribution.': Exact limits are obtained from binomial tablesl33 or by using the 
F-statistic approachd according to Miettinen272 (see also Armitage)12. 
Figure S. Probability estimation for a clinical decision analysis. 
Sometimes, data are available that bear on the clinical problem that is addressed. But even 
in that fortunate situation, inference and adjustments are necessary, because the clinical 
characteristics (age, sex etc.) of the study population do not exactly match the characteristics 
of the key patient, and the data have been gathered in the past, and their applicability in the 
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present and near future has to be judged. Even the use of data from the national vital statisticsss 
forestimationofthelifeexpectancyofa patient requires a step of inference I becauseitisassumed 
that the (cross-sectional) age- and sex-specific mortality rates are still valid many years from 
now. 
Always when a probability estimate has to be made, a step of inference is necessary, where 
it is judged whether the figures bear on the clinical situation under consideration. When the 
clinical literature is considered, the data should not be taken at face value, but selection and 
other bias mechanisms should be kept in mind. See for example Sackett"'.32' and Begg.26.27 
Publication bias refers to the fact that studies with Significant results, low complication rates 
etc. have a higher chance of being published than studies with less favourable results. 
Adjustments may therefore be necessary. Several formal methods exist for combining study 
results. Meta-analysis is a general term for combining results from experimental studies using 
multivariate Oogistic regression) techniques. Overview analysis is now used to denote the 
procedure of combining estimates of the effect size in a pooled odds-ratio using the 
Cochran-Mantel-Haenszel statistic." The method is appropriate for combining the results of 
randomized clinical trials. Several modifications have been proposed, especially for base-rate 
and dosage differences.Zl2.304 Eddy's confidence prome method uses Bayesian statistics to 
combine the evidence from different kinds of studies: cohort studies, case-control studies and 
randomized and non~randomized clinical trials. Distributions for a specific parameter are 
created, checked visually and combined mathematically.''' Even when such formal methods 
are employed, or when only one or two sets of statistically analysed data are available, inference 
and interpretation is necessary. Thus, every probability estimate is subjective, whether it stems 
from a statistical analysis or not. Figure 5 shows the necessary steps in a schematic way. 
Many times, a decision maker can only make vague statements about the likelihood of 
disease. This is not more than natural, as most of us do not seem to think of likelihood in 
quantitative terms.37,348Vague, verbal statements concerning likelihoods are of no use in a 
decision analysis. Thus, the analyst has to elidt probabilities from the expert. The process 
consists of aJ comparing with well known relative frequencies, bJ narrowing down and cJ 
multiple consistency checks.'" This is certainly necessary, as it has been demonstrated that 
people are subject to many biases when making probability judgments.'" 
Sometimes information is difficult to obtain, because of costs and time, or methodological 
constraints. A logical approach would be to obtain expert judgment of probabilities, and 
examine by sensitivity analyses whether more infonnation on a certain factor in the analysis 
would be of influence. 
Whether a probability estimate is produced by a clinical expert, a prediction rule or a 
computer program, it should have two properties: The first is obviOUS, but nevertheless 
sometimes neglected.: extremeness. An estimate close to zero or to one gives far more guidance 
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than an assessment near 50%. The other desirable property is calibration. When the risk of 
serious permanent disability P(Mb) is estimated in N "identical" patients, surgery should 
actually lead to serious disability in P(Mb) xN patients. Calibration and extremeness pull in 
opposite directions. Well calibrated probability assessments can be worthless, when for 
example in every situation an estimate of approximately 0.5 is given. The calibration of a single 
estimate cannot be assessed: This is why probability estimates in a decision analysis of the 
management of an individual patient may give rise to (endless) discussion. A body of theory 
has developed around the evaluation of diagnostic (and prognostid) rules, see 
others.144.145,146.173,174,234,39~ 
Paradoxical situations may result from taking the viewpoint of subjective probability. 
Imagine two independent decision teams analyzing the same clinical problem. They arrive at 
different estimates of a probability, and they produce different treatment advices, using the 
same data and infonnation. This would not make one or the other estimate invalid, but it rather 
illustrates the limits of generalisability of these probability-estimates. 
For the patient in the example, all estimates are based on clinical knowledge and the lit-
erature. For instance, the estimate of the annual ratef of rupture was made by contemplating 
several follow-up studies of patients with unruptured aneurysms,''''''' by combining data on 
the age-specific population-incidence ofSAR'''' and prevalence ofunruptured aneurysm'" (see 
Figure 6), The ratio of these two measures gives an estimate of the rate of aneurysm rupture. 
The most important conclusion is that it remains constant with increasing age. The actual value 
(0,5%) is probably an underestimate, because an unknown number of patients with sudden 
death (some of them due to subarachnoid haemorrhage, and manydueto other vascular events) 
were not included in the survey, because no clinical or autopsy evidence was available. Cohort 
studies suggest an annual rate of rupture of 1 % approximately.84.189;l98 The risk of SAH from 
unoperated ruptured aneurysm was considered as a reasonable upper bound of the plausible 
range of values.410 In Table 1 all estimates for the decision analysis are summarized. For a 
discussion of these estimates and of the clinical literature, see Chapter 4. 
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Figure 6. Age-adjusted prevalence of unruptured intracranial aneurysm?' (open circles) and 
popula60n incidence of subarachnoid haemorrhage'" (closed circles). 
Diagnostic testing 
Doing a test, for example a cr -scan of the brain to look for signs of hydrocephalus in a 
demented patient with gait abnormalities (see Chapter 8), or a duplex scan of the carotid arteries 
ina patient with TIA' sin order to judge whether an arteriogram should be obtained and perhaps 
endarterectomy should follow~ may give additional information about the existence of disease 
in a patient. When a test predicts with certainty that the patient has the disease or not~ it is said 
to offer perfect information. When it is also free of costs and causes no harm, it is called a perfect 
test. Most tests however~ arenol Assessment ofdinical signs and symptoms can be considered 
asa relatively cheap, fast and simple battery of tests"'(especially in neurology)," although they 
almost never offer perfect information and observer variability is sometimes large."""'" 
Many test results can be expressed. as continuous variables~ for example cerebrospinal fluid 
cell count (cells/3 rom'), creatinine-phospho-kinase level in serum (U II), or as categorical 
variables on an ordinal scale. The ability of test results to discriminate between disease and 
non-disease can be expressed as a likelihood-ratio (LRJ; ie. the ratio of the probability of a 
certain test result 1'" given the presence of disease (D ),and the probability ofa certain test result 
given the absence of disease (5); 
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Table 1. Estimates for the decision analysis of the management of a 59-year old man with an unruptured intra-
cranial aneurysm, TlA's and ipsilateral carotid stenosis. 
Stroke and myocardiallnfarcUon 
Annual rate of major non-fatal stroke 
Annual rate of falaJ stroke 
Annual rate of fatal myocardial infarction 
UkeUhood that tile TIA is caused by the aneurysm 
Endarterectomy 
Mortality 
Morbidity 
Efficacy 
Subarachnoid haemormage 
Annual rate 
Mortality 
Morbidity 
Aneurysm surgery 
Mortality 
Morbidity 
Acetyl-salycyllc acid 
Efficacy (vascular death) 
Efficacy (non-fatal stroke) 
Increase in mortality and morbidity trom SAH 
LR P(T*ID) 
P(T*I D) 
Point value 
3% 
1.5% 
3% 
25% 
2% 
4% 
50% 
1% 
55% 
15% 
1% 
4% 
15% 
30% 
5% 
Plau~ble range 
(2%-4%) 
(1%-2%) 
(2%-4%) 
(5%-50%) 
(1%-4%) 
(2010-8%) 
(25%-75%) 
(.5O/~2'Io) 
(50%-60%) 
(10%-20%) 
(0.5%-2'10) 
(3%-6%) 
(10%-20%) 
(20%-40%) 
(1%-10%) 
(1) 
The likelihood-ratio can be combined with the prior odds in favour of disease (before the 
test result is known) (P(D)J(I- P(D)) or P(D)/P(i5)) in order 10 compute the poslerior odds (the 
odds in favour of disease, given Ihe lest result), using Bayes' rule or theorem: 
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P(D IT*) LR-P(r:..)_ 
P(D I T*) P(D) 
(2) 
For those who do not like to think in odds, Bayes' theorem can be written as 
and 
where 
P(D IT*) P(T*ID)·P(D) 
P(T*) 
p(o I T*) P(T*I D)· p{O) 
P(T*) 
Methods 
(3) 
(4) 
(5) 
Many textbooks on statistics and epidemiology descnoe this formula and its derivation, 
see for example Hays'" or Ingelfinger.'87 
Figure 7 shows a hypothetical distribution of test results in diseased and non-diseased. 
Table 2 gives the likelihood-ratio and posterior odds for each test category of results, and for 
different prior odds. It dearly demonstrates the effect of different priors. The table shows how 
easy the computations with the odds and likelihood-ratios are. 
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o 
20 
Meningitis 
with seizures 
(N = 100) 
Seizures only 
(N .100) 
CSF cell count 
Fl!Jure 7. DistJibution Of hypolheUcaI lesl results. X-axis: CSF-cell count (cell513 mm') in 100 padents with seiZJJres and men-
ingm" (lower bats) and 100 patients with seizures only (uppar bars). 
Table 2. HypotheUcallikelihood-raUos and posterior odds for different categories CSF-cell count in paUents with seizures 
and meningitis and seizures only. 
posterior odds 
Test result LA prior = 1/1000 prior=: 1/10 prior = 1 prior = 10 
10 1112 1112000 1/120 1\12 111.2 
30 112 112000 1120 112 5 
50 2 1/500 1/5 2 20 
70 3 1/333 1!.l.33 3 30 
200 6 1/167 111.67 6 60 
1000 
"' "' "' "' "' 
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A decision rule is now easy to make. The choice of a cut-off point above which test results 
should be regarded as indicative of disease is determined by the benefits and loss of treatment 
of and no treatment of disease and non-disease,and the prior odds. Determining a cut--off point 
before the prior is known is a futile effort. 
The ability of a diagnostic test to discriminate between disease and non-disease is deter-
mined by comparison with a gold standard; i.e. an independent procedure that denotes the 
right diagnosis with certainty.' 
Some prefer to describe test characteristics by sensitivity, Le. the prohability that the test is 
positive when the patient has the disease, or per I D) and specifidty, Le. the prohability that 
the test is negative when the patient does not have the disease, or p(r I [5). When the test 
results are represented by continous variables the use of sensitivity and spedfidty implies a 
cut-off pOint, above which test results are regarded as indicative of disease, and below as 
indicative of non-disease. When this "cut-off' level is low, the sensitivity will be high and the 
specifidty low, and when the cut-off level is high, the other way around. Trade-offs between 
sensitivity and specifidty can be visualized by ROC-analysis, which will be further discussed 
in Chapter 2, section 25.178,260,270,285 The use of these concepts means loss of information, as any 
result (whether extreme or not) below the cut-off value is considered to mean the same thing. 
Sometimes, these simplifying concepts can be useful, for example when estimates of 
test-characteristicshavetobemadewithscarcedata,seeChapter8.Ingeneral,itisunreasonable 
to consider the test characteristics as parameters that are independent of the clinical context 
where the test was evaluated. Generally there will be a relation between the severity of signs 
and symptoms, referral and prevalence of disease.213 
Bayes' rule can be generalized to the case of (n) diseases Du .. ,Di,..Dw and m tests Tz,··,Tj, .. T m' 
P(D,I T) P(D,)· P(T'I D,) 
± P(D.)· P(T'I D.) h' 
(6) 
where 1" stands for a particular combination of test results, its prohability computed using the 
simplified form of Bayes' rule:' 
(7) 
In order to relax the assumption of conditional independence, which is implied by Bayes' 
theorem, a global assoctation factor (0:; x:; 1) can be used.'" 
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(8) 
(oc means "is proportional to"). 
A value x = 11m suggests that all tests are completely dependent, x = 112 suggests pairwise 
dependence, and x = 1 suggests conditional independence. 
In Chapter 8 the base 2 log-odds form of Bayes' theorem is used because of its computational 
ease when more than one test is involved: 
{ P(DdT) J {P(D,)) {P(T""ID')J posterior likelihood = 10 ") = 10 1 P(D) + x . 10 • , I-P(D,IT -, P(I"ID,) 
(9) 
whereLR =P(T'I D,)IP(I"'I D,),is the likelihood ratio for a test with result·: 
Figure 8 shows part of decision tree that represents the use of the diagnostic test. In a 
non-trivial problem, treatment will follow a positive test result, and no treatment a negative 
test result. 
Positive Treat 
P(T+) 
Test 
Negative Wait 
P(T-) 
No disease 
l·P(DJT+) 
Disease 
P(D[T+) 
No disease 
l·P(DJT-) 
Disease 
P(DJT-) 
Rgure 8. A binary test. 
2.3 Preferences for health outcomes 
No disease. treated 
Disease. treated 
No disease, not treated 
Disease, not treated 
Health outcomes can have several attributes that are pertinent to a decision problem, for 
example, duration of life, and quality. Quality of life itself has numerous attributes, physical, 
psychological and socio-economical. An attribute can have one or more levels, for example the 
attribute duration of life can have the levels O,l,2, .. ,i, .. n years. In a non-trivial decision problem, 
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outcomes have at least one attribute, with at least two levels. Of course, only those attributes 
thatwill be affected by the decision should be taken in to consideration (the sure thing principle, 
see further). 
In the one attribute, two levels situation, the construction of a utility scale is trivial, and the 
analysis is merely a risk analysis. The two attributes, two levels situation is also a special case: 
when the preferences for the two attributes are independent, one may decide not to create a 
utility scale for the different health levels, but to compute a ratio of expectations oflevels. This 
is called a risk~benefit ratio) In the one attribute, more than two levels situation a utility scale 
is necessary to compare strategies, when there is no dominance.k 
In the example there are two attributes, duration of life and quality of life, with numerous 
and three levels, respectively. The relative attractiveness of the three outcomes can be repre-
sented by numericals, called utilities, on a scale of 0 to 1. For example, the utility of the outcome 
"disability" in the decision tree is represented by U(Disability). The central axiom of utility 
theory and decision analysis is that a decision maker should maximize the expected utility. 
The expected utility of each option is computed by taking the sum of all path probabilities 
multiplied by the utility of their outcome. 
Now, the decision maker is advised to choose strategy Wait when EU(Wait) > (EU(Clipping) 
;;, EU(Endarterectomy) ;;, EU(Clipping and Endarterectomy), and strategy Oipping when 
EU(Clipping) > (EU(Wait ;;, EU(Endarterectomy) ;;, EU(Clipping and Endarterectomy). This is the 
main axiom of subjective expected utility theory. 
Utility should not be confused with the quality oflife measurements in patients with stroke, 
cancer and other chronic, potentially disabling conditions.7S,1l1,183.245,356,414 Utility is a measure of 
the strength of preference for a certain unresolved outcome in the presence of uncertain 
alternatives. The assessment of these preferences presumes an adequate description of these 
outcomes. However, information from quality of life studies can be valuable in the assessment 
of utilities. 
Utility is defined as the substitution probability of a hypothetical standard reference 
gamble.'''$% Assume that (immediate) death is the least attractive, and "well" is the most 
attractive outcome. These will be given the (arbitrary) values 0 and 1.1 The utility of the inter-
mediate outcome (i.e. U(Disability) is defined as a hypothetical choice situation presented to 
the decision maker, see Figure 9. The decision maker is then requested to choose between A, 
which may lead to immediate death with a probability 1-r, or to recovery (with a probability 
r) and B, resulting in permanent disability. For very high values of r one would certainly prefer 
to wait, and for very low values to treat. It is theoretically possible to think of a unique value 
of r, that leads to indifference between the two options, in other words, EU(A) =EU(B). This 
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implies that (1- r)· 0 + r . 1 = U(Disabiliry). The value of r that leads to indifference between the 
two strategies for the decision maker in a standard reference gamble, is called the substitution 
probability for U(Disability). 
A 
Die 
1-' 
U(Oead) = 0 
Survive U(Well) = 1 
8 
U(Oisability) =? 
Agure 9. Standard reference gamble. 
In the example, the decision maker distinguishes two attributes of the outcomes, ie. quality, 
determined by the absence or presence of disability and duration of life in years. Theoretically, 
a countless number of different outcomes is possible~ as the patient may die any time after the 
decision has been made. How should utilities for these outcomes be assessed? 
FIrst theundedying assumptions of utility theory will be described. They will be presented 
informally~ in words, for the exact mathematical formulation the reader is referred elsewher-
e.118,3lS,393,396 
Connectivity: The decision maker can indeed make judgments about indifference or preference 
when faced with two risky choices. 
Transitivity: When A is preferred over B, and B is preferred over C, then it follows that A is 
preferred over C. 
Sure thing: When A and B have one component or attribute in common (for example a duration 
of 10 years) then preferences for A compared to B should not depend on the strength of 
preference U(10 years,q). Thus, when the patient learns that he will neverreachretirement 
with any of the two options, this should not influence his choice?~J. 
In a decision problem with uni-dimensional outcomes the standard reference gamble may 
be used to elicit preferences directly. Mostly however, the multi-attn outed outcomes and their 
associated gambles are too complex, and the decision maker cannot express preferences or 
indifferences, or major violations of the assumptions of utility theory will follow. 
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The standard reference gamble is theeretically the most attractive method for utility elici-
tation, because it directly provides the decision analyst with a substitution probability. In 
practice, however, patients are anxious and emotionally disturbed. They may turn out to be 
inconsistent in their preferences, or not able to digest information. Moreover, the procedure of 
utility elicitation may provide information on future events that have a negative utility in 
themselves (for example the knowledge of harbouring an unruptured aneurysm).m Hilden 
pointed out that the option of living a fixed amount of years that is frequently used in standard 
reference gambles and other elicitation techniques, is abstract and may even be abhorring to 
some.l77 
Some have advocated other elicitation techniques, such as visual-analog scaling or direct 
scaling, the time trade-off method,237,309,373,374 and conjoint measurement.246 In visual-analog 
scaling the respondent is presented with two extreme conditions, and he should indicate his 
preference for a third intermediate condition by placing it on a 0-1 or 0-100% scale in between 
the two extremes. In the time trade-off method the respondent is asked how many life years 
he is willing to give up, in order to prevent living in a certain disease state, instead of living a 
normal healthy life. In conjoint measurement, the respondent should choose repeatedly 
between sets of two alternatives, and a utility function is fitted to his answers. The latter has 
the advantage of relatively easy elicitation procedures and ''built -in" consistency checks.246 
It appeared that different methods of elicitation led to different utility-values.'" This can 
be explained by the fact that most peeple do not have a fixed number in their heads that only 
needs to be "drawn out" or elicited. Moreover, elicitation techniques that do not consider 
preferences for outcomes in the presence of uncertain alternatives, by definition do notmeasure 
what is needed. 
In view of the abovementioned difficulties in utility elicitation, a pragmatiC approach seems 
appropriate. This pragmatic approach is adapted from Von Winterfeldt'" and Weinstein,'" 
and employed in most of our studies (Chapters 4-7, and 10). 
1. Determine the attributes of the Qutcomel ie. duration life and health status. 
2. Try to find a natural scale for each attribute, i.e. number of life years lived or age attained. 
3. Attach values to the levels of the natural scale or levels of the attribute that adequately 
represent preferences in the face of uncertainty. 
4. Perform the necessary computations and sensitivity analyses. 
5. Only when the results of the analys is depend on the exact values of the utilities, an attempt 
to elicit utilities should be made. 
Utility functions for life years 
In many applications, life years lived (L Y) form an attractive natural scale. However, even 
when disability does not playa role, life years lived are almost never a good single decision 
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criterion. A utility function for life years can have the simple fonn U = I, where t is the number 
of life years lived. It can easily be shown that this function does not adequately represent 
preferences for duration of life. According to this function, a decision maker should be indif-
ferent between a gamble of living ten years in full health or dying immediately, both with a 
probability of 50%, and living for five years with certainty. McNeil investigated this problem 
in patients with lung-cancer and concluded that they generally opt for the safe alternative, and 
are indifferent only when the safe alternative offers a much lower life expectancy than the risky 
one.In otherwords,theyarein general risk-averse.""In thedecision theoretic and psychological 
literature the term risk-aversion seems to be reserved for risk attitude with regard to the taking 
of immediate risks, such as In (immediate) surgery, but a better term would be aversion to 
early risk, or early risk aversion. Early risk-averse people have convex utility functions for life 
years, whereas early risk-seeking individuals have concave utility functions, see Figure lO.n 
That the connotation "early" is necessary is illustrated by the case of the cigarette smoker, who 
takes a (calculated) risk and reduces his life-expectancy, but may nevertheless have a convex 
(early risk-averse) utility curve. Early risk-aversion can be (partly) explained by psychological 
mechanisms (fear, regret and disappointment) and by discounting of future life years. 
D •• 
0.6 
~ 
5 
o~~~~~~~-L~~~~~~~ 
m ~ 00 ~ 00 ~ 100 
Age 
Figure 10. Utility function for remaining life years of a 69·year-old man, adjusted to a scale ofD-l, where U(O) = 0, and 
U(31) = I. 
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Whenlife years areused asa natural scale, a decision treethat displays all possible outcomes 
would be extremely 'bushy", and therefore the expected number of years lived, or the 
life-expectancy of the patient is usually computed. This is done for a patient aged a years by 
summing for each subsequent year, ~O, 1, ... , 101-a the product of the annual mortality m, 
(the probability of dying before 1+1 for a patient who is alive exactly at the start of yeart), and 
t, the number of life years that has elapsed. In other words, it is the expected value of the 
survival time 1:.,. Alternatively one can sum the survival probabilities S, overt (the probability 
of being alive, at least until time t), because St -St+l =m" 
101-a 101-a 
2: m,·L,'-" 2: S,. 
(10) 
t~O t~O 
Preferences for time can be introduced by an annual discount rate ex: 
101-a 
2: S,·(I-a)'. 
(11) 
,., 
An adjustment for the fact that patients do not die exactly at time t, but approximately 
halfway between t and t+1, can be made by doing the calculations in the previous formulas 
for t and for t+1, and averaging the result. 
Quality adjusted life expectancy 
Not only the risk of immediate death differs between the strategies, but also the risk of 
long-term disability. Figure 11 illustrates again why plain survival is not a good decision cri-
terion: the overall and disability-free survival differ between the strategies. Therefore, quality-
(or preference-)'" adjusted life expectancy is computed by taking survival probabilities for each 
health state (Well, Disability) separately and weighing these with the utility u, corresponding 
to the health state h, 
2 101-a (12) 
2: 2: S,,·u,(i-a)', 
IIml t",O • 
where S", is the probability of being alive and in health state h, at least until time t. The 
utility value of living with disability compared to death or a life without it of equal duration 
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can be estimated using a hypothetical standard gamble. In the example, WDisabiIityJ is taken 
at 0.75, thus it is assumed that the hypothetical patient is willing to take any gamble with a risk 
of death versus nonnallife to prevent living with a severe handicap, where the risk of death 
is lower than 0.25. 
This utility function presumes that utilities of health outcomes do not depend on duration 
of survival, and that discount does not depend on health state. Theassumptionof riskneutrality, 
implied by the use of time-trade-off techniques advocated by Torrancem~74does not apply in 
our opinion, when it is modelled according to equation 12.136 
When it appears necessary to estimate utility functions one may use the standard reference 
gamble and fit the results to a utility function as described above, oruse the approach suggested 
by Mehrez""'''-''' merely assess preferences for complete "lifetime health profiles", again using 
the standard reference gamble.129,195 
Regret' and disappointment (and especially its anticipation) sometimes playa major role 
in human decision making. Regret is defined here as the psychological effect of comparing the 
realized outcome with the expectation of another choice that could have been made. Disap" 
pOintment is defined as the psychological effect of comparing the realized outcome with prior 
expectations of the same choice.29 In the unruptured aneurysm problem, the patient may 
anticipate on the experience of regret when he will become severely handicapped because of 
aneurysm surgery and realize that a choice for the conservative option would have quite 
probably given him several years more in good health. This may render the surgical option 
less attractive. Some argue that anticipated regret can at least partly explain discrepancies 
between results of descriptive and normative studies of human decision making.""" Antici-
pated regret thus defined has its basis in presumed foreknowledge of the result of an alternative, 
not-chosen strategy. We propose that a rational decision maker should not want to trade off 
(health-)benefits to achieve a state of higher psychological well-being. In our opinion the 
strength of clinical decision analysis lies in its prescriptive nature, based on rationality, 
Therefore, we incorporated neither regret nor disappointment in the utility functions of 
Chapters 4-8 and 10. Risk-attitudeis considered only in so far it can be explained by discounting 
of future life years. 
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overall survival. X-axis: time in years, Y-axis: proportion alive. 
2.4 Expected utilities and sensitivity analysis 
The expected utilities for each strategy are computed, using the utility function described 
in this section. In Table 3 expected utilities in the form of life expectancy (LE), discounted life 
expectancy (dLE), quality adjusted life expectancy (QALE) and discounted quality adjusted 
life expectancy (dQALE) are presented. Evidently, the results of the analysis are influenced by 
the way we constructed the utility scale, but in this case, the preferred strategy remains the 
same. 
Table 3. Results of the decision analysis. Highest values for each method are underlined. 
Ufe expectancy 
discounted and 
Strategies unadjusted discounted quality quality 
adjusted adjusted 
Wait 8.40 6.54 8.12 6.35 
Aneurysm surgery M2. ~ ~ .Ma 
Endarterectomy 8.26 6.42 7.89 6.16 
Endarterectomy and aneurysm surgery 8.66 6.66 8.28 6.39 
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In a sensitivity analysis the values of one or more parameters in the decision model will be 
varied over a plausible range, in order to examine the sensitivity of the decision to changes in 
one or more assumptions. In a one-way sensitivity analysis or influence analysis the value of 
only one parameter is changed, and the effect of these changes on the expected utility of each 
strategy is examined. One-way sensitivity analyses areused in Chapters4-8 and 10 of this book. 
They can also be used in the "construction phase" of the decision analysis to check the model 
for internal consistency and logical or computational errors, but mostly, influence analyses are 
used to check the "robustness" or stability of the decision to plausible changes in estimates. 
Figure 12 shows the results of an influence analysis of changes in the mortality PM) associated 
with clipping of the aneurysm. This figure shows that changes in the mortality from clipping 
within the plausible range do not lead to different recommendations. Would this have been 
the case, and the plausible range was defined in the informal way as described previously, a 
problem with interpretation might have arisen, because the significance of deviations from the 
point estimate, within the plaUSible range would be unclear. 
6.8 
6 
..--- point estimate 
~_=-~ plausible range 
5.8 ~--:-::-----c:-::---~---c--:-:::----::-: o 0.Q1 0.02 0.03 0.04 O.OSmortality 
0.02 0.04 0.06 0.08 0.Q1 0.12 morbidity 
Surgical risks 
Rgure 12. One way influence analysis. X-axis surgical mortality and morbidity.p Y-axis: £Expected utility in dOALE. Black dot: 
base-case estimate. 
Variation of more than one parameter at the same time (two- or more-way influence 
analysis) can lead to quite complicated graphs. When analysing the effect of plausible changes 
in two parameters PM) and P(T) (the probability that the TIA originates from thromba..em-
holism from the aneurysm), and on the expected utility of each strategy <Figure 13) simulta-
neously, one may determine the cutting edges of - for example - the two graphs for Oipping 
and Wait. The cutting edge is formed by a line in a plane that is parallel to the X-Y plane. It 
represents combination of values for PM) and P(T), that lead to equal expected utilities for 
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both strategies. When only the intersection of the two planes is displayed ina figure, the analysis 
is called a threshold analysis, because at one side of the threshold or intersection combinations 
of values for the two parameters favour aneurysm surgery, and on the other side, waiting. 
Two- or more--way sensitivity analyses are not commonly used, because they are complicated 
and not easy to interpret visually. TItreshold analyses are used in Chapters 5, 7, 8 and 10. 
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Wait '.0 
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Figure 13. Two-way influence analysis: the effect of changes in the mortality from clipping P(M) (X·axis) and the probability 
that the riA is caused by thrombo-.emboDsm from the intracranial aneurysm P(7) (Y-axis) on the expected utility EU of each 
strategy (Z-axis). 
A threshold analysis is sometimes (confusingly) called a two-way sensitivity analysis. 
Figure 14 shows how the threshold value of the mortality from dipping of the aneurysm 
changes with different values for PIT), the probability that the TIA is caused by throm-
bo-embolism from the aneurysm. 
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Rgure 14. Threshold analysis. X--axis: probability that the T1A is caused by thrombo-embolism ftom the intracranial aneu-
rysm P(T). Y·axis: Surgical mortalfty and morbidity. Straight ffne: Wait· Clipping threshold. The black dot represents the 
point estimates for the base..case, the bars represent the plausible ranges for each parameter. 
The threshold analysis shows that no combinations of surgical risk and probability that the 
TIks are caused by thrombo-embolism from the aneurysm within the plausible range favour 
WAIT. But what about combinations of values at the edge or out of the plausible range? What 
about the secondary uncertainty surrounding the other estimates in the analysis? How certain 
can we be about these results? In a probabilistic sensitivity analysis or full Bayesian analysis 
the uncertainty about each estimate is considered simultaneously. This type of sensitivity 
analysis is used in Chapter 4. 
In a full Bayesian analysis cumulative distributions or density functions are estimated for 
all stochastic parameters in the decision model. They should represent the belief of the decision 
maker. The smaller the secondary uncertainty, the smaller the variance of the distributions. 
The purpose of the Bayesian analysis is to obtain probability distributions for the expected 
utility of each strategy, or a distribution for the difference in expected utility between the 
strategies. Others have suggested the percentage chance that one strategy is best (by a given 
amount), but this has been proven as insufficient and misleading when there are more than 
two strategies.135 In a Monte Carlo simulation values for the parameters Pl = Pl' ...• p,. in the 
decision tree were randomly drawn from their prohability distributions, inserted in the tree, 
and the expected utility based on these estimates was computed. By repealing this many (1000) 
times, distributions for the expected utility of each strategy, and for the difference in dQALE 
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between strategies could be approximated, see Figures 13 and 14. A Bayesian influence analysis 
(the Bayesian equivalent ofa one-way sensitivity, or influence analysis) is obtained by repeating 
the Bayesian analysis for fixed values of one of the parameters p}l2 
The distributions for each parameter were created by interpreting the point value as mean 
m, and the upper bound b of the plaUSible range as upper limit of a 95% confidence intervaL 
Thedistributions have the formF(x) = $ •• (g (x», where $ •• is the normal distribution with mean 
j.Land standard deviation (5, andg(x) is a convenient transformation function. It is not true that 
I' = g(m), because F(x) may be skewed. The mean m is given by the formula 
, 
m = f xF'(x)dx. (13) 
, 
By taking z = g(x), or equivalently x = g*(z) (where g> is the inverse function of g) equation 
11 can be rewritten as 
~ 
m = f g*(z) $ •• (z)dx, (14) 
-
where $ •• is the probability density function of the normal distribution. By definition, 
I'-g(b) CJ=1::% 
(15) 
By solving these last two equations for 11 and CJ the distributions can be defined. Tertiary 
uncertainty can then be viewed as the uncertainty about the exact form of the distribution. For 
probabilities and utilities a logistic transformation is used, g(x) = In(xll-x), as described by 
Doubilet." Table 4 lists for each parameter the point value, plausible range and characteristics 
of the associated probability distribution. 
If we would only be interested in choosing the best strategy in one unique decision problem, 
we could have spared ourselves the trouble of formalizing secondary uncertainty, because this 
would not change the conclusion from the analysis. The expected utilities of the four strategies 
are 6.35, 6.59, 6.16 and 6.39 discounted quality adjusted life years, respectively.'78 They are 
(almost) equal to the means or expectations from the probabilistic sensitivity analyses. With 
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Table 4. Parameters forthe Bayesian analysis (11 and (J represent the mean and the standard deviaffon of the transfonned 
nonnal distribution). 
point value plausible transfor-
range mation 
Stroke and myocardial infarction 
Annual rate of major non-fatal stroke 3% 2010-4% In(-In) 1.44 0.036 
Annual rate of fatal stroke 1.5% 1%-2% In(;n) 1.25 0.044 
Annual rate of fatal myocardial infarction 2.5%Q 1.5%-3.5% In(;n) 1.31 0.049 
Probability that the aneurysm causes the TIA 25% 12.5-50% logtt -1.17 0.597 
Endarterectomy 
Mortality 2% 1%-4% logit ·3.97 0.404 
Efficacy 50% 250/0-75% logit 0 0.561 
Subarachnoid haemorrhage 
Annual rate 1% 0.5%-2% In(;n) 1.54 0.091 
Morbidity 55% 50%-60% logit 0.20 0.104 
Mortality 15% 10%-20% logit ·1.74 0.183 
Aneurysm surgery 
Mortality 1% 0.5%-2% logtt -4.69 0.408 
ASA 
Efficacy (non-fatal stroke) 30% 20%-40% logit .(J.86 0.230 
Increase in mortJmorb. from SAH 5% 1%-10% logit -3.03 0.423 
Discounting and quality adjustment 
Annual discount rate 5% 0%-10% In ·3.07 0.393 
Utility of disability 75% 62.5%-87.5% logit 1.13 0.410 
or without probabilistic information about the impact of secondary uncertainty, the option 
with the highest expected utility should be chosen, whether the difference between the strat-
egies equals 0.001 utile or 0.01 utile, and whether the two distributions overlap for 9% or 99% 
of their area (see also Figure 15). However, when a decision is likely to be repeated in the near 
future, it would be pleasant and reassuring to know how certain one can beabout thedifferences 
in expected utility from each strategy. The distributions of the differences in expected utility 
are shown in Figure 16. Clearly, the preferred strategy is Oipping. 
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Agure 15. Distribution functions of the expected utility of the four strategies, derived from a Monte Garlo simulation. 
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Difference in expected utility 
Figure 15. Cumula.ve distJibuUon ol1he difference in expected uUlity between Wail and Clipping, Wail and Endarterectomy 
and Wait and CliPPing and Endarterectomy, respectively. Dotted lines represent 95% confidence limits. 
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2.5 Related methods for prescriptive decision making 
In this section we will briefly mention several other explicit, (semi-)quantitative methods 
for prescriptive decision making. Some, like cost-effectiveness analysis, ROC-analysis and 
influence diagrams are quite closely related with clinical decision analysis, and deserve to be 
mentioned on these grounds. The first two types of prescriptive decision making are employed 
in several studies that are outlined in Chapter3. This concise review is of course not exhaustive. 
Operations research methods for specific problem types, such as Delphi methods for eliciting 
group opinion, queueing theory, solutions for the travelling salesman problem, linear 
modelling, etc. will not be discussed here."''' 
ROC analysis 
In continuous tests a cut-off level has to be defined, when only a dichotomous action 
(treatment-no treatment) can follow (see also section 2.2). In patients with seizmes for example, 
20 mono-nudear cells per 3 rom' cerebrospinal fluid (CSF) may be interpreted as a sign of 
meningitis or it may be discarded as "normal", because a cellular reaction may occur after 
seizures, head trauma, cerebral infarction and infection elsewhere in the body. Decreasing this 
so-called cut-off value will increase the sensitivity, but decrease the specificity of the test. 
Increasing the cut-off level will work the other way around. 
ROC curves are graphs of sensitivity versus l-specificity. Theycan be helpful in determining 
optimal cut-off levels, and in comparing the performance of multiple tests. For an example of 
an ROC (receiver operating characteristic) curve, see Figure 17. In the left part of this figure a 
hypothetical frequency dis tribution of the test results in patients with and without disease is 
displayed. Obviously, moving the cut-off value in the direction oflowercellcounts will increase 
the sensitivity (the chance of a positive test in patients with the disease Per I D)), but it will 
decrease the specificity (the chance of a negative test in those without the disease per 115)). In 
the right figure the cumulative distribution P(1'" I D) is on the Y-axis, and the cumulative dis-
tnoutionP(1'" 115) (1 - specificity) is on the X-axis. Generally speaking, combinations of values 
in the upper left comer of the graph are attractive. 
The area under the ROC curve has been proposed as a convenient measure of test perforw 
mance.""5S, The choice of a cut-off pOint, and of a diagnostic test also depends on the prior 
probability of disease, preferences for health outcome associated with the test, and with the 
risks of performing the test. Not the sensitivity and specificity of a test, but its predictive value 
should be the chief consideration. Hilden gave a realistic example how using the area under 
the ROC curve may lead to erroneous conclusions about the diagnostic perfonnance of a test. 
He therefore suggested some modifications: weighing of the X ... xis and Y-axis with the prior 
probability (p(D) and P(D)) and with the utility of treatment (i.e. U(Treall1*,D) and 
U(Treal 11*,D)). However, a perhaps more sensible way to compare diagnostic or prognostic 
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tests would be touse likelihood-ratios (see section 22), measures of fit of posterior probabilities, 
and a modified error score, or sOme measure of the variance of the predicted probabilities, as 
an indication of the extremeness of the predictions.217 
0.8 
>. 0.6 
~ 
... 
c 
CD 
(J) 0.4 r 
0.2 
o 
20 
40 
60 
/ 
500 oL-____ ~ ____ ~ ____ -L ____ ~ ____ ~ 
o 0.2 0.4 0.6 
1-specificity 
0.8 
Agure 17. Hypothetical ROC curve. Cumulative distribution of CSF cell count in patients with meningitis and seizure, as a 
function of 1 - the cumulative distribution of CSF cell count in patients with seizures only. Along the curve, corresponding 
levels of CSF cell count are given. 
Cost-effectiveness analysis 
In a cost-effectiveness analysis the same type of calculations is made as in a risk-benefit 
analysis (see section 2.3), but now one of the two attributes is health-care cost. 
Mostly cost is considered from the perspective of society at large, not from the stand-point 
of the individual patient. For a discussion of the intricacies of measuring health care cost, see 
Drummond." Sometimes in a cost-effectiveness analysis QAL Y's are substituted for the first 
attnoute. These QALY's may stem from evaluation of health services, and from assessments 
of health status of affected patients, which makes them essentially different from the QALY 
that is used to approximate preferences for health outcome under conditions of uncertainty, 
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although the elidtation techniques may be confusingly similar."" Preferences for health out-
come under conditions of uncertainty do playa role in the "rationing by patient choice" as 
described recently by Eddy.'02.103 Of course, when a marginal cost-effectiveness ratio is 
contemplated, a judgment whether the benefit is worth the cost is still necessary, just as in a 
risk-benefit analysis, where one has to judge whether the (increased) benefit is worth the risk." 
Medical technology assessment comprises a body of methods for the economic evaluation 
of (new) medical technologies in a broad sense, i.e. including health-benefits, costs, risks and 
feasability from a societal point of view.'43,lOO Examples concern breast cancer screenmg,'01,384 
liver transplantation34 and magnetic resonance imaging for suspected multiple sclerosis.Z18 
Influence diagrams 
influence diagrams are decision support tools that make use of interconnected nodes that 
represent actions and states of the world, assodated with (conditional) probability distribu-
tions. Unlike a decision tree, the nodes are not ordered exactly confonn the flow of time. The 
rules of probability theory do apply, however. In Figure 18, the example is displayed in an 
influence diagram. Influence diagrams combine nicely with the confidence profiles method 
developed by Eddy, but other ways of spedfying conditional distributions are of course allo-
wed.336,348 
Health 
states 
'-----{,Strol<~.4==:::t===~~ 
PIgure 18. Partially specified influence diagram. 
Prospect thecry 
Patient 
utiflties 
Even in seemingly simple choice situations people tend not to act or choose according to 
the prindples presented in section 2.3 (connectivity, transitivity and sure thing). Part of these 
deviations may be caused by framing. For example, an option may seem more attractive when 
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fonnulated as a 50% chance of surviving, instead of a 50% chance of dying."" For decision 
analysis and the theory of subjective expected utility to be useful for description, a fourth 
prindple was fonnulated by Kahnemann and Tversky:'99 invariance. Different presentations 
of the same choice problems yield the same preference, that is, the preference between options 
should be independent of their description. 
In prospect theory, several prindples of rational choice are relaxed. Probability weights 
rr{p) are introduced, where 1t(0) = 0, and the function is normalized so that 1t(1) = I, but the 
function is not well behaved near the tail. For low probabilities, rr{p)+1t(I-p)S I, and 
rr{pr)lrr{p) <rr{pqr)lrr{pq),Jor 'd 0 <p,q,r $1. Thus, the function overweighs small and under-
weighs high probabilities. 
The authors also propose a value function v, which is S-shaped, concave above a reference 
point, and convex below it. A significant property of this function is called loss aversion, i.e. 
that the response to losses is more extreme than the response to gains. This explains why people 
tend to demand more (money) for a good they want to keep than they would be willing to pay 
to obtain it, if they did not possess it. These adaptations offer an explanation for the violations 
of invariance, and of the sure thing principle in non-transparent choice situations. 
Kahnemann and Tversky'99 state that they modified a normative model for descriptive 
purposes. They never claimed that normative models based on subjective utility theory should 
thus be adapted and used for prescriptive purposes. Thus, the gap between normative and 
descriptive, and between nonnative and prescriptive models remains. The lesson for the latter 
category of model builders is that they should be careful of framing effects and of using 
non-transparent utility elidtation methods for assessment of preferences for future health 
states. This can be accomplished by presenting outcomes as losses and absence of gains sim-
ultaneously, and by expJidtly presenting outcomes not affected by the decision. 
Clinical algorithms 
Oinical algorithms are flow diagrams that give a simple management advice. They are 
espedally helpful in emergency settings, for nursing tasks and for educational purposes."""""" 
The algorithm can be based on expert opinion, (formal) consensus, on prediction rules and on 
decision analysis.96,2S9.286From the outside it does not always show which method was used to 
derive the guide-lines. Because a tree structure is sometimes used,"" it may be confused with 
a decision analysis. 
The analytic hierarchy process 
In the analytic hierarchy process developed by Saaty88.327 a dedsion problem is decomposed 
in terms of subgoals. These subgoals are assigned weights, based on strength of preference of 
the decision maker. These weights are combined into one measure, using matrix algebra. But 
as there is no relation between risks, probabilities and assigned weights, the results are difficult 
to interpret.'" Dolan concluded that the analytic hierarchy method results in 'better recom-
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mendations than decision analysis"because his study resulted in stronger (i.e. more extreme) 
recommendations than the original decision analysis." Obviously, this argument is not 
sufficient. 99 
Expert systems 
Expert systems are computer programs that make use of formalized knowledge in a way 
that looks like human inference.393 The most successful expert systems have a configuration 
that was basically designed by Shortliffe for MYCThI, an expert system for the selection of the 
appropriate antibiotic therapy for hospitalized patients. The knowledge base of such an expert 
system consists of "if ... then ... else rules, with a certainty factor attached. The inference engine 
combines the production rules that are appropriate to the problem." The handling of the cer-
tainty factors and their interpretation is problematic.219,223 
Decision support from expert systems may consist of a simple, straightforward advice. By 
asking for the production rules that were used for the advice, insight may be improved and 
the usefulness of additional information can be assessed. Playing "what if' games may also be 
particularly useful, in order to detennine whether additional information should be obtained. 
Problems that are suited for an expert-system approach are complex and fuzzy. Preferences 
for health outcome playa secondary role. Several expert systems (most of them MCYIN-look-
alikes) have been described. Examples in the realm of the clinical neurosciences are PLEXUS, an 
expert system for diagnosis, localisation and prognosis after brachial plexus injury.'91 Other 
systems are MICRoSTROKE (stroke type detennination),'" and DEMENTIA (differential diagno-
sis).310None of these systems have been formally evaluated for their diagnostic of prognostic 
capacities, such as has been described for systems in other clinical domains,239 and should be 
required from any diagnostic system.l44,l45 
Conclusion 
After reviewing the existing methodology for patient-oriented decision support, it seems 
that clinical decision analysis compares favourably with the other techniques. The theory is -
to a certain level- intuitively appealing, and has a firm mathematical foundation. There are 
practical problems in assessment of preferences for health outcomes, but these will not dissolve 
by choosing another methodology. in our opinion, when there is a difficult choice between 
several uncertain diagnostic or therapeutic management alternatives in patient-oriented. 
decision making, clinical decision analysis tecimiques are called for. 
Notes 
a. 'Decision maker' is an abstract entity. He may be represented by the treating physician(s), by the patient, or 
both. 
b. This statement is an informal expression of odds (0), where 0 = p/(l- p) eo p = 1/(1 +(110)). 
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c. Using the n.orma.l approximation of the binomial distribution, one takes the mean J.L = p and standard deviation 
a ~ ..,Jp • (1- P y., 0.01 HJ.067. As a rule, the normal approximation should only be used when p xN > 5. 
d. The F-sto.tistic approach would lead to an estbnoted 95% confidence interval of 0.019 .. (J.074. 
e. Except for extreme situations: When a predictor estimates the risk ofa certain event at 10-', and the event occurs, 
then he can be called poorly calibrated, at least, more poorly then someone who estimated the risk of that eDent 
at OS. 
f. A rate is an epidemiological term, denoting the number of events divided by the number of patient-years at risk. 
It is equal to the l=d rate under the assumption of a constant annual risk (an exponential functian with 
proportion survi'ving(at risk, without event at time t S, =e-i", where A. is the (hazard) rate, equal to I/J.L, the 
inverse of the expectation of t. For small annual probabilities ({P, = S,-Sl ... l} < 5%), PI equals A. 
g. Meningitis is a general term for inflammation of the meninges, i.e. the membranes that CCYOer the brain. 
h. The gold standard should be regarded in relation to the purpose of the study. For example, carotid angiography, 
although not perfect is accepted as a gold sto.ndard for the assessment of carotid stenosis, because of the 
evidence that a relation exists between the degree of stenosis as determined by this procedure, and the effec-
tiveness of carotid endarterectomy. Thus, the choice of a gold standard is in itself a pragmatic one. 
i. This is sometimes referred to as "independent" or "idiot" Bayes, because interdependence of test results is not a 
consideration. 
j. This approach can be convenient when the attributes are difficult to compare,for example when a diagnostic test 
is done that causes slight inconvenience, when there is a low probability of serious, but treatable illness. Not 
only the absolute, but the incremental risks and benefits however, are of interest. Still, an acceptable (in-
cremento.l) risk .. benefit ratio has to be defined anyway, before a decision can be made. 
k. Consider two strategies, A and B, both leading to a one attribute, three level (Sl, S2,; SJJ outcome, where 
U(sJ > U(s.,J > U(s;) with probabilities PA(Sl) ~PO(Sl) and PA(s, v sJ >PO(SI v sJ Under these conditions 
there is dominance of A over B, and strategy A is always preferred over strategy B. 
I. Because of the link with probability calculus, a scale of 0 .. 1 is preferred. The utility scale has the properties of an 
intercal scale. Transformations of the form zf =au+b are allowed. 
m. However, this would only be a problem when patients would not yet be fully informed of their condition. See 
also the Discussion (Chapter 11). 
n. In this figure the utilities were adjusted to a scale of 0-1, but in many applications (including those in the 
following chapters) this is not done when the underlying natural scale consists of life years. 
o. Regret is by some - but not in this study - used with the meaning of utility loss. 
p.ln the analysis the mortality and morbidity of clipping are linked by the formulo. P(Mb) ~ 2xP(Mt)+O.02 
q. This rate was adjusted for life table mortality due to myocardial infarction. 
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Chapter 3 
A review of decision analyses in the 
clinical neurosciences 
Oinica! decision analysis is increasingly recognized as a useful scientific tool for the 
management of individual patients, for the planoing of research, and for consensus meetings 
and development of practice guide-lines.'" Since the publication of the first applications of 
decision analysis in the early sixties and seventies, the theory has gained wider acceptance. 
The methodology has now matured~ and several interesting applications in the neurosciences 
that are of practical value to the thoughtful clinician have now been published. The number 
of papers on neurological subjects is steadily growing. A review of applications in the neu-
rosciences is therefore appropriate, the more so because the studies cover many sub-specialties 
(neuro-opthalmology, neuro-oncology, etc.) and some have been published in 
not-so-well-known journals. In this chapter the results of a systematic search for applications 
of decision analysis in the neurosciences is presented. This review gives an impression of the 
area that has been covered by the analyses, their methodology, applicability and their up-to-
date-ness. 
3.1 Methods 
A clinical decision analysis is a study that explicitly addresses the inevitable uncertainties 
in a clinical problem and combines these with preferences for health outcomes in a consistent 
framework that obeys the laws of probability calculus and subjective expected utility theory, 
leading to a management advice for an individual patient, or for a group or type of patients. 
Articles dealing with decision analysis (Le. prescriptive clinical decision making) in the 
neurosciences were either gathered from one of the recognized bibliographies60,206.212,.216,396 or 
from a MEDLINE search, using the search strategy depicted in Figure 19. The Mesh words 
DEOSION rnEORY, DEOSION TREES, DEOSION ANALYSIS and DEOSION SUPPORT TECHNIQUES were 
introduced between 1980 and 1988. Before 1980, articles dealing with (the application of) 
decision analysis could mostly be found under DEOSION MAKING, COMPUTERIZED and BAYES' 
rnEOREM. 
Each selected paper contains a decision analysis that results in a clinically relevant man~ 
agement advice. Sometimes the clinical problem can be reduced to one of uncertainty only, 
and the application of probability theory is sufficient to derive satisfactory solutions. In other 
instances, it can be shown orit is obvious that preferences for (multi-attributed) health-outcome 
playa role. Then, either subjective expected utility theory, risk-benefit or cost-effectiveness 
analysis is used to weigh the diverse outcomes, see also Chapter 2. 
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Figure 19. Medline Mesh search strategy. 
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In this review, only published studies that address problems in the realm of the clinical 
neurosciences in a clinical or primary care context are considered. Studies analysing mass 
screening (e.g. spina bifida screening)'" and prophylaxis (e.g. addition of vitamins to alcoholic 
beverages)S3 are therefore excluded from this review. Publications that concern flow-diagrams 
and algorithms~ based on consensus~ expert opinion or prediction rules are not considered. 
Thus, undoubtedly valuable, decision-<lriented papers on diagnosis or prognosis only are 
excluded from this review. Abstracts, and studies not written in English are also excluded. 
All studies are assessed on aspects of clinical applicability. This presumes a clinically rel-
evant case and context description and consideration of all possible strategies~ although the 
tree may be pruned from clinically irrelevant strategies. The explicit use of mathematics is not 
necessary for easy clinical application, but makes understanding and checking easier. Some-
times the authors have anticipated on the application of the decision analysis on other~slightly 
different patients, for example by taking into account age and severity of symptoms. This will 
be called the "extendibility" of the analysis. When the decision analysis makes use of diagnostic 
or prognostic rules, it is important that the authors have considered transferability to other 
settings, where the relative incidences of disease may differ considerably. Of course, as clinical 
knowledge and understanding progresses~ the advice from a decision analysis may become 
outdated~ either because new clinical-epidemiological information on diagnosis~ prognosis or 
treatment effects has become avaiIable~ or because new diagnostic or therapeutic strategies or 
techniques have emerged. 
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3.2 Results 
The aspects that have been mentioned in the methods section will be summarized in Table 
5; each study will be reviewed below. 
Arteriavenous malformatrons 
Conservative treatment is recommended as the appropriate management of unruptured. 
arteriovenous malformations (A VM's) by Jansek)"who applied principles of decision analysis 
to this clinical problem. The time span covered in !ansek's analysis does not extend beyond 20 
years. This results in an underestimate of the life-time risk of rupture, introducing a bias in 
favour of conservative management. Theauthors use a rather high estimateofsurgicalmortality 
and morbidity (10% and 27% respectively), which is based directly on series of patients with 
ruptured A VMs. Again, this is a bias against surgery. Preferences for future life years are not 
considered. The possibility of incomplete extirpation is ignored. We conclude that this analysis 
recommends conservative management without good justifica tion, although it provides basic 
insight into the problem. 
Aminoff's analysisS,9 is a Simplification of the analysis of Iansek.184 Oinical characteristics 
of the patients are not described, and age is nota variable in the analysis. Thus, the main clinical 
considerations are left out of the model. Probability estimates are taken directiy from the lit-
erature. Duration of survival was not incorporated in the outcome values ie. mortality and 
morbidity from haemorrhage was given the same values as mortality and morbidity from 
surgery, despite the fact that the latter are immediately occurring events. We conclude that this 
study has simplified the decision problem to such an extent that it is not possible to make 
meaningful inferences. 
FIsher used decision analysis to review the management options for unmptured A VM's. 
He ignored the possibility of unsuccessful surgery and assumed that a bleeding A VM will 
never be treated surgically. The author uses average values from the available literature for 
risks of surgical mortality !morbidity and for mortality and morbidity of haemorrhage. A rather 
high annual rate of first haemorrhage (2.5% instead of2.0%) is used. Most of these assumptions 
introduce a bias in favour of surgery,'" although the high estimates of surgical risks partly 
compensate this bias" Anyhow, one should be careful when drawing conclusions from this 
analysis. 
Auger13 described a decision analysis of the management of patients with unruptured 
arteriovenous malformations, using comparable assumptions as in Chapter 7. However, just 
as in Fishe"''' the questionable assumption is made that patients attach a lower (0.95) utility 
value to life with an unruptured AVM before operation, than after successful operation." 
Without this assumption, the difference in expected utility between operation and no operation 
decreases with 1.5 QALY to less than 1 QALY, even for young patients, according to this 
analysis. None of the studies considered radiosurgery explicitly. 
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Carotid stenosis 
An early study of O'Donne! compares the test accuracy of non-invasive procedures with 
angiography in the diagnosis of carotid stenosis,'" using ROC analysis. The authors conclude 
that combinations of ~ some now obsolete- non-invasive tests (Doppler ultrasound, carotid 
"phonangiography" and oculoplethysmography) should be used to increase sensitivity. Their 
informal analysis of risks of angiography and of treatment effects -necessary to compute a 
cut-off point-lacks the rigour of their data analysis. 
Jonas' analysis of intact months of patient survival (IMPS) is not a decision analysis, but 
merely a crude method to compare the results of endarterectomy trials.1%.197 However, it 
provides some insight, in that the trade-off between complications and efficacy of endarter-
ectomy is emphasized. 
Matchar's initial analysis of endarterectomy concerned a 55-year old man with verte-
bro-basilartransientischaemicattacksandangina pectoris.2SS Thisquitedetailed analysis shows 
that for the particular patient endarterectomy would improve the quality adjusted life 
expectancy by only a tiny amount. The authors assume that endarterectomy would reduce the 
risk of stroke by 50% during 10 years, quite optimistic for a patient with TIA from the posterior 
circulation. The analysis is extended to a broader group of patients in a separate paper by the 
same authors.254 They arrive at quite detailed guide-lines for patients with low, intermediate 
and high risks of stroke, but do not link these advices with patient profiles. Later, the authors 
analysed non~invasive diagnostic strategies for carotid stenosis, using estimates of test~per~ 
formance from a thorough review of the dinicalliterature, 113 combining these with the original 
analysis. The analysis has been published almost back to back with a position paper from the 
Health and Public Policy Committee of the American College of Physicians that provides 
guide-lines for the management of patients with (a)symptomatic carotid stenosis.l62 
Hankey and Warlowl54 combined their own data on the prevalence of mild, moderate and 
severe symptomatic carotid stenosis with estimates of the sensitivity and specificity of duplex 
ultrasonography. They aimed at determining the most cost-effective diagnostic strategy, 
considering health care costs, the occurrence of disabling strokes after angiography, and per-
centage unnecessary angiographies, the latter depending on the definition of Significant ste-
nosis. Prevented strokes or (stroke-free) survival is not considered as an outcome measure. 
At the time that these studies were conducted, the results of the major symptomatic carotid 
endarterectomy trials,''''''' that suggest a benefit of endarterectomy for patients with a 70%-99% 
carotid stenosis, were not yet known. With the publication of the interim results of these carotid 
surgery trials all previOUS analyses need to be updated. 
Cerebral complications of cardiac disease 
Several decision-analytic studies have addressed the decision to prescribe anticoagulants 
for patients with atrial fibrillation".296 and dilated cardiomyopathy.''' All these studies suggest 
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that anticoagulants are indicated for most of these patients. However, low-dose coumarines 
and aspirin""" are considered only by Naglie"', who concluded that the decision to prescribe 
anticoagnlants was sensitive to plausible changes in estimates of the dis-utility of long-term 
treatment. Secondary prevention of stroke in (old) patients with atrial fibrillation (who have a 
higher risk of stroke, but maybe also an higher risk of haemorrhagic complications) has not 
been studied by decision analysis.' 
The study of Kwoh221, an analysis of the decision whether or not to implant a pacemaker 
in an 85-year-old patient with repeated syncope provides useful insight into a diagnostic 
problem by which a neurologist is also repeatedly confronted. The author complains of lacking 
data, butdoesnotuse his analysis to guide further research. Since the publication of this analysis 
interesting studies on diagnostic factors in syncope have appeared.'" This study elegantly 
illustrates that treatment with an uncertain diagnosis can be more effective from a clinical 
viewpoint than just ordering another test. 
Herpes simplex encephalitis 
Two decision analyses of the management of patients with possible herpes simplex 
encephalitis (HSE) have been published in the early eighties."·" Management options were 
then adenine-arabinoside (Ara-A), brain biopsy or watchful waiting. These analyses have now 
become outdated because of the advent of acyclovir. It isinteresting to compare the quantitative 
assumptions that were made in these studies, because they are based on the same scientific 
information. Only in Barza's pape"" the clinical context is described, which makes the 
assumptions easier to follow. Both authors stress the paudty of data, but Braun emphasized 
the sensitivity of brain biopsy as the great unknown, whereas Barza thinks that first of all more 
information about the toxidty of Ara-A is needed. The computed treatment thresholds are not 
very different (24% and 40%). However, the management advices that are based on these 
analyses are worded quite differently. Braun" advises direct treatment with Ara-A, whereas 
Barza" suggests that brain biopsy is the best approach in the majority of patients. A problem 
in interpretation is again that patient profiles are not linked to the risk of suffering from HSE. 
Braun mentions that brain biopsy has the advantage of diagnosing other treatable disease, such 
as toxoplasmosis and tuberculosis, but he does not consider this explicitly. Sa"wyeras considers 
treatment with acyclovir instead of Ara-A. As acyclovir is less toxic and more effective, only 
the possibility of other treatable causes of encephalitis is a justification for brain biopsy. The 
analysis suggests that for patients with a low CSF glucose biopsy results in a higher chance of 
complete recovery, but in patients with unknown ornonnal CSF glucose, the dilemma whether 
or not to do a brain biopsy results in a toss-Up.207 A systematic analysis of (combinations of) 
other diagnostic tests than CSF glucose was not carried out. The use of polymerase chain 
reactions has not been considered.269 
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Intracranial aneurysms and subarachnoid hemorrhage 
Levey'" reported an analysis of the decision to screen with angiography for occult intra-
cranial aneurysms in patients with polycystic kidney disease. A rather high (2%) annual risks 
of rupture, but a low risk of grave complications from subarachnoid aneurysmal haemorrhage 
(37%) was assumed. Parameters that appeared crucial to the results of the analysis were the 
prevalence of intracranial aneurysms in this group of patients (estimated from autopsy studies 
at 30%(9'1'0-30%), and surgical risks. According to this analysis the benefit of screening 
amounted to 1.2 years (2.5% of the total life expectancy) for patients aged 20, decreasing to 
almost zero for patients aged 70. The authors conclude that the benefit of screening is so small 
that it cannot be recommended. 
Interestingly, Chapman"reported a study of 88 patients with polycystic kidney disease, of 
whom 60 underwent high resolution contrast enhanced cr scanning, 21 angiography, and 11 
both procedures. In four patients, anewysms were discovered, for a prevalence of 4%, con~ 
siderably lower than the estimate in Levey's study.'" However, many aneurysms may have 
remaIned undetected, which is also suggested by the low yield from cr (2 aneurysms in 60 
patients) as compared to angiography (2 aneurysms in 32 patients). The authors defended the 
choice of cr scanning as the primary investigation by referring to the risk of complications 
from angiography, a factor that has been proven by Levey'" to be of minor importance to the 
decision to screen. Moreover, the authors pose the unsustained conclusion that screening every 
5-10 years for occult aneurysms is justified for all patients with polycystic kidney disease, totally 
neglecting the results of the decision analysis. In an accompanying editorial this study has 
raised some critical comments.404 
Van Crevel'" described a decision analysis of the management of a 45-year old hypothetical 
female patient, in whom an 8 mm left middle cerebral artery aneurysm was found by angio-
graphy. The risk of aneurysm rupture and its consequences was compared with the risk of 
elective surgery, using discounted quality adjusted life expectancy. The authors give 
recommendations for the management of similar patients of other age, with other surgical risks. 
This analysis forms the basis of several other decision analytic studies (see also Chapters 4,5 
and 6)."'''''''' 
Auger" reported a decision analysis of the management of unruptured intracranial aneu-
rysms that is qulte similar to our studies (Chapter 4 and Chapter 5). However, no surgical 
mortality was assumed, the risk of aneurysm rupture was estimated at an annual rate of 4%. 
1bis estimate is based on one personal series402 and disregards the other evidence,189,198 that 
suggests a lower rate of apprOximately 1 %84 see also Chapter 2. Life with an unruptured 
untreated aneurysm is valued at 0.975 of a life in full normal health, an assumption that is 
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already discussed previously. The value of years of survival in the near is the same as in the 
distant future. These questionable assumptions favour surgery, but they are not extensively 
studied by a sensitivity analysis. 
Van der Meulen'" used decision analysis to investigate whether cerebral angiography is 
indicated in patients with clinically definite infective endocarditis, in order to detect mycotic 
aneurysms before rupture occurs. The authors conclude that for most patients angiography 
decreases the survival probabilities, because surgical treatment of a detected mycotic aneurysm 
is more harmful than medical treatment only. 
McNutt:'''' described a decision analysis of the management of a 87-year-old woman with 
aneurysmal subarachnoid hemorrhage, who suffered a subendothelial myocardial infarction 
on the fourth day after admission. Five strategies are compared, operate lrnmediately, after 
one, two or three weeks, or never operate, balancing the increased risks of surgery against the 
risk of rebleeding, using a time horizon of four weeks. No specific assumptions are made about 
the other factors affecting prognosis, such as delayed cerebral ischemia, hydrocephalus and 
mortality from other causes, but this may be regarded appropriate here, according to the 'sure 
thing principle' (see Chapter 2, section 23). It was concluded that as the opportunity for 
lrnmediate surgery (the best choice according to the analysis) has already passed, never operate 
was the preferred option. Tranexamic acid however, was not considered.. 
FJeminglZl used decision analysis to explore possible management options in a 34-year-old 
woman who awoke four days after delivery of a healthy baby girl with a bi-occipital headache, 
had a grand mal seizure, and experienced. complete loss of vision when she regained con-
sciousness. A computed tomographic scan of the head showed no blood, but a cisternal tap 
revealed bloody liquor. Spectophotometry was not performed, but might have taken away the 
suspicion of subarachnoid hemorrhage. Other conditions were deemed unlikely. Four-vessel 
angiography was carried out, but the procedure was aborted because of transient ischemia, in 
the territory of the left middie cerebral artery. In the analysis a strategy of watchful waiting 
was compared with angiography for detection of an intracranial aneurysm, on the basis of 
quality adjusted life expectancy. Fear of repeat angiography was explicitly considered in the 
analysis, quantified as the amount of life expectancy the patient would be willing to forgo to 
avoid angiography. The probability of aneurysmal subarachnoid hemorrhage as the cause of 
the patient's complaints was taken at 5%. The possibility of finding an asymptomatic aneurysm 
on angiography (population prevalence for a patient of this age: 0.5%-2%), leading to wrong 
conclusions about the risk of haemorrhage, was not considered. 
Multiple sclerosis 
Hische'" used logistic discriminant analysis to estimate a likelihood ratio as continuous 
function of the IgG index from a sample of patients with multiple sclerosis and a group of 
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patients with <liseases that are likely to cause problems in differential diagnosis. The gold 
standard for the diagnosis of multiple sclerosis is based on clinical criteria only,'" instead of 
prolonged observation. An easy-te-use nomogram is presented that relates the prior probability 
of multiple sclerosis and the IgG index to a posterior probability. 
lansek184 and Kempster"" assessed the diagnostic impact of visual evoked responses and 
CSF analysis on the management of patients with one spinal lesion. They conclude that in 
certain cases CSF analysis and myelography can be omitted in favour of a policy of follow-up, 
but they only analyze diagnostic probabilities and not the (dis-)utility of erroneous diagnosis. 
Magnetic resonance imaging (MRI) is not considered. An earlier study of the same group 
describes the diagnostic behaviour of trained neurologists and residents in a case of possible 
multiple sclerosis.18 
Moony's'" cost-effectiveness analysis of the use of MRI in suspected multiple sclerosis was 
meant to set priorities for technology assessment research in multiple sclerosis. The authors 
conclude from their analysis that study of the test characteristics of MRI, but most of all of the 
effects of resolving uncertainty in the diagnosis on well-being in patients with suspected 
multiple sclerosis is most welcome. However, the authors assumed a quality-adjustment factor 
ofO.S for the timespent'labelled multiple sclerosis, without further symptoms' which isdifficuJt 
to relate to patients' preferences for health outcomes under conditions of uncertainty. 
The study of Mushlin"" is a rigourous ROC analysis of the accuracy of MRI in the diagnosis 
of multiple sclerosis. Management alternatives, i.e. no diagnostic imaging, contrast enhanced 
Cf, and other diagnostic entities are only mentioned in the discussion, but not extensively so, 
anda case and context description is not provided. Therefore, this study is not further included 
in this review. 
Temporal arteritis 
Several studies have tackled the problem of prescribing prednisone or doing a biopsy in 
suspected temporal arteritis. Elliot's decision analysis'l7l does not present a typical patient and 
does not descnoe the clinical setting. which makes its clinical applicability limited. Moreover, 
only monetary costs are used as an outcome measure, and not patients' preferences, which 
further hampers its usefulness in a clinical setting. Two large series of patients with temporal 
arteritis became available after the publication of this analysis.l63,325 They were included in the 
analysis of Nadeau2S1, whose study does not suffer from the problems mentioned above. 
However, questionable utility assumptions were made (i.e. that the utility loss from steroid 
complications is valued twice the utility loss from untreated temporal arteritis, without spec-
ifying a basis for this crucial assumption. The strategy "no treatment, no biopsy" is not formally 
evaluated. Chang's analysis compares risk-benefit ratio's of the management of patients with 
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polymyalgia rheumatica and suspected arteritis temporalis." The study is up to date and 
recommends that patients without signs of aanial arteritic symptoms should not be given 
steroids. 
Other neurologic conditions 
Acosta'analysed diagnostic strategies using Cf, angiography and perimetry in patients 
with unexplained loss oivision, in order to distinguish hemianopsia from monocular blindness. 
According to the analysis, the most cost-effective strategy consists of performing (repeated) 
perimetry, until progressive blindness or hemianopsia develops. In the analysis individual 
patient characteristics are not included, nor is the context or clinical setting described. 
Balla" proposed an algorithm in which asymptomatic patients with head-injury should 
undergo skull x-ray, and only undergo Cf -scanning of the brain when a fracture is visible. The 
author estimates that 3% of the patients with a skull fracture have an intracranial haematoma 
(ICH), and thatforevery patient with ICH thus detected 1400-1650 skull x-rays and 40 Cf scans 
will be necessary. Whether this suggested approach can be called "cost-effective" depends on 
the mortality and morbidity that is averted. But this has not been estimated. 
Bardy"used Bayes' theorem to compute theprohability of finding a mass lesion in patients 
who present with a first seizure. Several diagnostic factors such as age of the patient and family 
history were not considered. No utility asswnptions were made. 
Carrera" estimated the cost of finding cases with treatable disease by computed tomo-
graphy among patients with headache or temporal lobe epilepsy and a normal neurological 
examination. They do not go beyond this rather crude analysis by -for example- considering 
the utility of false-negative and false-positive examinations, or the benefit of treatment. 
The group of Bolhuis33 and Defesche"used Bayes' theorem in the differentisl diagnosis of 
(autosomal recessive) spinal muscular atrophy and (X-linked recessive) Becker muscular 
dystrophy. They elegantly showed how probabilistic information changed the intuitive con-
dusionsabout the most likely diagnosis, which had profound implications, because a pregnant 
sister of the patient under consideration needed genetic counselling. Assessment ofdystrophin 
or the dystrophin gene was not considered. 
Eckman" considered the prophylactic treatment with chemotherapy in a 47-year-old man 
with Eaton-lambert syndrome and a negative Cf-thorax and bronchoscopy. They concluded 
that given the available data on the risk of developing small cell lung cancer, and the effec-
tiveness and toxidty of therapy, a waiting strategy is better for all presumable likelihoods of 
cancer. 
Joffel94 used logistic discriminant analysis in series of children with convulsions and fever, 
to find diagnostic factors indicative of meningitis. Selecting children with either an abnormal 
neurologic examination or a focal seizure, or a previOUS visit to a physician (!) resulted in 100% 
sensitivity witha low spectfidty (62%). The authors conclude that children without any of these 
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signs can do without an LP. However, no independent validation of the study results was 
obtained. Although the study was aimed at finding ways to make the lumbar puncture 
unnecessary, a formal comparison between the risks and discomfort associated with LP, and 
its benefits was not made. In a more recent retrospective analysis Offringa286 arrived at similar 
conclusions. 
Kenrs study"lOis an ROC analysis of reported study results on the diagnostic accuracy of 
MRI, cr and myelography in the diagnosis of spinal lumbar stenosis. No definite management 
advice could be given, as the authors considered virtually all studies inconclusive, mostly 
because of methodological shortCOmings. 
Levin230 analysed the diagnostic management of optic nerve tumours with MRI and cr in 
children using Bayes' theorem, and suggests an approach that is based on clinical information 
and cr scanning. Tables with prior probabilities of meningeoma, glioma, and the predictive 
value of clinical and radiographic diagnostic tests are presented. 
liang'" computed the amount of radiation used and the cost in dollars per day of suffering 
averted when ordering x-rays for patients with acute low back pain in a primary care setting. 
He concludes that for patients who have a normal physical and neurolOgical examination, the 
risks and costs of ordering roentgenograms do not seem to justify the relatively small benefit 
Magid's"7 cost-effectiveness analysis of prevention of Lyme disease after tick bytes con-
sidered prophylactic treatment or careful follow-up, c.q. serologic testing. The costs and risks 
of treatment are low. The analysis suggests that patients with a risk of infection exceeding 3.6% 
should receive prophylaxis, and when this risk is lower than 1 %, treatment is not necessary. 
The authors discuss the problem of estimating the risk of infection in a patient with a tick-bite, 
but they do not summarize their recommendations in this regard. A randomized trial of pro-
phylactic treatment after tick bite against placebo yielded non-conclusive results. These two 
studies are complementary, as the risk of infection was very low (1.2%) in the placebo treated 
group.'" 
McNeil'" illustrated how cost-effectiveness calculations help in deciding about the use of 
laboratory testing (theradiobromide-partition test)b and more effective treatment (rifampicin) 
for possible tuberculous meningitis in developing countries. 
Schipper'" showed that the diagnostic performance of cr and myelography for detection 
oflumbar herniated disk is comparable, and argues that cr should be the investigation of first 
choice, because of its non~invasiveness. 
Simon344 analysed the cost--effectiveness of CT investigation of demented patients, and 
concludes that the cost-effectiveness of cr, but not of MRI compares favourably with other 
health-care interventions. Unfortunately the author does not adjust the crude prior probability 
of treatable lesions for the many assumptions about his patient in his analysis. 
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Wiesel"" compared routine treatment with intramuscular penicillin to LP and intravenous 
penicillin in patients with latent syphilis. The latter strategy increases the estimated cure rate 
from 99.7% to 99.9%, at the expense of 0.3% mostly transient complications. The author does 
not go beyond a comparison of these risks, although he suggests that on the basis of these 
results CSF examination in asymptomatic late syphilis can be done without. 
Zarin'18 computed in an elegant analysis the risk-benefit ratio of initiating lithium therapy 
after a first or second attack of manic-depressive disorder. Outcomes are expressed in time on 
lithium per attack avoided. Carbamazepine and other Uess toxic) treatment modalities'27,134 
were not considered. 
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Table 5. Decisioll analyses in the ciinicalneurosciences. Legend: TY: type of analysis (RI = risk analysis, RB = risk-benefit analysis, RO = ROC 
analysis, CE = cost-effectiveness or cost-benefit analysis, U = lIIi1ity analysis); CA: case description; CX: colllext description; CL: complete-
ness; EX: extendibility; UD: IIp-to·date-ness (T= new technology, E = new evidence). 
Author Year Ref. Condition Strategies TY CA CX CL E UD 
Acosta 1981 2 Sudden blindness CT; angiography; perimetry CE N N N Y 
Aminoff 1985 8,9 Arteriovenous malfonnation Surgery or not U N Y Y TIE 
Auger 1992 13 Arteriovenous malfonnation Surgery or not U N Y Y Y Y 
Auger 1991 13 Intracranial aneurysm Surgery or not U N Y Y Y T 
Balla 1984 17 Head injury Skull x-ray or not R N Y Y Y Y 
Bardy 1991 22 First seizure Cfor not R N N N E 
Barza 1980 24 Herpes encephalitis Biopsy; Ara-A; no treatment R Y Y Y Y TIE 
Beck 1981 25 Atrial fibrillation Anticoagulation or not U Y Y Y Y Y 
Bolhuis 1987 33,78 Hered. neuromuscular disease Genetic counselling R Y Y Y N T 
Braun 1980 43 Herpes encephalitis Biopsy; Ara-A; no treatment R N N Y Y T 
Carrera 1977 50 Temporal lobe epilepsy CTor not CE N Y N Y 
Chang 1983 58 Arteritis temporalis Biopsy; corticosteroids, no treatment RBN Y Y Y Y 
Dippel 1992 86,367 Intracranial aneurysm Angiography or not U Y Y Y Y Y 
Eckman 1986 98 Eaton-Lambert syndrome Prophylactic chemotherapy or not U Y Y Y Y Y 
Elliot 1983 107 Arteritis temporalis Biopsy; corticosteroids; no treatment CE N N Y Y 
Fisher 1989 121 Arteriovenous malfonnation Surgery or not U N Y Y N TIE 
Chapter 3 
Table 4. (Continlled). 
Author Year Ref. Condition Strategies TYCACXCLE UD 
Fleming 1988 123 Subarachnoid haemorrhage Angiography or not U Y Y Y N E 
Hankey 1990 154 Carotid stenosis Duplex; auscultation; angiography CEN Y Y N E 
Iansek 1983 185 Aneriovenous malformation Surgery or not R N Y Y N T 
Iansek 1985 184,209 Multiple sclerosis Myelography or not U Y Y Y N T 
Joffe 1983 194 Febrile seizures Lumbar puncture or not R N Y Y N E 
Kent 1992 210 Lumbar spinal stenosis MRI, CT, myelography RO N Y Y N Y 
Kwoh 1984 221 Syncope Pacemaker or not CE Y Y Y Y Y 
Levey 1983 229 Intracranial aneurysm Angiography or not U N Y Y Y Y 
Levin 1991 230 Optic nerve tumour MRI; CT R N Y N N Y 
Liang 1982 231 Low back pain Lumbosacral x-ray or not RB N Y Y Y Y 
Magid 1992 247 Lyme disease Prophylaxis after tick bite or not CEY Y Y Y Y 
Matchar 1988 113 Carotid stenosis Non~invasive testing U Y Y Y Y E 
Matchar 1986 254,255 Carotid stenosis Endanerectomy or not U N Y Y Y E 
McNeil 1980 261 Tuberculous meningitis Clinical assessment vs bromide test CE N Y N Y 
McNutt 1987 263 Subarachnoid haemorrhage Surgery or not R Y Y N N Y 
A review of decision analyses in the clinical neurosciences 
Table 4. (Continlled). 
Author Year Ref. Condition Strategies TY CA CX CL E UD 
Moony 1990 278 Multiple sclerosis MR1 or not CE N Y Y Y Y 
Nadeau 1988 281 Arteritis temporalis Biopsy; corticosteroids U N Y N Y Y 
Naglie 1992 282 Atrial fibrillation Warfarin; aspirin; no treatment U N Y Y Y Y 
O'Donnel 1980 285 Carotid stenosis Non~invasive testing RO N Y Y N E 
Offringa 1992 286 Febrile seizures lumbar puncture or not R N Y Y N Y 
Pauker 1986 296 Atrial fibrillation Anticoagulation or not U N Y Y N Y 
Sawyer 1988 335 Herpes encephalitis Biopsy; Ara~A; Acyclovir; no treatment R Y Y Y Y E 
Schipper 1987 338 Lumbar herniated disk Cf; myelography; both R N Y Y T 
Simon 1985 344 Dementia Cf; magnetic resonance imaging; none CE N Y N N Y 
Ter Berg 1992 366 Arteriovenous malfonnation Surgery or not U Y Y Y Y Y 
Ter Berg 1988 365 Intracranial aneurysm Surgery or not U Y Y Y Y Y 
Tsevat 1989 376 Dilated cardiomyopathy Anticoagulation or not U N Y Y Y Y 
Van Crevel 1986 382 Intracranial aneurysm Surgery or not U Y Y Y Y Y 
Van der 1992 385 Mycotic aneurysm Angiography or not R Y Y Y Y Y 
Meulen 
Wiesel 1985 405 Asymptomatic late syphilis Lumbar puncture or not R N Y Y Y Y 
Zarin 1987 418 Manic-depressive disorder Lithium therapy or not RBN Y Y Y Y 
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3.3 Discussion 
Forty-seven decision analyses of 28 different management problems in the clinical neu-
rosciences were identified. Figure 20 shows how the numberof decision-analytical applications 
in neurologyissteadily growing. Nineteenanalyses employed the theory of subjective expected 
utility, nine used costo.ef:fectiveness analysis, two used ROC analysis, and seventeen studies 
were risk-, or risk-benefit analyses. 
The decision analyses were analyzed on aspects of clinical applicability. Twenty-seven 
analyses lacked a case-description, and four studies did not even disclose a context, although 
they were supposed to give specific advice about medical management Obviously, this poses 
a constraint on applicability: Confusion about the application of a decision analysis can often 
be avoided with a descriptive branch that precedes the first node in the tree and provides a 
clinically re1evantcontext and case description. This branch serves asa reminder that the results 
of a decision analysis should be applied to individual patients .. 
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Figure 20. Published decision analyses in the clinical neurosciences. 
Extendibility is more than a graph of prior probabilities with delineation of test and 
treatment thresholds. in eighteen studies the authors had not advised the reader at all how to 
extend the results of the analysis to patients with (slightly) different clinical profiles. Progress 
in clinical research is fast. It is sometimes a matter of years before an analysis becomes outdated, 
either because new technology has been developed and introduced, or because new knowledge 
of prognosis, diagnosis and treatment effects has been produced. Seventeen studies at last were 
clearly not up-to-date, because of these reasons. These studies concern ten clinical problems 
(arteriovenous malformations, febrile seizures, subarachnoid haemorrhage, herpes 
encephalitis, lumbar spinal stenosis, hereditary neuromuscular disease, carotid stenosis, 
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multiple sclerosis, herniated disk and manic-depressive disorder). A new, updated analysis 
by different authors has been published for the first four conditions, and in the case of multiple 
sclerosis ("singularspinal sclerosis")l84 a decision analysis (but nota cost-effectivenessanalysis!) 
has been made superfluous by the availability ofMRL 
Several studies only applied Bayes' theorem on estimates of prior probabilities and test 
characteristics, derived from the literature, although many additional assumptions were 
necessary before a management advice could be given. In several studies the expliot con-
sideration of patients' preferences would have improved the recommendations. The role of 
secondary uncertainty was unclear in many analyses. Sensitivity analyses, let alone 
probabilistic sensitivity analysis was not used. Oearly, there is room for improvement. 
Decision analysis is a tool to generate useful advice in complex clinical decision situations, 
when there are several identifiable management options, with high risks. Carrying out a 
decision analysis requires time, a clear mind and expert knOWledge of the clinical domain. The 
decision analyst should have knowledge of decision-analytic techniques, and should feel 
comfortable in the area of clinical epidemiology and biostatistics. The availability of adequate 
computer resources and a database of the clinical literature is almost obligatory. 
Althougha large spectrum of diseases in clinical neurology has beencovered by theanalyses 
discussed here, the group of heredo-degenerative disease has apparently not drawn much 
attention, perhaps because of the lack of therapeutic possibilities. However, difficult diagnostic 
decisions with implications for genetic counselling have to be made in this area. Other areas 
that would benefit from decision~analytic research effort include in our opinion: management 
of cervical spondylotic myelopathy, perhaps in combination with a randomized clinical trial 
of surgical treatment,'" the diagnostic management of patients with progresSive polyneuro-
pathy and the diagnostic and therapeutic management of patients with lumbar spinal stenosis. 
From the 51 classic dilemmas in the clinical neurosciences compiled by Warlow and Gar~ 
field""" more than half cannot be solved by just carrying out a large randomized trial, either 
because individual variability is large, and the disease in question comparatively rare, or 
because a very long-term follow-up would be required to obtain valid results. Only a few of 
theseha ve been adequately addressed by decision anaiysis. Evidently, thereis still a lot of work 
to do. 
Notes 
a. Koudstaal Pl. Personal communication. 1993. 
b. The radiobromide-partition test measures the distribution between serum and CSF of intravenously injected 
"Er. It has a sensitivity of approximately 90% and a specificity of85%, when a cut-off ratio of1.6 is used. 
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Transient ischaemic attacks, carotid stenosis 
and an intracranial aneurysmO 
Carotid angiography for transient ischaemic attacks may reveal an unruptured aneurysm 
of the circle of Willis. This is not surprising, because the prevalence of unruptured aneurysms 
in these patients is at least 0.5%, but probably several times higher.25M12 The combination of an 
unruptured aneurysm and a stenotic or ulcerating symptomatic carotid lesion causes a man-
agement problem that will be analyzed using decision theory. There are two surgical options: 
aneurysm surgery and endarterectomy. These can be combined into 4 strategies, each with its 
own benefits and risks: 
1) Wait (no carotid endarterectomy and no dipping of the aneurysm). 
2) Aneurysmsurgery, to prevent subarachnoid haemorrhage (and -insomecases- to prevent 
stroke as well). 
3) Carotid endarterectomy, to prevent stroke. 
4) Carotid endarterectomy and aneurysm surgery to prevent both stroke and subarachnoid 
haemorrhage. 
Each of the strategies can becombined with acetyl-salicylic acid (ASA), making the total number 
eight. 
Surgery of unruptured aneurysms and endarterectomy for symptomatic carotid artery 
disease have been the subject of previous decision analyses.2S4.3S2 In the unruptured aneurysm 
problem, the decision for surgery depends mostly on the cumulative risk of rupture (and 
therefore, on the age of the patient) and on the surgical risks. For endarterectomy a similar 
trade-off between surgical and long-term risks can be made. Until recently, a beneficial effect 
of endarterectomy for patients with a symptomatic carotid lesion was not established. The 
preliminary results of two large randomized trials indicateabeneficial effect of endarterectomy, 
but only for patients with a stenosis of 70% or more.110,l16,220,284 For the patients in the present 
analysis the benefits of both procedures are reduced, because the life-expectancy is shorter as 
a result of co-existing disease. Furthermore, endarterectomy is not indicated when the TINs 
are caused by thrombo-embolism from the aneurysm, making dipping doubly effective 
because both the risk of stroke and SAR will be reduced. At last, even the prescription of 
acetyl-salicylic acid (ASA) needs careful consideration, as it may lead to more severe compli-
cations from SAR. 
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4.1 Patients and methods 
Patients 
Three patients with the above mentioned combination oflesions will be discussed, all from 
the neurological department of the Dijkzigt Hospital in Rotterdam. The clinical characteristics 
of the patients are summarized in Table 6. The first patient will be used as a "key-patient" to 
illustrate our analysis. This 63-year-old man had an attack of transient blurring of vision of the 
right eye, four weeks before admission. Apart from complaints of dysbasia he was in excellent 
condition. Neurological examination was unremarkable. Blood pressure was 170/80, BeG, 
chest X-ray, routine blood samples and computed tomography of the brain showed no 
abnormalities. Four-vessel cerebral angiography revealed a 50% stenosis of the right internal 
carotid artery at the bifurcation and a 4 mm aneurysm of the right middle cerebral artery. 
Amaurosis fugax cannot be explained by an aneurysm of the middle cerebral a~ery, but in 
patient 2, and less so in patient 3 thrombo-embolism from the aneurysm as well as from the 
carotid lesion may have caused the TINs.'13 
Table 6. Clinical characteristics of the three patients. 
Key-patient Patient 2 Patient 3 
Patient 
Age 63 58 69 
Sex male male male 
Carotid lesion 
Location right bifurcation left bifurcation right ICA 
Desree 50% stenosis ulcerating plaque 50% stenosis 
Aneurysm 
Location rightMCA leftMCA right PCoA 
Size 4mm 10mm 5mm 
TlA 
Symptoms amaurosis fugax hemi-paresthesias hemiparesis 
Ukelihood that the IA 
caused the TIA 0% 50% (25-75%) 25% (5%-50%) 
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Decision analysis 
Decision analysis consists of identification of the available management strategies, 
determination of the possible events and health states resulting from each strategy and 
quantification of the likelihood of these events and health states. Then follows for each strategy 
the computation of the survival distribution and the life expectancy in each health state. The 
life expectancy can beadjusted for quality of life, and for time preferences by discounting future 
life years. The strategy with the highest life expectancy should be considered as good advice. 
Sensitivity analyses are used to examine the influence of plausible changes in each estimate on 
the life expectancy of each strategy and to examine the simultaneous effect of the uncertainty 
in all estimates in a full Bayesian analysis,l42,216,396 see also the results section. 
The basic assumptions may be illustrated by a decision tree, see Figure 21. The choice 
between 'Wait', 'Aneurysm surgery', 'Endarterectomy' or both' Aneurysm surgery and 
endarterectomy' is represented in this tree. The second choice, the prescription of acetyl-sali-
cylic acid CASAl is not represented in the tree, in order to avoid unnecessary duplication. 
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Legend to Figure 21. Decision tree for the management of patients with T1A's and an unruptufed intracranial aneurysm. 
SeIlemaDc representaDon of s~alegies: 'Wait; 'Aneurysm surgery', 'Endarterectomy' and 'Aneul)'sm surgery and endarter-
ectomy', All strategies can be combined with ASA Squares: decision nodes, circles: chance nodes, rectangles: outcome 
nodes. Upper case leners (A-F) refer 10 idenDcaI sub~ees. 
When the strategy 'Wait' is chosen, the patient may suffer a subarachnoid haemorrhage 
(SAB) that results in death, severe Ctisability or recovery, or a stroke may occur, resulting in 
death orCtisability (minor strokes and TINs are not considered). The occurrence of at most two 
events (two strokes, or a stroke and SAB) is modelled in the tree. It is assumed that after a 
non-fatal subarachnoid haemorrhage the aneurysm will be clipped, completely preventing 
rebleeding. In order to simplify the tree for presenta tion, branches representing events 
occurring after one, two, three and more years have been combined into one single branch. 
'Aneurysm surgery' may result in peri-operative mortality or serious morbidity_ After 
successful clipping, SAR is completely prevented. If the TIN sarecaused by thrombo-embolism 
from the aneurysm, clipping will prevent stroke as welL After a non-fatal outcome of surgery, 
ASA can be prescribed. ASA reduces the incidence of Ctisabling strokes and vascular death 
(fatal myocardial infarction and stroke),l1,49,292 but it may increase the risk of complications from 
SAB. The structure of the subtrees with and without ASA is identical but the probability values 
used in the analysis differ. 
'Endarterectomy' carries a risk of mortality and permanent morbidity. After a successful 
procedure, the risk of stroke is reduced. The combined procedure - aneurysm surgery and 
endarterectomy - is carried out in two stages, without appreciable delay_ When aneurysm 
surgery results in permanent morbidity~ no endarterectomy will follow. 
4.2 Available data and estimates 
Based on a review of the literature, best guesses for the parameters in the decision tree are 
made. Because of the uncertainty from lack of knowledge and variability, ranges of values will 
be suggested. The estimates will be summarized in Table 7. 
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Table Z Estimated probabifities for the decision analysis of a symptomatic carotid lesion and an unruptured IA For sources 
see text. 
Key patient Patient 2 Patient 3 
Stroke and myocardlallnfarC1lon 
Annual rate of major non-fatal stroke 3%(2%-4%) 1 % (0.5%-2<'10) 3%(2%-4%) 
Annual rate of fatal stroke 1.5%(1%-2<'10) 0.5% (0.25%-1%) 1.5% (1 %-2<'10) 
Annual rate of fatal myocardial infarction 3%(2%-4%) 2%(1%-3%) 3%(2%-4%) 
Endarterectomy 
Mortality 2"10 (1%-4%) 2%(1%-4%) 2%(1%-4%) 
Morbidity 4% (2<'10--8%) 4%(2%-8%) 4% (2"/0-8%) 
Efficacy 50% (25%-75%) 10% (5% -20%) 50% (25%-75%) 
Subarachnofd haemorrhage 
Annual rate 1% (0.5%-2<'10) 1.25% (.5%-2.5%) 1% (0.5%-2<'10) 
Mortality 55% (50%-60%) 55% (50% -60%) 55% (50%-60%) 
Morbidity 15% (10%-2O%) 15% (10%-20%) 15% (10%-20%) 
Aneurysm surgery 
Mortality 2<'10 (1%-4%) 3% (1.5%-6'l1o) 1% (0.5%-2%) 
Morbidity 8%(6%-12%) 15% (12%-21%) 4% (3%-&1o) 
ASA 
Efficacy (vascular death) 15% (10%-20%) 15% (10%-2O%) 15% (10%-20%) 
Efficacy (non-fatal stroke) 30% (20%-40%) 30% (20%-40%) 30% (20%-40%) 
Increase in SAH mortality and morbidity 5%(1%-10%) 5%(1%-10%) 5% (1'%-10%) 
Subarachnoid haemorrhage 
The annual rate of rupture of an incidental aneurysm, has been estimated at approximately 
1 %.164,189,306,38U09 Rosenom323 suggested a rate of 2% after comparing the prevalence of IA's and 
incidence of SAH, but this is an overestimation in our opinion, because the IA prevalence was 
not adjusted for age. The size of the aneurysm may be related to the risk of rupture."'-"'""'"'" 
Therefore, the annual rate of rupture is taken at 1.25% (.5-2.5%) for patient 2. 
Long-term analgesics use has been suggested as a risk factor for rupture of intracranial 
aneurysms in a matched case-control study of risk factors for presence of lA' S.76 This stud ywas 
not designed to investigate risk factors for rupture of lA's, and there was no control for possible 
confounders.'" Thus, we assume that the risk of aneurysm rupture is not increased by ASA 
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The mortality associated with SAH is taken at 55% (50%-60%) and the risk of irreversible, 
serious disability at 15% (10%-20%). Complete recovery is expected in 30%.7,169""""" When the 
patient is treated with ASA, we estimate that 5% (1%-10%) should be added to the risk of 
morbidity and mortality after SAH. 
Aneurysm surgery 
There are only few data available on the surgical mortality and morbidity associated with 
the clipping of an intact aneurysm. Very low mortality rates (0-2%) were reported in a few 
small series.'''''''''''''''' Because of their size, these studies do not allow detailed study of specific 
risk factors for surgical mortality and morbidity. Therefore, expert opinion was used to assess 
surgical risks in the three patients, see Table 8. Apart from surgical skill and the condition of 
the patient, the rate of surgical complications will depend on shape, size and location of the 
aneurysm. The extent of the carotid lesion was felt to be of minor importance. Again, a wide 
range of plausible values is assumed. 
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Table 8, Results of the decision analysis of a symptomatic carotid lesion and an unruptured IA Highest values for each 
patient and outcome measure are underlined. 
Ufe expeCiancy 
discounted and 
quality quality 
Patients and sllategies unadjusted discounted adjusted adjusted 
Padent1 
Wait 10.50 7.69 10.07 1M 
Aneurysm surgery 1077 1&1 .1.QJl 7.44 
Endarterectomy 10.40 7.60 9.89 7.28 
EndMerectomyand IA surgery 10.65 7.72 9.98 7.28 
Patient 2 
Wait 14.31 9.61 13.99 9.44 
Aneurysm surgery ~ 1Jl.Qg 1457 MZ 
Endarterectomy 14.02 9.40 13.53 9.12 
EndMerectomyand IA surgery 14.96 9.81 14.11 9.27 
Patient3 
Wait 8.40 6.54 8.12 6.35 
Aneurysm surgery ~ ~ ~ ~ 
EndMerectomy 8.26 6.42 7.89 6.16 
Endarterectomy and IA surgery 8.66 6.66 8.28 6.39 
Stroke and myocardilll infarctum 
The annual rate of a major stroke in untreated patients with unilateral symptomatic 
moderate carotid stenosis (like patients 1 and 3) has been estimated at 4.5% (3%_6%).",110;"0.284 
We estimated the mortality froma major strokeat33%, morbidity at 67% .114,llS,116,351,.400In patients 
with threatening stroke myocardial infarction is a common cause of death, about twice as 
frequent as death fromstroke.14,114,11S,116.220Thus, the annual mortality frommyocardial infarction 
is taken at 3% for patients 1 and 3. For patient 2, who has a less severe stenosis than the other 
two patients, these risks are lower, i.e. a 1.5% annual stroke risk and a 2% annual fatal myo-
cardial infarction risk. We assume that treatment with ASA will result in a 15% (5%-25%) 
reduction in the rate of fatal stroke and of fatal myocardial infarction and in a 30% (20%-40%) 
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reduction in the rate of non-fatal disabling stroket conform the antiplatelet triallists' collab-
oration study." It is assumed that the effectiveness of ASA in reducing the stroke rate does not 
depend on the source of the TJA's (aneurysm or carotid artery). 
Endarterectomy 
For patients with a severe symptomatic stenosis the risk of any major stroke is reduced by 
80%, both in the North American Symptomatic Carotid Endarterectomy Trial Collaborators' 
study (NASCET) and in the European carotid surgery trial (ECST). For patients with a less than 
30% symptomatic stenosis in the ECST the procedure does not seem to have any benefit 
Enrollment of patients with a moderate (30%-69%) symptomatic stenosis still continues.""" 
The only other large randomized trial of endarterectomy was conducted almost 20 years ago. 
In the group ofTiA patients, the rate of strokeafteruncomplica ted endarterectomy was reduced 
by two-thirds, but this benefit was neutralized by peri-operative mortality and morbidity.'" 
We estimate the efficacl of endarterectomy at 50% (25%~7S%) for patients 1 and 3, who 
have a 50% stenosis, and at 10% for patient 2, who has an ulcerating lesion without significant 
stenosis. It is not likely that the effect of endarterectomy in individual patients will persist. 
Therefore we let the efficacy of endarterectomy decline to 10% after five years in patients 1 and 
3, and (with a similar rate) to 2% in patient 2. The peri-operative mortality and morbidity was 
taken at 2% (1%-4%) and 4% (2%-8%), respectively. In the two recent multicentre trials the 
surgical mortality was lower (1 %), but these studies represent the work of highly experienced 
surgeonsllO,2S4 After release of the cross-clamp during endarterectomy middle cerebral artery 
blood flow as measured by transcranial Doppler is increased, but probably because of 
auto-regulation, the mean common carotid artery pressure is not.354 We therefore did not 
consider endarterectomy as a risk factor for aneurysm rupture. 
4.3 Results 
Computation of life expectancies 
Patient 1, who is 63 years old, has a life expectancy of 15.0 years according to the Dutch life 
tables," but because of the excess mortality from myocardial infarction, stroke and aneurysm 
rupture his life expectancy would be 10.2 years without further treatment, using the base-case 
estimates. ASA increases the life expectancy with 0.2 to 0.5 years for each strategy. Aneurysm 
surgery and ASA yields the highest life expectancy, 10.77 life years, 0.27 life year more than 
'Wait & ASA'. Howevert for most patients aneurysm surgery is less attractive than suggested 
by crude Iife-expectancies, because it has a risk ofirnmediatedeath. ThIs is illustrated in Figure 
22, that shows the survival probabilities with each of the four ASA...gtrategies for patient 1. 
'Wait & ASk offers the highest disability-free life expectancy for patient 1, but' Aneurysm 
surgery & ASA' offers the highest overall life-expectancy. Therefore health status should be 
taken into account. Each life year spent in disability is weighted with a 'utility' U = 0.75 
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Rgure 22. SUNival and disability free suNivai for /he four strategies with ASA, for /he key pa6enL X·axis: Age in years. 
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(plausible range 0.625-0.875), compared to death (U;O) and a year in normal health (U;1).'" 
This results in a quality adjusted life expectancy (QALE) that is somewhat lower than the crude 
life expectancy. The surgical options are affected more severely by this adjustment because of 
the risks of surgical morbidity. 
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Most patients attach more value to nearby than to distant life years."" An annual discount 
rate of 5% (0%-10%) is therefore used, ie. each further lifeyearis only valuedat95% (90%-100%) 
of the year preceding it. In this way, the unattractiveness of 'immediate risks' is taken Into 
account. For patient 1 discounting decreases the life expectancy of the surgical option more 
than the life expectancy of 'Wait & ASA'. When both considerations are effective, the (dis-
counted quality adjusted) life expectancy of 'Wait & ASA' and 'Aneurysm surgery & ASA' are 
equal. For patient 2, 'Aneurysm surgery & ASA' is slightly better In terms of discounted quality 
adjusted life expectancy, but this benefit strongly depends on the chance that the aneurysm 
causes the TIA's, see the sensitivity analyses. For patient 3, 'Aneurysm surgery & ASA' yields 
the highest discounted quality adjusted life expectancy. The ranking of the strategies for this 
patient is only slightly affected by discounting and quality adjustment. 
Sensitivity analyses 
The Influence of plaUSible changes in the estimates on the dQALE of the strategies is 
investigated. Figure 23 illustrates the toss-up situation with regard to conservative treatment 
and aneurysm surgery for the key-patient Plausible changes in the mortality and morbidity 
from aneurysm surgery, and in the annual rate oHA rupture have a relatively large Influence 
on the difference between aneurysm surgery and conservative treatment. Endarterectomy is 
never the preferred strategy. The benefits of treatment with ASA outweigh its risks (increased 
mortality from SAH) in the three patients. 
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Rgure 23. One-way sensi6vity or influence analysis for the key patient. Dependency of the difference in dOALE between 
'Wait' and 'AAeUrysrn surgery, 'Waft' and 'Endarterectomy' and 'Wait' and 'Aneurysm surgery and endarterectomy' on plaus-
ible changes in estimated probabilities, Positive values favour 'Wait', All strategies include ASA. 
Full Bayesian analysis 
The many strategies, assumptions and variables that have to be considered in this clinical 
problem have made the analysis quite complex. The sensitivity analysis above considered each 
variable separately. An overall statement on the desirability of the available strategies for 
patient I, when the uncertainty in all estimates is taken into account simultaneously, needs a 
full Bayesian analysis."2 For each variable, probability distributions were defined conform 
Doubilet'""2 (see also section 24, Chapter 2). Then, the cumulative distribution functions of 
the difference in expected utility between Wait & ASA' and 1) 'Aneurysm surgery, ASA', 2) 
'endarterectomy, ASA' and 3) 'Aneurysm surgery, endarterectomy & ASA', were estimated in 
a series of 1000 Monte Carlo simulations. Figure 24 shows the 95%-confidence limits for the 
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difference in dQALE between 'Wait & ASA: and thetbreesurgical strategies for the key-patient 
Themean of the difference is equal to thatin the base-case analysis,almost 0 discounted quality 
adjusted life year. 
'7 
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FIgure 24. Full Bayesian analysis, taking into account the uncertainty in all estimates simultaneously. The cumulative dis-
Vibution of the difference in discounted OAL Y (X·axis) between Waft" and 'Aneurysm surgery' (f), 'Endarterectomy' (2) and 
'Endarterectomy and Aneurysm surgery' (3), respectively, estimated in a series of fOOO Monte carlo simulaUons. All 
strategies include ASA Dotted lines show the 95% confidence limits. 
in order to make generalizations of this analysis to other patients, we computed 95% 
confidence intervals from series of Monte Carlo analyses with fixed values for the chance that 
the aneurysm causes the TIA' s,and for the age of the patient Three situations were considered: 
a) the aneurysm cannot be responsible for the TIA's, as in the case of the key-patient, b) the 
TIA'sareequaIly likeIyto be caused by the aneurysm ornot, as in patient2,andc) the aneurysm 
certainly causes the TIA:s. The last situation is important because it reveals the maximum 
benefit to be gained from clipping of the aneurysm. in the computations all other estimates 
were taken equal to those of the key-patient When the probability that the aneurysm is 
responsible for the TIA:s equals 50% or more, the difference between 'Wait and ASA: and 
'Aneurysm surgery and ASA: exceeds 0.5 discounted QALYand is 'statisticaIlysignificant' for 
patients aged 70 years or less, see Figure 25. 
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Agure 25. The influence of the assumption that emboli from the aneurysm cause the rIA's on the decision to clip the aneu-
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4.4 Discussion and conclusions 
Decisionanalysis has been used for three patients with transient ischaemic attacks, a carotid 
lesion and an unruptured aneurysm. A clinically useful treatment advice is obtained from the 
analysis_ FlISt, ASA is strongly advised for all three patients. Endarterectomy cannot be rec-
ommended with confidence, even when the risk of stroke would be very high, the complication 
rate very low, and its efficacy high. With respect to surgical or non-surgical treatment of the 
aneurysm, a toss-up situation exists for patient 1, and surgical treatment of the aneurysm has 
the edge in patient 2. For patient 3 clipping of the aneurysm is strongly recommended, despite 
the gaps in our knowledge. The decision is stable; it is only changed by the three-fold combi-
nation of a low probability of rupture, high surgical mortality and morbidity, and a high dis-
count rate. For patient I, there will be no great loss if one or the other option is chosen, provided 
that platelet aggregation inhibitors are administered. 
Additional considerations may make the decision more clear-cut for patient 1 and 2 We 
did not include minor strokes and transient ischaemic attacks, and we did not consider the 
inconveniences caused by surgery, nor the psychological stress of living with an unruptured 
aneurysm. For a discussion of this latter aspect, see Chapter 11. Some of these factors favour 
surgery, others not However, when one is forced to make a decision it would not be logical to 
choose the option with the lowest dQALE. 
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We included endarterectomy in the analysis, although a beneficial effect of the procedure 
for our type of patients has not been demonstrated. Further results of on-going trials have to 
be awaited."'But even with low surgical risks, endarterectomy does not result in a large benefit 
for our type of patients. 
We have been able to makea decision oriented synthesis of the available knowledge on this 
complex clinical problem. Not only an individualized treatment advice is produced, but also 
the insight into the clinical problem has been deepened. This makes it possible to apply the 
results of this analysis to patients with a similar problem. We identified the risk of rupture of 
the IA and the surgical mortaiity and morbidity of clipping, and the chance that the aneurysm 
caused the TIA as the most influential sources of uncertainty. 
Forpatients with TIA's, a moderate carotid stenosis and an intracranial aneurysm that does 
not seem to be related to the symptoms, clipping of the aneurysm, nor endarterectomy can be 
recommended with confidence, but when the IA is just as likely the source of the TINs as not, 
clipping is recommended up to the age of 70, when the surgical risks are as high as in the 
key-patient 
Of course, clinical judgment is crucial in adopting these conclusions, especially when the 
patient exhibits features that are not considered in the analysis. 
Notes 
a. This chapter is adapted fram: Dippel DWJ, Vermeulen M, Braakman R, Habbema JDF. Transient ischaemic 
attacks, carotid stenosis and an intracranial aneurysm. A decision analysis. Accepted fur publication. 
b. Efficacy is defined as the relative reduction in risk of any stroke, i.e. «P(stroke) - P(stroke I endarterectomy)) I 
P(stroke)) x 100%. A value of 0% means no reduction, and 100% means total elimination of stroke risk 
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Treatment of intact familial intracranial aneurysmsa 
The familial occurrence of subarachnoid hemorrhage (SAR) from intracranial aneurysms 
<W has been reported in severalstudies.''',283,363,364 Althougha certain proportion of the familial 
lA's can be explained merely on the grounds of lA-prevalence, the greater part has been 
considered as a distinct lA-group with an autosomal dominant mode of inheritance.' '''''''''' 
Elective screening for intact lA's in asymptomatic first-degree relatives of families in which 
two or more individuals have IA's has been strongly advocated and carried out."'''''''' We 
studied two families, affected withlA, by means of intravenous digital subtraction angiography 
(iv-DSA). Four intact lA's, present in four different first- degree relatives, were successfully 
operated. We discuss the management of unruptured familial lA's based on these four cases. 
5.1 Patients 
Two families were studied. Family 1 contained seven members with lA's, one with SAH 
and two other members with Marfan syndrome and an unclassified congenital anomaly syn-
drome. Infamily 2, one member had a ruptured lA and another had a SAH withoutlA-detection 
(Figure 26). Elective screening for lA's was carried out in the asymptomatic first-degree 
relatives. The clinical data of these families are described elsewhere.' ''',363''' In four patients 
intact lA's were detected, three of them belonging to family 1 (patient l-III-14, l-III-29, l-III-32), 
and one to family 2 (patient 2-JI-2). The characteristics of these patients and their aneurysms 
are summarized in Table 9. The routine laboratory analysis of all patients showed normal 
values: no cardiovascular abnormalities were present, except for mild hypertension in patient 
l-III-14. The surgical management was uneventful in all patients except for patient l-III-14. 
Postoperatively this patient had mild mixed aphasia and right facial weakness, which deficits 
disappeared within two weeks. 
Table 9. Cfinical characteristics of the four patients with an unrup1IJred familial aneu-
rysm. 
Patient Sex/Age Site Size Peculiarities 
1·111-14 Mi51 LMCA 10x15 mm no clear neck 
1-111-29 Mi47 PCA 6x15 mm aneurysmaJ SAH 1965 
1-111-32 Mi34 LlCA 5x6mm no clear neck 
2-11-2 F/34 peA 6mm 
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Family 1 
1 2 
II 1 2 [ 3 4 5 •• 7 
III 13 14 26 27 [ 2S 29 30 31 32 ,,6 34 
IV 
Family 2 
n 2 .. • Anourysmal SAH ll!l ® SAH or sudden death ~, I§l @ IA de!ecl.od by CCA II 12~~s 6. i!!l ® IA detected by iv-OSA 
Filiure 26. Pedigree of family 1 and family 2. 
5.2 Methods 
Essentially, decision analysis offers a method to balance qualitatively and quantitatively 
different factors against each other. Oinical decision analysis is mostly used to aid in decision 
making under conditions of uncertainty.315,396 However, it can also be used as a method to 
validate decisions that have already been carried out. In validating the neurosurgical treatment 
of the four patients we used a recently published decision-analytical study concerning the 
managementofintactnon-familialaneurysms. "'The risks and benefits of diagnostic evaluation 
are not considered in the present study. 
InFigure 27 the decision tree is shown. The decision 'no surgery' is represented in the upper 
part of the tree. Minor and transient morbidity related to a possible SAH in later life is not 
considered. This part of the tree is a condensation of subtrees, representing the probability that 
the aneurysm ruptures after one year, after two years ... etc. The decision for neurosurgical 
treatment is represented in the lower part of the tree. Again, minor and transient morbidity is 
not considered. It is assumed that after the neurosurgical procedure there is no risk of rupture. 
The occurrence of familial IA's in association with other diseases, such as the Ehlers-DanIos 
syndrome, is not considered in the analysis. Multiplidty of lA's is also excluded. 
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By definition, members of families affected with lA's have a greater tendency than normal 
subjects to develop an intracranial aneurysm. Consequently, there may also be a substantial 
risk of development and (after that) rupture of a second aneurysm for the patients in this study. 
This is illustrated by the clinical course of patient 1-ill-29. The development of a second 
aneurysm has not been reported in studies concerning familial aneurysms. We did not include 
this possibility in the decision tree, but we will discuss it after the presentation of the results 
of the base-case analysis. 
WAIT 
rupture 
recovery 
disabiltty 
death 
no rupture 
success 
disabiltty 
SURGERyL-___________ d_e_a_th __ _ 
Figure 27. Decision tree for the management of unruptured familial intracranial aneurysms. 
5.3 Available data and estimates 
The estimates that emerge from this section are summarized in Table 10. The annual rate 
of rupture of non-familial IA's has been estimated at 1 % (0.5-2%).164,382.409,410,411 The mean age of 
patients with SAH from familial aneurysms is significantly lower than that of patients with 
SAH from non-familial aneurysms.'95 This may be explained by lA development at a younger 
age, and/or by a higher tendency to rupture. Therefore we assumed a larger plausible range 
for the annual rate of rupture (.5-3%). The probability of rupture may increase with size."" We 
assumed patient 1-ill-14 and 1-ill-29 to have a slightly higher probability of rupture than the 
other two patients, because of the size of their aneurysm. Mortality and morbidity after SAH 
of familial aneurysms is assumed to be similar to that of non-familial SAH: 55% and 15%, 
respectively?,l69,293 
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Surgical mortality of intact non-familial lA's has been reported in small series from highly 
experienced centres at 0-2.5%, and the irreversible morbidity after surgery has been reported 
to be 6.5% or less.'65.330.332A13 We used subjective estimates of surgical risks in the four patients. 
Main factors that were considered are: size and shape of the aneurysm, and location. These 
subjective estimates compare well with the results ofWirth:~13 In this series, irreversible mor~ 
bidity was 2.3% for lA's 5mm or smaller, 6.8% for lA's 6-15 mm and 14% for lA's 16-25 mm. 
In general, large lA's in less accessible sites with difficult anatomical relations are associated 
with higher morbidity.218.m fucreasing age was not associated with higher morbidity.'" 
We addressed the possible development of a second aneurysm as follows. From the 
age-related prevalence of unruptured aneurysms, as reported by McCormick'" in an autopsy 
study, the approximate annual rate of developing an aneurysm can be calculated for the general 
population. A minimum estimate of this risk would be 0.3% annually. The maximum 
approximation arises from the assumption that the second aneurysm develops immediately 
after the treatment decision has been carried out. Thissituation may be approximated by adding 
up a mortality rate of 0.6% (I % x55%, or risk of rupture x mortality from SAB) to the life table 
mortalities. 
A utility structure based on discounted Quality Adjusted Life Years is used.'" Using the 
Dutch life tables for men and women (1981-1984)," we calculated the probability of being in 
state WELL, DISABlLllY OR DEATH in each year n (0 < n < t) in which t equals 100 minus the age 
of the patient. The expected utility of each strategy equals the total sum of the probabilities of 
being in each state (WELL, DISABILITY or DEATH) times the corresponding utility value of that 
year n. This utility value is expressed as U(X)x(l-a)", in which a is the discount value. Dis-
ability is valued at 0.75 (0.625-0.875) compared to perfect health (1) and death (0). The 
appreciation of nearby life-years is supposed to be larger compared to distant years."2 
Therefore, 5% annually will be discounted, with a range of 0%-10%. 
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Table 10. Estimated values and probabilfties. 
All patients 
Mortality from SAH 
Morbidity from SAH 
Annual discount 
Utility 01 disability 
Annual rale of rupMe 
Surgical mortality 
Surgical morbidity 
Annual rate of rupMe 
Surgical mortality 
Surgical morbidity 
Poinl value (plausible range) 
HII-14 
55% (50%-60%) 
15% (10%-20%) 
5% (0%-1001a) 
75% (62.5%-87.5%) 
1-111-29 
1.25% (0.5%-3%) 1.25% (0.5%-3%) 
3% (1.5%·6%) 2%(1%-4%) 
15% (12%-21%) 8%(6-12%) 
1-111-32 2-11-2 
1% (0.5%-3% 1% (0.5% .. 3%) 
1% (0.5%-2%) 1% (0.5% .. 2%) 
4%(3%-6%) 4%(3%-6%) 
Expected utilities (EU) of both therapeutic options were computed for all four patients 
(Table 11), by "averaging out" the decision tr .. .'15-'" In every patient, the option of surgical 
treatment yields the highest EU in the base--case analysis, although the difference between the 
two options is zero when rounded in patient l-ill-14. 
Table 11. Expected utilmes of ""nserva,ve EU(WAIT) and neurosurgical treatment (EU(SURG) for petient 
1-111-14, 1-1/1-29, 1-1/1-32 and 2-11-2, in discounted quality adjusted Iffe expectancy (dOALE). A value of 0 
stands for immediate death. Ii = EU(SURG) - EU(WAIT). (d)LE = (discounted) life expectancy without 
mortality from surgery, or subarachnoid haemorrhage. 
Patient EU(WArT) EU(SURG) Ii dLE LE 
1-111-14 13.0 13.0 0.0 13.9 24.8 
1-111-29 13.8 14.3 0.5 14.9 28.4 
1-111-32 16.1 17.0 0.9 17.4 40.6 
2-11-2 16.8 17.8 1.0 18.2 46.6 
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Plausible changes in estimated data do not change the preferred option for patient l-ill-32 
and patient 2-II-2, see Table 12. For example, with a low, but plausible estimate of the annual 
rate of rupture of the aneurysm of 0.5% (instead of 1 %), surgery would still be the favoured 
treatment decision for these two patients, according to the analysis. For patient l-ill-29, a low, 
but plausible annual rate of rupture would change the preferred option to conservative 
treatment. For patient l-ill-14 there appears to be no clinically significant difference between 
the two options. 
Table 12. Sensitivity analyses for paUent 1·111·14 and paYent 1·111·29 showing the effect of plausible changes in esUmales on 
the differences between the expacted uUliUes of conservaUve treatment (EU(WAIT)) and neurosurgical treatment 
(EU(SURG). 
Patient 1·111·14 Patientl·III·29 
WAIT WRG /; WAIT WRG /; 
Annual rate of rupture 
05% 13.5 13.0 -0.5 0.5% 14.5 14.3 -0.2 
3% 11.9 13.0 +1.1 3% 12.6 14.3 +1.7 
Mortality and morbidity from SAH 
500/0/10% 13.1 13.0 -0.1 50%/10% 13.9 14.3 +0.4 
60%/20% 12.9 13.0 +0.1 60%/20% 13.7 14.3 +0.6 
Utility of disability 
62.5% 12.9 12.7 -0.2 62.5% 13.8 14.2 +0.4 
87.5% 13.0 13.2 +02 87.5% 13.9 14.5 +0.6 
Annual discount 
0% 22.5 232 +0.7 0% 25.5 27.3 +1.9 
10% 8.7 8.5 -0.2 10% 9.0 9.1 +0.1 
Surgical mortality and morbidity 
1.5%/12% 13.0 13.3 +0.3 1%/6% 13.8 14.5 +0.7 
60/0121% 13.0 12.3 -0.7 4%/1ZOIo 13.8 13.9 +0.1 
For patients l-ill-14 and l-ill-29 we perfonned a more extensive sensitivity analysis, in 
which estimates of surgical mortality and morbidity, the annual rate of rupture and annual 
discount are varied over their plausible range of values (Figure 28). In this figure the influence 
of our maximum and minimum assumptions regarding the development of a second aneurysm 
are incorporated. From this figure it can be concluded thatforpatient l-ill-29, only combinations 
of high surgical mortality and morbidity, low risk of rupture and high discount clearly favour 
conserva tive treatment. Forpatient l-ill-14 the situation is morecomplex: there exists an almost 
84 
Treatment of intact familial intracranial aneurysms 
perfect toss-up?O'l Thus, not only surgical mortality, risk of rupture and discount value, but 
also our estimates of the development and rupture of a second aneurysm become critical to 
the decision to treat the patient neurosurgicall y. 
5.5 Discussion 
As far as we know, elective neurosurgical treatment ofintact familial lA' s has been reported 
before in 7 individuals belonging to four other families."·""l2'.29' No definite agreement exists 
about the surgical treatment of intact lA's, both with isolated and familial occurrence. Neu-
rosurgical treatment of non-familial intact aneurysms has been advocated for aneurysms 5 mm 
or larger, 1~ 7 mm or larger,290 or 10mm or larger.402. These estimates were based on the supposed. 
risk of rupture of the aneurysm, in relation to size. A Significant part ofIA'ssmaller than 5 mm 
however, also rupture.20S There are more factors involved in the management decision. Van 
Crevel382 showed for this kind of clinical problem how decision analysis can help in combining 
explicit estimates of all relevant parameters in a systematic and consistent way. It is an 
advantage of this method that all assumptions are made explicit. Also, the place that each 
probability and value should have in the process of clinical decision making is clarified, whether 
it is precisely quantifiable ornot. This may promote and facilitate the discussion of this complex 
management problem. Thus, the estimated probabilities and values are open to challenge. For 
instance, the neurosurgeon (C.T.) who treated three of the four patients, made markedly lower 
individual estimates of surgical mortality and morbidity, but at that moment he was already 
aware of the satisfactory outcome of the patients. Moreover, our estimates of surgical mortality 
and morbidity are rather high in comparison with the available literature. But one has to realize 
that only very experienced neurosurgeons have published therr results. In general, excellent 
surgical results will have a higher probability of being published than average results. This 
"publication bias" has been discussed in detail by Sackett."""" 
Decision analysis helps to identify gaps in clinical knowledge that are really worthwhile 
exploring."" In the course of this analysis it appeared that empirical data on the natural history 
(with respect to the probability of rupture and the development of new aneurysms) of familial 
aneurysms are lacking. However, it will be difficult, and sometimes even unethical to conduct 
a study to find out the risk of rupture of familial aneurysms. On the other hand, we were short 
of representative data on the results of surgery of intact intracranial aneurysms. There is a need 
for well documented series that make it possible to identify risk factors for surgical mortality 
and morbidity such as size, shape and location of the aneurysm. More knowledge of these 
factors would ha ve made our analysis more accurate. 
Although there are many blank areas in this decision-analytic approach of the management 
of familial aneurysms, we think that we have shown that the decision to treat the aneurysm 
neurosurgically in patients l-ill-29, l-ill-32and 2-1I-2 was a rightful one. In the last two patients, 
plaUSible changes in estimated data do not change this decision. For patient l-ill-29, only the 
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FIgure 28. Threshold analyses lor 
pa~ent 1-111-14 and patient 
1-111-29. The graphs show for 
surgical mottality and morbidity 
(X-axis), annual probability of rup-
ture of the aneurysm (Y ""'is), 
discount and maximum (dotted 
lines) and minimum (base-case) 
estimates of the and rupture of a 
second aneurysm the combina-
tion of parameters that results in 
an equal Expacled Utility of the 
two treatment strategies (WAIT 
and SURGERY). The black dOl 
shows the base-case-estimates 
that are used in the analysis. 
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(rather unlikely) combination of a low probability of rupture, a high surgical mortality and 
morbidity and high discount favours conservative treatment. For patient IMm~14 a toss·up 
exists, so both options are open. Still, a neurosurgeon who feels that familial aneurysms carry 
a greater risk of rupture than a normal, "idiopathic" aneurysm, or who thinks that the psy-
chological burden ofliving with an unruptured, familial aneurysm will be very heavy for this 
patient, behaves not unreasonably by clipping the aneurysm of patient l-ffi-14. 
Notes 
a. This chapter is adapted from: Ter Berg JWM, Dippel DWJ, Habbema JDF, Bijlsma JB, Van Gijn J, Tulleken 
CAF, Willemse J. Treatment of intact familial intracranial anew-ysms: A decision-analytical approach. 
Neurosurgery 1988;23:329-334. 
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Chapter 6 
Screening for unruptured familial intracranial aneurysmsO 
Several studies of families with an unusually high frequency of ruptured intracranial 
aneurysms GA's) have been reported."·126,lS'-"',364 The etiology of the aggregation ofIA's in such 
families has not been established, but hypo theses focus on collagen deficiencies:l1 In the clinical 
literature, the working definition of 'familial lA's' is applied when two relatives harbour a 
definitely established (ruptured) IA. 
Ter Berg detected unruptured lA's in two patients by means of iv-DSA and earlier in two 
others by means of conventional cerebral angiography (CCA) by screening two families.'" 
Electiveneurosurgical treatment wassuccessful.363..36SIn the present study,.. the decision to screen 
has already been carried out, with favourable results. A good result however, does not guar-
antee that the best choice was made. Therefore, we will assess the decision to screen retro-
spectively. Decision analysis is used as a framework to combine clinical infonnation, subjective 
estimates of uncertainty and preferences for health_outcomes.19,2~,396 The results should be 
considered as guide-lines for decisions, that have to be adapted to individual patients. 
Four clinically relevant strategies will be considered in this analysis, i.e. no angiography at 
all (DONOTSCREEN) screen directly (SCREEN NOW), screen directly and again after several years 
if the first angiogram was negative (SCREEN 1WlCE), screen after several years only (SCREEN 
LATER). We will use a baseline value of five years for the screening-interval, conform T er Berg.368 
Each screening strategy can be carried out using ia-DSA or iv-DSA. The latter seems safer, but 
is less accurate. In a scenario analysisl42 magnetic resonance angiography (MRA) will be ana-
lyzed tentatively. 
6.1 Moterial and Methods 
Patients 
Forty patients (36 belonging to Family 1 and 4 belonging to Family 2, Figure 29) were 
screened with iv-DSA in 1982.'" Two new lA's were detected. Ages ranged from 10 to 54; 25 
patients were younger than 30. Five years later screening was repeated in 31 members of family 
1. No new lA's were detected. Member 1-111-34 of family 1 (a 39-year-old male) was admitted 
two years after the second screening with a ruptured posterior communicating aneurysm. 
Ia-DSA also revealed two aneurysms of the right internal carotid artery and the basilar trunk, 
all approximately 3 mm. On review, the earlier angiograms were negative.337 
Member 1-111-33 , a woman aged 37 with five relatives who had an angiography- or 
autopsy-proven IA before screening, and two relatives who suddenly died without firm 
diagnosis: will be used as a key patient throughout the decision analysis. 
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Agure 29. Pedigree of family 1 and family 2. Member 1-1/1-33 is used as a key patient throughout the analysis. 
Methods 
The events and outcomes that relate to each strategy will be described in an orderly way. 
A decision tree is used as an illustrative tool. The likelihood of events and outcomes (prob-
abilities) and the desirability of outcomes relative to each other (utilities or losses) arequantified. 
The probability estimates are based on a concise review of the relevant literature. Then, the 
expected loss (ELl of each strategy is computed. The strategy with the lowest expected loss can 
be considered as a good advice. At last, sensitivity analysis is used to examine the effect of 
plausible changes in quantifications on the expected loss of each strategy, to test the stability 
of the advice and to validate the results of the analysis for other patients.216,3lS 
The 'expected loss' can be defined as the (abstract) health-loss that occurs on average, by 
following the chosen strategy. Loss of life expectancy (LE) will be used as a proxy for the 
expected loss in this analysis. It is computed for each strategy by subtracting the expected 
survival from the life expectancy according to the Dutch life tables.56 The survival for each 
strategy is estimated by combining data from the Dutch life tables with estimates related to 
the presence of LA's and to the diagnostic and therapeutic interventions. 
Differences between strategies in LE lost do not necessarily match patient preferences, 
because morbidity is not considered. Therefore quality adjusted life expectancy (QALE) is 
computed as follows. Three health states are defined (Alive & Well, Disability and Death) and 
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the expected number of life years spent in each health state is computed for each strategy. Each 
year lived in disability is weighed with a utility value of 0.75 (plausible range: 0.625-0.875), on 
a scale of 0 (Death) to 1 (Alive & Well). Alive & Well corresponds to "no or moderate disability", 
and disability to "severe disability" according to the Glasgow outcome scale. 
Many patients attach more value to nearby than to distant life years."" Forexample, surgical 
management - with the possibility of immediate death - will generally be considered as less 
attractive than conservative management when both options yield an equal life expectancy. 
Therefore, the expected loss is expressed as loss in discounted life expectancy (dLE), by valuing 
each life-year at 95% (plaUSible range: 90%-100%) of the year preceding it. Both procedures are 
combined in the computation of discounted quality adjusted life expectancy (dQALE) lost. 
Decision tree 
In strategy DO NOT SCREEN in the decision tree of Figure 30, an unruptured IA may cause 
SAH resulting in death, serious permanent neurologic disability, orrecovery. Compared to the 
calculations in the analysis, the time aspect has been simplified in the tree. Haemorrhage and 
development of new IA's, which may occur at any time in the future, have each been combined 
into one branch. !tis assumed thataftera non-fatalSAH the lAis clipped, completelypreventing 
further haemorrhage. Cavernous carotid artery aneurysms are not considered because they 
seldom rupture, and operation is hazardous. 
Strategy SCREEN NOW involves a choice of the type of angiography (iv-DSA or ia-DSA). 
These may be complicated by mortality or permanent major (neurologic) morbidity. Following 
a positive iv-DSA, ia-DSA is used to confinn the IA and to locate it more accurately. Strategy 
SCREEN TWICE is first identical to SCREEN NOW, but after several years, angiography is repeated. 
Strategy SCREEN LATER implies on the one hand a risk of haemorrhage before screening, but on 
the other hand a larger probability of finding an lA, because new lA's may develop. The 
remaining part of the tree is identical to that of SCREEN NOW. 
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Rgure 30. Decision tree for patients from a famHy affected with intracranial aneurysms. IA:::: intracranial aneurysm, SAH::-
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6.2 Available Data and Estimates 
The estimates for the key-patient (member l-IlI-33) are summarized in Table 13. Because 
of the uncertainty surrounding these estimates, plaUSible ranges are suggested. 
Probability of harbouring an aneurysm 
The risk of harbouring an IA is based on McCormick's autopsy study of unruptured 
intracranial aneurysms:'" The probability of harbouring an unruptured IA at age 10 is 0.5%, 
steadily increasing to 8% at age 70. The key patient (aged 37) would have a probability of 
harbouring an unruptured IA of 1.2% (0.6%-2.4%). However, she has several close relatives 
with a definitely established IA. We therefore assume an increased risk, although the exact 
relation between the number of affected family members and the probability of harbouring an 
IA is not known. The relative risk R due to the familial disposition' is taken at 3 (1-5). An 
upper-bound of 5 corresponds to a 50% cumulative inddence of IA's (ruptured and unrup-
tured) at age 80, as in an autosomal dominant mode of inheritance with complete expression. 
Natural history of aneurysms 
Intracranial aneurysms rupture at a rate of 1 % (0.5%-2%) annually.l12,164..189,306,38U09,410,411 The 
haemorrhage may result in mortality, morbidity or recovery with probabilities of 55% 
(50%-60%),15% (10%-20%) and 30% (20%-40%) respectively.'·16'.m.382ACl 
Ruptured aneurysms are on average larger than unruptured lA's. Therefore, the mean rate 
of growth is estimated at 0.075 mm (0.06 mm-O.09 mm) annually, Le. every year 7.5% of IA's 
enlarge 1 mm.''''"'''''"'''' It is assumed that the IA's do not become symptomatic when they reach 
large sizes. The annual probability of a new IA is estimated from McCormick.'" 
Angiography: test characteristics 
No estimates of the sensitivity and the spedficity of angiography for intracranial aneurysms 
are available. Artifacts are virtually impossible when a three-direction ia-DSA shows an IA. 
Thus, it is assumed that ia-DSA has a 100% spedfidty. 
Because the likelihood of being detected by angiography increases with aneurysm size, we 
estimated its influence on the sensitivity of angiography, by comparing the distribution of 
aneurysm sizes in an autopsy study'" and a study of conventional cerebral angiography (CCA) 
of unruptured IA's.'" After adjusting for the effect of fixation / non-perfusion by a factor of 
1.5 (as proposed by McCormick)'" and for differences in age-composition, the ratio of these 
two distributions gives the relative likelihood of being detected on the angiogram, by aneurysm 
size. This likelihood is converted to a function of size-related sensitivities by assuming a 
minimum size of 5 mm (3 mm-l0 mm) where the probability of being detected by ia-DSA is 
100%. The estimates are extrapolated to iv-DSA by assuming that a sensitivity of 100% isreached 
ata size of 10 mm (range: 5 mm-15 mm). 
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The overall sensitivity of angiography (i.e. the probability of discovering an IA of any size, 
when the patient really harbours an aneurysm) depends on the size distribution of IA's, which 
differs according to the age of the patient and the preceding diagnostic procedures. In the key 
patient ia-DSA would have an overall sensitivity of 75% at the time of first screening. At the 
second screening it would be lower (63%) because the first screening was negative and the 
distribution of IA-sizes will have been shifted towards smaller ones. Postponement of the first 
screening for five years leads to larger IA-sizes and to a higher sensitivity (79%). The effect of 
new lA's on the size distribution is negligible. 
Table 13. Point values and plausible ranges of perame/ers entering the decision analysis for peOent 1-111-33. a 
woman of 37 with 5 close relatives with a definite ruptured IA 
Natural history of aneurysms 
Probability of IA (population prevalence) 
Relative risk of familiailA 
Annual rate of rupture 
Mortality of SAH 
Morbidity of SAH 
fa-OSA 
Mortality 
Morbidity 
Specificity 
Overall sensiti~ty (SCREEN NOW) 
Overall sensiti~ty (SCREEN TW"E) 
Overall sensitivity (SCREEN lA TEA) 
Iv-OSA 
Mortality 
Morbidity 
Specificity 
Overall sensitivity (SCREEN NOW) 
Overall sensitivity (SCREENTW"E) 
Overall sensitivity (SCREEN lATEA) 
SUllJery 
Mortality 
Morbidity 
Patient preferences 
Annual discount 
Utility of disability 
Angiography: cumplications 
point value range 
1.2% 
3 
1% 
55% 
15% 
0.02% 
0.2% 
100% 
75% 
63% 
79% 
0.01% 
0.1% 
95% 
38% 
38% 
41% 
2% 
6% 
5% 
0.75 
0.61'10-2.4% 
1-5 
0.5%-2% 
50%-60% 
10%-20% 
O.01%.Q.04% 
0_1%.Q,4% 
27%-93% 
28%·95% 
30%-83% 
0.006%- 0.02% 
0.06%'().2% 
90%-100% 
24%-63% 
27%-7f!J1o 
20%-53% 
1%-4% 
4% -10010 
0% -10% 
0.625-0.875 
No mortality and a permanent morbidity rate of 03%-0.4% has been reported in two large 
studies.""" Iv-DSA is usually regarded as less dangerous than intra-arterial angiography, but 
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the evidence is limited. In one study no mortality and a permanent morbidity of 0.2% was 
reported, but all patients were studied for extracranial vascular disease.15 Aaron's study is not 
considered, because an intracardial catheter was used, resulting in a high morbidity.' 
Therisks from angiography seem to increase with age.=""Therefore we assumed a linear 
relationship between age and complication risks. The mortality is assumed to be 10 times lower 
than morbidity. For the key patient these estimates result in a risk of permanent major com-
plications and death of 0.2% and 0.02% for ia-DSA, and 0.1 % and 0.01 % for iv-DSA. 
Surgical mortality and murbidity 
Surgical mortality of intact non-familial lA's has been reported at 0-2.5%,and theirreversibl e 
morbidity at 6.5% or less.'&5.218.29Q,330;l32A13 These figures are quite susceptible to publication bias.'" 
Consequently we used subjective estimates,'" and investigated a wide range of values for 
surgical mortality (1 %-4%) and surgical morbidity (4%-10%). 
6.3 Results 
Bf1$e-.case analysis 
For each strategy, both for ia-DSA and iv-DSA the LE lost is computed, see the leftmost 
column in Table 14. 00 NOT SCREEN gives patient 1-ill-33 - who has a 3.6% risk of harbouring 
an lA - an expected loss of 024 life years (approximately 3 months) compared to the situation 
in which one would be certain that she did not harbour an lA. SCREEN NOW with ia-DSA results 
in a lower loss (0.13 life years or 1.5 months) because lA's that are discovered will be treated, 
and this outweighs the risk of the diagnostic procedure and surgery. Postponing screening for 
five years (SCREEN LATER) does not seem to be beneficial for this patient. SCREENTWICE provides 
the lowest loss of the four strategies when LE is used as outcome measure. Strategies involving 
iv-DSA have a slightly higher expected loss, apprOximately 0.05 life years or 2-3 weeks more. 
The lower risk of complications with iv-DSA is apparently outweighed by a lower diagnostic 
accuracy. All losses are quite small, because of the low prior probability of an lA. For com-
parison, a 37-year-old woman who harbours an lA with certainty looses on average 6.9 life 
years.382 
AlthoughSCREENNOW provides a higher life-expectancy than 00 NOT SCREEN, the timespent 
in disability is larger (0.07 versus 021 life years). Patients will differ in thelr preferences for 
these outcomes. Therefore we also computed the loss in quality adjusted life expectancy 
(QALE). This increases the expected loss for each strategy, but DO NOT SCREEN is least affected. 
In the same table it is shown how preferences a discount rate of 5% (0%-10%) affects the 
results. The loss for all strategies is reduced, but again, DO NOT SCREEN is spared. Combining 
preferences for time and health outcome on one scale of discounted quality adjusted life 
expectancy (dQALE) results in almost equal losses for SCREEN NOW and DO NOT SCREEN, and 
also for the other two strategies. 
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Table 14. Expected losses of seven strategies for patient 1~111-33 , expressed as loss in life expectancy with 
quality adjustment. discountmg and both. The third (non-significant) digit is rounded to 0 or 5. NormalOfe 
expectancy for a 37 year-old woman, without mOl!aJity from IA rupture or surgery would be 43.09 years, and 
16.00 years with discounting. 
Ufe years lost due to lI1e intracranial aneurysm 
Quality 
No Quality adjustment and 
Strategy adjustment adjustment Discounting discounting 
00 NOT SCREEN .235 .250 .055 .060 
ia-DSA 
SCREEN NOW .130 .180 .035 .050 
SCREEN TWICE .120 .190 .030 .060 
SCREEN LATER .150 200 .040 .055 
Iv·DSA 
SCF!EENNOW .180 .220 .045 .055 
SCREEN TWICE .160 .215 .040 .060 
SCREEN LATER 200 .235 .050 .060 
Sensitivity a""lyses 
We investigated the effect of plausible changes in each estimate on the preferred decision,"z 
see Table 15. Not shown are plausible changes in the probability of complications from SAH, 
the growth rate of the IA, surgical mortality, specifidty and sensitivity of iv-DSA. They have 
a very low impact, especially on the difference in expected loss between DO NOT SCREEN and 
SCREEN NOW. The relative risk of a familialIA is the most influential factor in this analysis. High 
values favour SCREEN NOW. 
When the mortality and morbidity associated with ia-DSA is increased to 0.04% and 0.4% 
respectively, the expected loss of SCREEN NOW with ia-DSA equals the expected loss of SCREEN 
NOW with iv-DSA. 
We assumed that the annual rate of rupture of IA' 5 is constant with respect to size. When 
we let it increase linearly with size, such that a 15 mm (10-20mm) IA has 1.5 (1.25-2.00) times 
the probability of rupture of a 2 mm IA, this does not lead to different conclusions. 
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Table 15. Sensitivity analysis for palient 1~/1-33: The differences in number of cJiscounted quality adjusted fife 
years lost between strategy 00 NOTSCREEN and strategy SCREEN NOW for ia.lJSA and iv-DSA are shown. 
Negative values favour DO NOTSCREEN. 
Ia-DSA Iv-DSA 
base-line values 0.01 0.00 
Natural h1stooy of aneurysms 
Probability of IA 
0.06% 0.00 0.00 
2.4% 0.03 0.01 
Relative os!< of famiOJ IA 
1 .(1.01 0.00 
5 0.04 0.02 
Annual rate of rupture 
0.5% .(1.01 .(1.01 
2% 0.02 0.03 
la-DSA 
MOrlality/mortlidity 
0.01%/0.1% 0.01 0.00 
0.04%/0.4% 0.00 0.00 
Iv-DSA 
MOrlalitylmortlidity 
0.006%10.06% 0.01 0.01 
0.02%10.2% 0.01' 0.00 
Value judgments 
Utility of disability 
62.5% 0.00 0.00 
87.5% 0.02 0.01 
Annual d~count 
0% 0.07 0.03 
10% 0.00 0.00 
Generalizations 
In order to generalize theresulls to other patients, we examined thejoint effect of the relative 
riskofafamilialIAandageonthedifferenceindQALElostbetweenOONOTSCREENandSCREEN 
NOW (Figure 31). At a young age the risk of harbouring an IA is very small, and therefore the 
benefits of screening are low. With increasing age, benefits increase, and an optimum is reached 
between 40 and 60. At older age, lifetime rupture risks decrease rapidly because of a lower 
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life-expectancy. This results in a smaller benefit of surgical treatment, although the risk of 
harbouring an IA increases. The differences between DO NOT SCREEN and SCREEN NOW for iv-
DSA (not shown) are about half the value of those for ia-DSA. 
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Rgure 31: The effect of age and of the rela,ve risk of a familiallA (R) on the choice between screening directly with ia-DSA 
and no screening. Y-axis: difference in expected Joss between DO NOT SCREEN and SCREEN NOW in discounted quality 
adjusted fife years (dOALE). X-Axis: Age in years. Solid line: base-case estimale (R=3), dashed lines: R.l and R=5, 
respectively. A horizontal dotted line representing an equal/oss is shown for orientation. The position of patient 1-111-33 is 
indicated by an open circle. The differences in EL between 00 NOTSCREEN and SCREEN NOW with iv-DSA are approximately 
half as large as with la-DSA A dashed line depicts the effect of screening with magnetic resonance angiography (MRA), 
when it would be would be completely reliable. 
ScenariD analysis 
Magnetic resonance angiography (MRA) has the advantage of non-invasiveness, but the 
detectionandstudy of diseased vessels iscomplicated by the great number of visualized art enes 
and veins."'''' We computed the expected loss of the three screening-strategies using this new 
device, as if it had a diagnostic accuracy mid-between that of iv-DSA and ia-DSA, without the 
associated mortality and morbidity. Then, the dQALE lost for the key patient of SCREEN NOW, 
SCREEN TWICE and SCREEN LATER amounts to 0.04, 0.03 and 0.04, which is slightly lower than 
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for ia-DSA. Because there is no mortality and morbidity and therefore no penalty on repetitive 
testing, SCREEN lWICE has the lowest expected loss in this situatioIl- The previous figure also 
shows the difference in dQALE lost between SCREEN NOW and 00 NOT SCREEN as ifMRA would 
be a perfect test. Even in this case the differences in expected loss are only slightly larger than 
with ia-DSA. 
6.4 Discussion and conclusions 
The analysis for the key patient results in a toss-up. Only when the likelihood of an IA is 
higher than our point estimate, a clinically significant benefit of screening will arise. Even then, 
however, the difference in loss of dQALE is only in the order of magnitude of several days. 
The results of this analysis certainly provide no justification for screening of patients who do 
not have a familial history. 
A decision analysis that yields small differences in expected loss between the strategies 
should be carefully reviewed, as "minor Simplifications" may lead to wrong recommenda-
tions.2O'l Therefore, we will elaborate upon several of our assumptions. 
Astrategy for the whole family is not considered, because the benefits of finding and treating 
an IA will vary individually. However, the results of screening one family member will affect 
the pnor probability of IA in yet unsereened members, and the balance between rtsks and 
benefits of screening. The time-loss (because of hospitalization) and transient morbidity due 
to angiography, surgery and SAH are not considered. Nor did we include the anxiety caused 
by the notion of possibly living with an unruptured IA. Note howeverthat a negative screening 
result does not completely exclude an IA, but only makes its presence less likely. Iv-DSA can 
be carried out on an ambulatory basis. For this reason it may be preferred over ia-DSA in 
individual cases, considering the small differences in expected loss. 
A screening device without mortality and morbidity, and perfect test charactertstics will 
only slightly decrease the expected loss. The difference in dQALE lost between SCREEN NOW 
and DO NOT SCREEN is in this case at best 0.07. Thus, use of non-invasive technology - such as 
MRA - will result in only a slightly larger benefit than ia-DSA. Cost considerations may then 
playa more prominent role in deciding about indications for screening. 
We used the relative rtsk as a summary measure of the evidence for an unruptured IA, by 
judging the family history. When two members of a family have suffered an SAH, and this 
aggregation was fortuitous, the rtsk that any other family member harbours an unruptured IA 
is not increased. But when this aggregation was based on a pathologic, hereditary process, 
other family members will have an increased risk of harbouring an unruptured IA. There are 
no laboratory tests that distinguish between 'normal' IA's and 'familial' IA's. The probability 
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of "chance aggregation" is much larger than one would expect. For example, a patient who is 
admitted with SAH has a 9% chance of having at least one dose relative out of 29 (up to the 
third degree) who also had an SAH. 
Family members up to the third degree will be considered, and the average number of 
children in a household (e) is taken at 3. Thus, there are 5 first degree (2 parents+ e children), 
2 second degree (2 siblings) and 22 third degree relatives (2x(c -I) parents' siblings, (c -I)xc 
cousins, and 2x(c -I)xc uncles or aunts), making the total number N of relatives to be con-
sidered29. 
Assume that each family member has a risk of harbouring an unruptured IA p = 0.Ql. We 
took the annual rate of rupture at r = 0.Ql, and the mortality from SAH at m = 0.55. The mean 
age a of the relatives is taken at 40. 
The probability that a patient who is admitted with SAH has at least one close relative with 
previous SAH just by chance, is described by: 
P = 1-(1-p(l- (1- r)'rr = 0.092 = 9.2% (16) 
When the estimate is restricted to relatives who are alive, the equation is extended to 
P = 1-(1-p(I_(I_r(l_m»)'»N = 0.047 =4.7% (17) 
The proportion of familial cases explained by fortuitous aggregation in Norrgard,"" can be 
estimated by taking <=2.8, and by considering only parents, siblings, parents' siblings and 
cousins (N=17). P would be 0.056 or 5.6 % which is quite near to the proportion reported in 
that study: 6.7%, (95% confidence interval (normal approximation): 3.5%-9.9%). 
Thus, the observation that two members of one family have a history of SAH should not 
increase one's suspidon much. On the other hand, a physician who thinks that the risk of 
harbouring an IA of a certain patient is substantially increased because of the possible familial 
dispoSition, may rightly deede for screening, especially for patients aged 40 to 60. He should 
use ia-DSA, which seems better than iv-DSA. A stepwise approach may be best, from the 
viewpoint of this decision analysis. Start screening the relatives whose age lies between 40 and 
60 and who are closely related to the propositus, in the first or second degree. And let the 
decision to screen others depend on the results of these first investigations. 
Notes 
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a. This chapter is adapted fr= Dippel DWJ, Ter Berg JWM, Habbema JDF. Screening for unruplured familial 
intracranial aneurysms. A decision analysis. Acta NeurolScand 1992; 86, 381-389. 
b. Patient Il-6 dropped from his chair and died soon afterward. Patient l-W-30 presented with acute headache and 
vomiting, neck rigidity, peripapi1lar haemarrhages and blood-stllined cerebrospinal fluid. 
c. In the epidemiologicalliteralure the relative risk is normally taken as the ratio of the incidence with and with-
out exposure to a determinant (R =P(IA WYP(IA IF»). In our case, howl!Der,P(IA IF) is unknown, 
and R is taken relative to the population incidenee (R =P(IA I F)/P(/A»). 
d. Identical to lxzse..case value. The strategies with ia~DSA do not depend on assumptions about iv-DSA But, in 
strategies with to-DSA, ia-DSA is used to confirm the presenee of an IA preoperatively. 
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Chapter? 
Unruptured intracranial arteriovenous malformationsO 
Familial occurrence of non-syndromal intracranial arteriovenous malformations (A VM's) 
has been seldom reported: only 16 families are known .... "·,, Familial occurrence of intIacranlal 
AVM's as a feature of a hereditary syndrome is still more exceptional. To the best of our 
knowledge, hereditary haemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease is 
the only known syndrome with a high frequency of vascular anomalies with both intIacran1al 
and spinal localization. HHT is a familial disorder with generalized angiodysplasia and 
multiple cutaneous, mucosal and visceral telangiectasia and other vascular anomalies with a 
hepatic, intIacranlal, intraspinal and pulmonary localization, including pulmonary 
arteriovenous fistulae (P A VF).334 HHT has an autosomal dominant mode of inheritance with 
high penetration and variable expression. Two families affected with both HHT and vascular 
anomalies of the central nervous system (eNS) in more than one relative have been reported.39•211 
Another family affected with A VM's is suggestive for HHT.41' 
We describe three patients belonging to two different families, affected with both HHT and 
unruptured, intracranial AVM's. The unruptured AVM's were detected using cerebral 
angiographic screening. 
The risks of surgery and its effectiveness depend on the size and location of the A VM Young 
patients have a high lifetime risk of haemorrhage, and therefore one may be inclined to take 
more risks when attempting to extirpate the A VM. However, no definite agreement exists about 
the indications for surgical treatment of unruptured A VM' S.57,358 Radiation therapy and arterial 
embolization are also risky procedures, and they seem to be less effective than surgery in 
eliminating the A VM.31.243,314 Embolisation is mostly used as a pre--operative procedure to 
eliminate deep arterial branches, and "stereotactic radiosurgery" is mostly confined to A VM's 
that are inoperable because of location near non-silent brain areas.287 These possibilities will 
not be considered here. The analysis will be restricted to a choice between surgery and con-
servative management 
The surgical treatment of both non-syndromal unruptured intIacranlal A VM's and (fam-
ilial) A VM's associated with HHT will be discussed on the basis of these three patients. In 
deciding about the best management option for each patient, the risks of harbouring an 
unruptured A VM, the risks associated with HHT, the risks and benefits of surgery and the 
patients' own preferences with regard to future life-years and to living with a serious neur-
ological handicap should be considered. As in previous studies of the management of 
unruptured intracranial aneurysms, we will use clinical decision analysis to incoxpoxate the 
available infonnation in a balanced framework.36,365,382 The results of this decision analysis will 
be generalized to patients with non-familial A VM's. 
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7.1 Patients and Methods 
Patients 
Angiographic screening forunruptured intracranial vascular anomalies using intravenous 
digital subtraction angiography (iv-DSA) was carried out on a group of 18 patients affected 
withHHT, known at the Department ofPu1monology, St. Antonius Hospital, Nieuwegein, The 
Netherlands (C)JW). A VM's were detected in three patients, see Table 16. The lesions will be 
described according to a grading system proposed by SpetzJer'" using three variables: size (1: 
<3cm,2: 3-6 cm,3: > 6=), pattern of venous drainage (0: superficial, 1: deep),and neurological 
eloquence of the adjacent brain region (0: non-eloquent, 1: eloquent). 
Table 16. Description of the three patients for the decision analysis of the surgical management of 
unruptured intracranial AVUs. 
Sex Age PAVF AVM location Grade 
A·Ii·S M 14 no r·MCA Hl·O 
A·I ·2 F 43 yes (resecled) I·PCA 2'()· 1 
EHIi·1 F 12 no I·ACA 1'()'() 
PAVF: Pulmonary Arteriovenous Fistula; ACA = Anterior Cerebral ArJery, MCA = Medial Cerebral 
Artery, PCA = Posterior Cerebral ArJery 
Family A (see pedigree, Figure 32) harbours six members who are affected with HHT, of 
whom four (patient 1-2, II-I, II-3 and II-6) were treated surgically for symptomatic PAVFs 
(hemoptysis and right to left shunt). The PAVF relapsed in patient II-I, II-3 and II-6. In patient 
II-5, male, aged 14 and right handed, iv-DSA revealed an unruptured grade 1-0-0 A VM, fed 
by the right middle cerebral artery and drained by the superior sagittal sinus. Follow-up 
angiography four years later did not show a change in size. In patient 1-2, female, aged 43, 
iv-DSA revealed an unruptured grade 2-0-1 asymptomatic AVM, fed by the left posterior 
cerebral artery and drained by the transverse sinus (eloquent region: hemianopsia). Follow up 
angiography after 3 years did not show a change in size. 
Family B has two members with intracranial vascular lesions. In patient ill-I, a twelve year 
old girl, iv-DSA showed an unruptured grade 1-0-0 A VM fed by the left anterior cerebral artery 
and drained by the superior sagittal sinus. Follow-up iv-DSA 4 years later did not show a 
change in size. Neurosurgical treatment was uneventful. Her father, who was also affected 
with HHT died from subarachnoid haemorrhage at age 29; the autopsy report mentioned an 
intracranial aneurysm of the anterior communicating artery. 
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Family A 
II 
Family B 
II 
III 
® t1!l HHT 
HHT 
and PAVF 
Rgure 32. Pedigree of two families with hereditary haemorthagic telangiectasia (HHT) and intracranial arteriovenous malfof-
maUons (AVM's), PaUents A+2, A-I1-5 and 8-111-1 harbour A VM's, 
Methods, 
In decision analysis, the clinical problem is structured in a decision tree, see Figure 33. The 
surgical option (SURGERY) carries a risk of mortality and morbidity. After surgery the A VM may 
have been completely taken out of the drculation or not. Incompletely extirpated A VMs may 
rupture again, It is assumed that after non-fatal rupture of incompletely extirpated AVM's, 
effective surgery is not possible. In the lower part of the tree the no treatment-option is con-
sidered (wAlTI. The patient has an annual rate of rupture of the A VM, and an annual rate of 
dying from other causes. Rupture of the A VM causes haemorrhage, and this may lead to 
recovery, permanent disability or death. Minor and transient morbidity related to haemorrhage 
and to neurosurgical treatment is not considered. It is assumed that a ruptured A VM will be 
surgically treated, Again, incomplete extirpation implies a risk of recurrent haemorrhage. 
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mortality 
d .. " I 
complete extirpa~on 
disability I 
SURGERY morbidity mortality d .. " I 
haemorrhage Jmorbldity 
disability I 
Incomplete,l Ino 
extlrpatlO~c complicatiOns disability I 
no haemOlThage 
disability I 
complete extirpa~on 
well I 
mortality 
death 00 
haemorrhage J. morbidity complications dlsablUty 
Incomplete). Ino 
B 
_" extirpation j; complications 
no haemorrhage 
_II I Patient with J AVM and HHT 
no haemorrhage 
_II I 
WAIT 
") mortality death I 
complete extirpation 
dlsabWty I 
morbidity ...l 
haemorrhage I Incomplete extirpation 
A 
complete extirpation I .. II I J. 00 
complications Ylncomplete extirpation 
-(§) 
Figure 33. Decision tree for a patient with an intracranial arteriovenous malformation (AVM) and hereditary haemorrhagic 
telangiectasia (HIfT). Two strategies are shown: expectant management (WAIT) and surgical management (SURGER~. Quad-
rengle: decision node, rectangles: outcome nodes, circles: chance nodes. A and B refer to the subtrees !hat represent the 
course of events after incomplete extirpation of the A VM. 
In the decision analysis, the probability of haemorrhage is computed for each year that the 
patient survives. The Dutch life tables of 1986 are used to estimate the annual mortality from 
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other causes" The time span that is covered equals 109 years minus the age of the patient. 
Risks and benefits of diagnostic evaluation are not considered in the present study. Also, the 
not unusual association of A VM with an intracranial aneurysm is not taken into account. 
Three health states are considered in the decision analysis: Well (no complications or minor 
handicap), disability (severe permanent handicap, making the patient dependent upon others) 
and death. Theaverage number oflife years lived in each health state iscalculated. Foran overall 
judgment, a utility structure based on discounted quality adjusted life expectancy dQALE) is 
used. For a detailed discussion of the use of dQALE see Chapter 2, section 2.3. Disability is 
valued at 75% compared to perfect health (100%) and death (0%)."" (Laterin the analysis it will 
be shown that the effect of quality adjustment on the results of the analysis is negligible.) The 
appreciation of future life years by patients is assumed to decrease gradually over time. 
Therefore, 5% will be discounted annually, with a range of 0-10%. The decision tree is evaluated 
by first computing the dQALE for each outcome. A further expectation is computed for each 
strategy by multiplying the probability of each outcome with its associated dQALE. The 
strategy with the highest dQALE should be regarded as a good advice. 
7.2 Available data and estimates 
In the following paragraphs, the literature will be reviewed to obtain estimates of the 
probabilities of events in the decision tree. Because of variability due to imprecision and 
uncertainty, plausible ranges will be suggested, see Table 17. 
Natural history of unruptured A VM's 
Several studies of the natural history of symptomatic arteriovenous malformations have 
been reported. A general problem of these studies (which are discussed in detail below) is that 
follow-up data are gathered by means of telephone-interviews and mailing of general phys-
icians and relatives. Thus, patients with a haemorrhage may be more likely to be included in 
the study than those who have not (yet) bled. Moreover, determination of the moment that the 
patient should be regarded as lost to follow-up can be difficult, because of the retrospective 
nature of the study. This may lead to too high estimates of the risk of haemorrhage. 
In Ondra's study'" of 160 patients with AVM who were followed for a mean period of 23 
years, 64 (40%) had at least one major haemorrhage. One hundred and fourteen 114 (71 %) of 
these patients originally presented with haemorrhage. The authors did not distinguish between 
first and recurrent haemorrhage during follow-up. This explains why they report a higher 
annual rate of haemorrhage (4%) than in the other studies (see below). It makes the study 
difficult to interpret and not very useful for our analysis. 
Brown'" reports a long term follow-up study of 168 patients with clinically unruptured 
AVM's, (mean follow-up 8.2 years). Using Kaplan Meyer estimates a mean annual rate of 
haemorrhage of 2.2% was computed. Crawford" reports a 17% 10-year risk of haemorrhage 
and a 20-years risk of 33%, in 49 patients who presented without haemorrhage, for an annual 
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rate of almost 2%. In Grafs series'" 71 patients presented with symptoms other than haem-
orrhage. The cumulative risk of haemorrhage was 14% in 5 years, for an "average annual rate 
of rupture" between 2% and 3%. In this study, a statistically significant increased risk of 
haemorrhage was observed for small (<3crn) A VM's, but this has not been reproduced in other 
studies ..... .291 The larger proportion of small A VM's among patients who present with a 
bleeding A VM compared to those who present with an unruptured symptomatic A VM is of 
course no evidence for an increased risk of haemorrhage for smaller lesions, as Crawford 
already noted." Olderstudies12S,13o.'''-", only havesmall groups ofunruptured A'IM! sand often 
lack angiographic confirmation and consistent follow-up information. 
Thus, the annual rate of haemorrhage of the A VM is estimated at 2% with a plausible range 
of 1 %-3% on the basis of the studies above mentioned. We base our estimate of mortality and 
morbidity due to haemorrhage (30% and 25% respectively) on these studies also. No data exist 
about the comparison between the tendency to rupture of a familial A VM associated with HHT 
and a non-familial, non-syndromal AVM. We assume that the risks of haemorrhage and its 
complications are equal for familial and non-familial AVM's. 
Mortality from other causes 
Although the three patients whom we consider had no symptomatic PA VF at the time of 
the treatment decision, it is conceivable that latent, mostly basally located PA VFs become 
symptomatic, as illustrated in 3 members of famlly A. This can be explained by haemodynamic 
factors, such as post--operative changes. P A VFs may rupture or otherwise result in neurological 
signs, dueto hypoxia, polycythaemia, thrombosis, air-embolism and paradoxicalseptic emboli. 
We investigated the effect of comortality by adding 0.5% (0%-1 %) annually to the life table 
mortalities.82..240.346 
Surgery of unruptured A VM's 
Values of 0%,4%,7% and 12% for the risk of permanent major neurological surgical mor-
bidityin grade I-II,ID, N and V patients respectively have been reported in a series of 100 cases 
of both ruptured and unruptured A'IM! S355 Cases in whom complete resection was not possible 
were excluded. In a retrospective series of 74 patients with low-graded (un)ruptured A VM's 
no mortality and a 4% morbidity was experienced.242 In another series of 40 "small and mod-
erately large" A VM's'" no mortality, and a 5% morbidity was recorded. Older studies reported 
higher surgical mortality rates: 11 % and 6% in a series oflOo'" and 145 symptomatic A'IM! s,' .. 
but a distinction between ruptured and unruptured A VM's was not made, and several of the 
patients were in poor clinical condition prior to operation. 
Still, published studies may give a too optimistic view of theresultsofneurovascularsurgery 
as has been argues before.365 We therefore investigated a wide range of values for surgical 
105 
Chapter 7 
mortality and morbidity for each patient. In the computations, the probabilities P(smrb) and 
P(smrt) of surgical morbidity and surgical mortality, respectively are linked by the formula 
P(smrb) = 2 x P(smn) + 0.025. 
Incomplete resection is not infrequent. This happened in 18 of 105 cases (from a total of 140 
patients treated for A VM) studied by angiography after excision because of uncertaInty about 
the surgical results." This means an overall frequency of incomplete extirpation of A VM's of 
12.5% However, results according to clinical grade were not reported. For Our patients, we 
used a 0% probability of incomplete extirpation. In order to investigate the effect of changes 
in this parameter, and to generalize the analysis to other patients we investigated a range of 
0%-25% as plaUSible values. 
Table 17. Point values and plausible ranges for the decision analysis of surgjcal management of unruptured 
AVM·s. 
Point value Plau~ble range 
All patients 
annual rate of rupture 2% 1%·3% 
mortality after rupture 30% 25%-35% 
morbidity after rupture 25% 2O% .. 3()01o 
incomplete extirpation 0% 00/0-25% 
annual mortality due to PAVF and HHT 0.5% 0% .. 1% 
annual discount rate 5% 0%·10% 
utility 01 disabmty 75% 62.5%-87.5% 
Patient A·II·S and 8-111·1 
surgical mortality 1.0% 0.5%·2.0% 
surgical mortJidity 4.5% 3.5%-6.5% 
Patient A·I·2 
surgical mortality 2.5% 1.25%-5.0% 
surgical morbidity 7.5% 5.0%-12.5% 
PAVF = Pulmonary Arteriovenous Fistula; HHT = Hereditary haemolThagic telangiectasia 
7.3 Results 
Base-case analysis 
The life expectancy associated with surgical treatment and waiting for each patient are 
computed by averaging out the tree, see Table 18. 
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Patient A-I-2, who is 43 years old, would have a life expectancy (LE) of 37.6 years without 
mortality from A VM and HHT. The mortality risk associated with these conditions decreases 
her LE by several years, to 30.9 years with expectant management Surgical management yields 
a 2.2 years higher LE, 33.1 years. Discounting future life years decreases the life expectancy for 
surgery more than for waiting, because of early surgical mortality. Quality adjustment does 
not change the results much. The two other patients are younger, and therefore have a higher 
lifetime risk of rupture'. For these patients, surgery yields the best results. With discounting 
the difference between expectant management and surgery exceeds one discounted quality 
adjusted life year. 
Table 18. Results of the comparison between surgical and expectant management of unruptured AVM's in 
the three patients in fife expectanCy with discounting (5%), quality adjustment or both. The life expectancy 
according to the Dutch life tabfes without mortaffty due to HHT or AVM with and without discounting is 
given for comparison. 
Patients 
A·I·2 A·II·5 B·III·1 
Sex· age F-43 M·14 F·12 
Lne expectancy (LE) (years) 
Iffe table 37.6 59.4 67.6 
surgical management 33.1 50.5 56.6 
expectant management 30.9 44.7 49.6 
difference in lE +2.2 +5.8 +7.0 
Discounted LE (dlE) 
life table 16.1 18.2 18.7 
surgical management 14.7 16.7 17.0 
expectant management 14.1 15.6 15.9 
difference in dLE +0.6 +1.1 +1.1 
Quality adjusted lE (QALE) 
surgical management 32.5 49.9 56.0 
expectant management 30.2 43.4 48.1 
difference in QALE +2.3 +6.5 +7.9 
Discounted quality adjusted LE (dQALE) 
surgical management 14.4 16.5 16.8 
expectant management 13.9 15.4 15.6 
difference in dQAlE +0.5 +1.1 +12 
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Sensitivity analysis 
In a sensitivity analysis (Table 19) we computed the dQALE for both strategies and 
investigated the effect of varying the values of each variable over a plausible range. Only high 
surgical risks change the preferred strategy for patient A-J-2 In the two other patients (not 
shown), the preferred strategy is not changed by plausible changes in estimated values. Other 
parameters of relatively great influence on the results of the analysis are: risk of haemorrhage, 
discount and risk of incomplete extirpation of the A VM 
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Table 19. Sensitivity analysis for pailent A·I·2: 1/Je effect of plausible changes in estimated probabil· 
ities and uillities on the discounted quality adjusted Ofe expactancy of surgical and expectant man· 
agement of unruptured intracranial A VM:S. The base.fine estimates are given for comparison. ~en 
the difference between dOALE of surgery and expectant management is positive, surgery is 
recommended. Apparent discrepancies are the result of rounding. 
SURGERY WAIT Difference 
Base-line estimate 14.4 13.9 +0.5 
Discount rate 
0% 325 30.2 +2.3 
10% 8.3 8.2 +0.1 
Mortality due to PAVF and HHT 
0% 15.4 14.8 +0.6 
1% 13.5 13.1 +0.4 
Annual rate of haemorrhage 
1% 14.4 14.4 +0.0 
3% 14.4 13.7 +0.6 
Mortality/morbidity of haemol!hage 
25%120% 14.4 14.1 +0.3 
350/J30% 14.4 13.7 +0.7 
Risk of incomplete extirpation 
12.5% 14.3 13.9 +0.4 
25% 14.1 13.9 +02 
Surgical mortalitylmorbidity 
125%15% 14.7 13.9 +0.8 
5'%/12.5% 13.8 13.9 -0.1 
Uti~ty of disabifrty 
62.5% 14.3 13.8 +0.5 
87.5% 14.6 14.0 +0.6 
PA VF = Pulmonary Arteriovenous Fistula; HHT = Hereditary haemorrhagic telangiectasia 
Unruptured intracranial arteriovenous malformations 
Generalization of the analysis 
Highsurgicalmortality andmorbidityimpliesarelatively low dQALE of surgical treatment. 
Thus, for a certain value of surgical mortality and morbidity the dQALE of expectant man-
agement and surgery will become equal. For patient A-I-2 the "threshold value" of surgical 
mortality and morbidity is 4.6% and 117% respectively. an the sensitivity analyses surgical 
mortality and surgical morbidity are linked algebraically, see previously.) When the actual 
estimate of surgical mortality and morbidity is higher than the threshold value, expectant 
management will be the preferred strategy. In Figure 34 the threshold values of surgical 
mortality and morbidity are computed for ages 0-80. For yoUnger, but otherwise identical 
patients the threshold-value will be higher, because the life-time risk of haemorrhage is larger, 
making it more worthwhile to operate. This is illustrated by the straight line. Also indicated 
in this figure is the effect of plausible changes in the estimated annual rate of haemorrhage and 
the chance of incomplete extirpation of the A VM: low risks of haemorrhage and high chances 
of incomplete extirpation decrease the threshold value. 
g 7.5%' 17.5"-
f 
~ 5%, 12.5% 
-g 
~ 
i 2.5%, 7.5% 
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Figure 34. Thresl10ld analysis of surgical results (y·axis). age (X-axis) and rate of rupture. Each line represems a value for 
the annual rate of haemorrhage and gives combinations of values for age and surgical mortality and morbidity that result in 
equal dQALE for expectant management (WAfT) and surgical management (SURGERy). For combinations of values above 
each line expectant management is favoured, and below each line surgery. The dashed lines give the threshold values of 
surgical mortality and morbidity when the chance of incomplete extirpation of the AVM is 25% and 50% respectively. The 
open circle indicates the /hresl1old value of surgical mortaOty and morbidity for patiem I·A·2 aged 43 and the black circle 
indicates the base-case estimates for this patient. The threshold values in this graph bear on women; for men they are 
0.2%-0.5% lower, because their lower life expectancy implies a /ower lifetime risk of haemorrhage. 
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7.4 Discussion 
Weighing the benefits of surgical treatment ofunruptured A VM' s, especially in association 
with HHT, is difficult because of the variability in clinical features, the inconclusive data 
concerning annual rate of rupture, mortality and morbidity after rupture, surgical morbidity 
and mortality, the probability of successful surgery and the relations between these factors. 
No prospective studies applying the A VM grading system241,355 have as yet been reported. Such 
data would be of great value. We assume that A VM's in association with HHT have the same. 
annual rate of rupture as non-syndromaIAVM's. Asfaraswe know, no data have been re ported 
that suggest otherwise. 
We did not explititly consider stereotactic radiation therapy and embolisation. These 
techniques may be helpful for young and otherwise healthy patients who do not seem to be 
clear-rut candidates for surgery, because of the location and/or size of the A VM (Le. a 
left-temporal A VM). Decision analysis can be of value here, but individualised estimates of the 
rate of complications after radiosurgery, noxmal surgery and after rupture will be necessary. 
In clinical practice, surgery is sometimes confined to people aged just below 30, because 
between 30 and 40 a "peak-incidence" of haemorrhage due to ruptured AVM's is obser-
ve(i.94,.l66,242.355 If one presumes a small, approximately constant annual rate of haemorrhage for 
an individual patient, there will be no theoretical basis to explain this "peak-incidence". It could 
well be caused by selection and classification artifacts in older patients. Moreover, not the 
annual rate of haemorrhage (or incidence density), but the life time risk (or cumulative inci-
dence) of haemorrhage should be the principal consideration. 
Other studies 
Other decision-analytic studies on the management of arteriovenous malformationsl86,9;121 
are discussed in Chapter 3. 
Pertuiset'"' proposed a score system for operability of supratentorial AVM's, which 
included anatomical (localization and sectorization, determination, caliber and straightening 
of feeding arteries), haemodynamic (volume, circulatory velocity, steal) and clinical con-
siderations (age, previOUS rupture, associated diseases malformations of vital organs), based 
ona review of 66 cases, 14 of these presenting with haemorrhage. The authors do not describe 
how or why these variables were selected, nor how the scoring weights were determined. The 
important age-faetor was dichotomized Oess than 51, over 50) and high-age was considered as 
a contra~indication to surgery, which is an unnecessary simplification of the clinical situation. 
The score only considers surgical risks, and not the Oong term) benefits of surgery. 
110 
Unruptured intracranial arteriovenous malformations 
Conclusions 
Integration of more specified clinical characteristics of A VM's In grading systems leads to 
more differentiated management recommendations. Surgery of unruptured AVM's (both 
syndromal and non-syndromal) is the treatment of choice in selected cases. Considerations 
should include: the age of the patient, the risk of haemorrhage of the A VM, the chance of 
incomplete extirpation, surgical mortality and morbidity, and the patient's preferences. 
Patients with low graded A VM's that have not bled should be operated upon, unless they are 
over 60 years of age (or have a reduced life expectancy because of other disease) and the risk 
of incomplete extirpation of the A VM is increased. 
HHT-patients appear to have an increased risk of harbouring vascular lesions of the central 
nervous system compared to the general population. In a review of215 patients with HHT and 
(primarily and secondarily) cerebral symptoms 77 patients with telangiectasia, arteriovenous 
malformations or intracranial aneurysms were documented.319 This high prevalence is also 
illustrated by our3 patients affected with unruptured A VM's, out of a group of18 HHTpatients. 
Thus, members of families affected with HIIT have a greater chance of harbouring intra-
cranial A VM's than in general. Screening of families affected with familial intracranial aneu-
rysms using intra-arterial or intravenous digital subtraction angiography has already been 
discussed elsewhere.""''''' Screening for unruptured A VM's -not considered in this study- may 
be carried out in HHT families affected with intracranial A VM's in two or more individuals, 
but perhaps also in HHT-families without association of intracranial A VM's. A first screening 
using computed tomography scanning or magnetic resonance imaging or angiography (MRI 
or MRA) may be the best choice, because AVM's are generally well visualized by these tech-
niques, and they are nearly non-invasive. In a recent report of a family with 8 members out of 
16 with cerebral A VM's, Aliard' makes a strong case for screening with MRI. The benefits of 
further angiographic screening can be estimated only indirectly after assessment of the grade 
of the supposed A VM and the characteristics of the patient. Decision analysis should be used 
to confirm this recommendation. 
Notes 
a. This chapter is adapted fram: Ter Berg TWM, Dippel DWT, Habbema TDF, Westermann CIT, Tulleken CAF, 
WiUemse J. Unruptured intracranial arteriovenous malformatiDns with hereditary haemorrhagic telan-
giectasia. Neurosurgical treatment or not? Acta Neurochirurgica 1993; 121: 34-42. 
b. The lifetime risk of haemorrhAge R can be estimated by thA formula R = 1-{I-r1", whATe r is the annual rate 
of haemorrhAge, and L is the life expectancy of the patient. For patient A-II-5 R = 1-(1- .02)"'= 69.8%. 
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Chapter 8 
Probabilistic diagnosis of normal pressure hydrocephaluso 
Although the number of publications on the management of nonnal pressure hydro-
cephalus (NPH) seems to decline more than 25 years since the first description of the syndro-
me,15I,128 there is no consensus about its diagnosis and treatment. 66 Many patients who seem to 
have NPH do not respond to shunting, probably because irreversible damage has been done, 
or because these patients actually suffer from primary degenerative or multi-infarct dementia. 
As NPH is a clinically defined syndrome, a certain diagnosis cannot be made. We therefore 
propose a probabilistic approach to the diagnosis of NPH and other treatable cerebral lesions 
in demented patients. Oinical and pathological studies that investigated the occurrence of 
NPH and other treatable cerebral lesions in dementia have not systematically analyzed the 
diagnostic value of information obtained from history and physical examination.4L347.61 In the 
present study we combine epidemiological data, subjective probabilities and clinical reasoning 
in order to assess the impact of diagnostic features and age on the probability of NPH and of 
an intracranial space-occupying lesion (SOL) in a demented patient, before and after computed 
tomography. Decision analysis is used to weigh the risks and benefits of shunting for NPH 
and to give recommendations for the diagnostic and therapeutic management of demented 
patients who may suffer from this condition. The analysis is restricted. to investigation with 
CT, because this belongs to the standard diagnostic management of patients suspected ofNPH. 
The role of other diagnostic tools is less clear. Cisternography does not seem to add useful 
prognostic or diagnostic information,".308.387 but MRI may proof useful in the distinction 
between NPH, multi-infarct dementia and white matter lesions.63 These two tools will not be 
considered here, for lack of evidence. The role of external lumbar drainage, lumbar puncture 
and continuous pressure monitoring will be discussed. 
8.1 Patients and methods 
Patients 
A fictitious patient will be used to illustrate the analysis. This 60-year-old woman suffered 
since six months from memory difficulties and disorientation in time. On neurological exam-
ination there was a fairly typical shuffling gait, but no other (focal) abnormalities. There were 
no depressive symptoms. Mini Mental Score was 20/30.'24 Details of physical, neurological and 
laboratory examinations are summarized in Table 20. Three other clinical profiles have been 
defined for comparison. They differ from the key patient with respect to the presence of gait 
abnormalities and urinary incontinence. These two features deserve some emphasis in our 
opinion because they are considered typical for patients with NPH, but their occurrence in 
patients with AD or MID may give rise to erroneous diagnoses and consequently, failure to 
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respond to shunting. In order to explore the effect of age on the likelihood of a treatable lesion 
four patients aged 75 with a similar clinical profile will be considered separately in the results 
section. We did not consider treatable lesions in patients with dementia of longerduration~ as 
their response to shunting is disappointing.'38 
Table 20.Clinical profiles differing in age, presence of gait abnormalities and urinary incontinence, and dUtation of 
the demen6a. Key paDent: bold text. All pa6ents: Sixty year old white female, aged 60. Blood pressure: 155195. 
Neurological examination: no dysphasia, no hemisyndrome, tendon reflexes brisk, but not abnormal. Muscle tone 
normal. Plantar responses flexor. No extrapyramidal signs. Laboratory: normal blood count and electrolytes. Thyroid, 
liver and renal function normal for age. No deficiencies of vitamin 812 or folate. Syphilis tests negative. Urine analysis 
normal. Lumbar puncture: CSF pressure normal and no clinical improvement (by measurement or assumption). 
profite duration of age urinary gait 
dementia (yrs) incontinence abnormalities 
1 0.5 60 No No 
2 0.5 60 No Ves 
3 0.5 60 Ves No 
4 0.5 60 Yes Yes 
For the purpose of this study, dementia is defined as a syndrome of deterioration from a 
known or estimated prior level of intellectual function which is not isolated to a single narrow 
category of intellectual performance, and which is independent oflevel of consciousness.63 The 
relative incidence (in a hospital setting) of the four major cerebral causes of the dementia 
syndrome (i.e. NPH, intracranial space-occupying lesion (SOL), multi-infarct dementia (MID) 
or Alzheimer's disease (AD» will be used as an estimate of the prior probability of each cause 
of dementia. These disease entities do not refer to a clinically defined syndrome, but to a 
presumed underlying cause of dementia. Other causes of dementia and depression are con-
sidered to be ruled out. Several other conditions may lead to a clinical picture of dementia and 
gait abnormalities, for example dementia pugilistica~ dementia associated with Parkinson~s 
disease~ chronic alcoholism and multiple sclerosis. Multiplicity of disease is not considered. 
Next, the occurrence of a eight diagnostic features -all of which are obtainable by taking the 
patient's history and doing a physical examination- is assessed for each type of dementia. To 
this purpose the literature was searched systematically. A Medline search of the medical lit-
erature published since 1982 on epidemiology and diagnosis in DEMENTIA, «PRE)SENILE), ALZ-
HElMER'SDISEASE,DEMENTIA VASCULAR,DEMENTIAMULTI-INFARcrandHYDROCEPHALUSNORMAL 
PRESSURE was carried out. Out of the 2242 journal articles a further selection was made by 
scanning the abstract for the above mentioned methodological aspects. Studies of the clinical 
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picture of the four causes of dementia were selected when the final diagnosis was based on 
prolonged follow-up, or histe-pathological confirmation. Sometimes only semi-quantitative or 
no estimates at all concerning the occurrence of diagnostic signs in each of the four causes of 
dementia were available in the literature. In that case we resorted to subjective estimates, made 
by the first author of this study" When exact data are not available plausible ranges for each 
point estimate were defined by taking a ratio for the upper and lower bounds of at least four. 
Then, a probability of each cause is computed for each patient. 
Bayes' theorem is used to convert the prior probability (see Table 21) of each of the four 
considered. causes of dementia C1 to a posterior probability, based on information contained 
in the absence or presence of diagnostic features DF (see Table 22). 
P(C,IDF) , P(C,)· P(DF 1 C,) (18) 
."'i. P(C;)· P(DF 1 Cl ) 
,-1 
DF stands for the eight "diagnostic features" from history and physical examination that 
are considered. The probability of a particular combination of DF is computed by taking the 
product of all the individual feature probabilities P(D, 1 Cl ), with k=1,2 .. 8: 
, (19) 
P(DF 1 Cl ) = IT P(D, 1 C;). 
'·1 
In order to adjust for the assumption of conditional independence, which is implied by 
Bayes' theorem, a global association factor ex, 0'; X,; 1) is used.172 
P(DF 1 C;';x( IT P(D, 19)X. 
hI (20) 
("0<:" = "proportional toft) 
A value of 118 for X implies that diagnostic probabilities are completely dependent, a value 
of 112 implies pairwise dependence, and a value of 1 implies complete independence. Likewise, 
a value of 2J3 (as is used in this study) means that every three diagnostic items yield the 
information of two completely independent ones. 
The log-odds form of Bayes' theorem is used to compute a score that can be converted to 
postenor likelihoods: 
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j P(G,! OF») j P(G,»)' prO, I G,) 
Score = !O x'Jo,\ I P(G, IOF) = 'J05ll _P (G,) + ,;, 'Jog(P(O, I G,» . X, 
(21) 
where the subseore associated with each diagnostic feature j is computed by taking 
(22) 
andP(OJ I C)is taken as the average of the diagnostic probabilities in the three other causes, 
weighted with their priors, and X is the global association factor. 
The likelihood of successful shunting S in a patient suspected ofNPH is computed by taking 
the product of the probability of successful shunting in patients who have secondary normal 
pressure hydrocephalus with certainty, and the probability of "idiopathic" or "primary" normal 
pressure hydrocephalus in the patients considered in this paper: 
P(S I Cr,OF) = P(S I NPH)· P(NPH I cr,OF). (23) 
The next equation gives the algebraic representation of the decision tree in Figure 35, for 
the special case where the expected utilities of each option are equal to each other: 
EU(Wait) = EU(Shunt) = (24) 
U = (l-P(M»· (P(NPH)· P(S)+P(NPH)· (I-P(S»· U +(l-P(NPH»· U). 
By solving this equation for P(M) we may obtain the value of the shunting mortality that 
results in equal expected utilities for Wait and Shunt, as a function of the probability of NPH 
(P(NPH). 
P(M)=I P(NPH).P(S).(I-U)+U 
U (25) 
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Normal pressure hydrocephalus 
The syndrome of normal pressure hydrocephalus consists of dementia, gait abnormalities, 
with or without urinary incontinence, in the presence of a dilated ventricular system, and 
"normal" cerebrospinal fluid pressure.'SO In a large autopsy series of 164 pre-senile demented 
people 5.5% were diagnosed as normal pressure hydrocephalus.'" The diagnosis was based 
on the presence of severely dilated ventricles, thickened pia and arachnoidea, no pathologic 
evidence of Alzheimer's disease and no other cause for the ventricular enlargement In. 270 
senile demented patients the frequency of NPH was 0.7%. The difference in relative inedence 
of NPH between senile and pre-senile demented patients"" may be explained by the large 
number of people with Alzheimer's disease at higher age."''"' 
Table 21. Prior probabilities of normal pressure hydrocephalus, multi-infarct dementia, intracranial space-occupy-
ing lesion and Alzheimer's disease. 
60 years 75 years 
point plau~ble range point plausible range 
value value 
Normal pressure hydrocephalus (NPH) 5.5% 2.0%-9.0% 1.0% 0.0%- 2.0% 
Intracranial space-occupying le~on (SOL) 8.5% 4.5%-12.5% 4.0% 2.0%-8.0% 
Multi·infarct dementia (MID) 15.0% 5.0%-45.0% 15.0% 5.0%-45.0% 
Alzheimers disease (AD) ~+ 33.5%-88.5% ~± 45.0%·93.0% 
100% 100% 
Many reports describe prognostic factors for successful shunting}38,139,lS'1,27l,369 but in the 
majority of these reports the number of cases is small, follow-up short, the NPH syndrome 
loosely defined, criteria for success after shunting not explicit, and assessment of clinical status 
not independent of pre-operative status.10,1S7,208,lBO As gait abnormalities will be criterion for 
inclusion in most of the studies, its frequency cannot be reliably estimated. In. one large study 
of patients considered for shunting it occurred. in 95%.222 In studies where urinary incontinence 
was not a criterion for inclusion, this sign occurred in approximately 50% of patients.32.301,381 
Slowness of thought and gesture are often mentioned. Focal signs are notably absent. Some-
times there are signs of cortico-spinal tract involvement. Extensor plantar responses have been 
found in 9 out of16 patients,"" and in 15 of the 74 patients in Larsson's study. Pseudo-bulbar 
signs, including primitive reflexes (snout, palmo-mental or grasp--reflex) were found in 70%.222 
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IntrllCTanial space-occupying lesions 
In a large autopsy study 4% of the senile demented patients had an intracranial space-oc-
cupyinglesion,and a subdural haematoma was discovered in 1 %.''' Of the pre-seniledemented 
patients8.5% had aspace-occupyinglesionandnonehada chronic subdural haematoma (CSH). 
In non-demented patients aged less than 60 years CSH is not infrequent and the condition is 
well known for its frequent neuropsychological manifestations.44The absence of CSH in this 
age-group in the autopsy study has to be explained by the alertness of physicians that leads to 
surgical drainage before dementia develops. In demented patients with a cerebral space-oc-
cupying lesion, gait abnonnalities are not uncommon. Fluctuations in the clinical course are 
may occur, because of edema or (focal) seizures. 
Multi-infarct dementia 
MID is a less common disorder than AD. The diagnostic term is used to designate dementia 
resulting from many large, cortical and subcortical infarcts and dementia resulting from small 
deep lacunar infarcts, which will not necessarily lead to similar clinical pictures.93,320 Estimates 
of the relative inddence of MID show wide variation. 63,l68.236In estimating the relative inddence 
of multi-infarct dementia, many authors refer to Tomlinson.37l The author himself states that 
his sample "was not truly a random one and consequently, conclusions could not be drawn 
about the prevalence of the various types of dementing processes in old age". Thus, the relative 
incidence of MID is taken at 15%, with a range of 5% to 45%.63,192.2l4 
In most studies the male to female ratio is 1:1."-" Common signs in MID are rtgidity of the 
lower extremities, extensor plantar responses, gait abnormalities, and convulsions. We only 
found semi-quantitative estimates of the likelihood of these signs in the literature. Stepwise 
detertoration is noted as a typical feature of MID. History of stroke, which is common in MID, 
is not considered because it overlaps with stepwise deterioration. Signs of cortico-spinal tract 
involvement will be highly correlated, and therefore plantar responses only were considered. 
Ina clin1co-pathologicalstudy pseudo-bulbar signs and prtmitivereflexes occurred in 50%-90% 
and urinary incontinence in 85%.79 However, it is quite likely that these clinical data were 
obtained late in the course of the disease, and therefore the frequency of these signs was esti-
matedat 70% and 50%, respectively. In another study with pathological confirmation stepwise 
detertoration had occurred in approximately 50%, and focal signs were also noted in 50%.2" 
We decided not to use the complete (modified) Hachinski score,''''''' because it is not clear 
whether it is useful for discrtmination of MID from other causes of dementia than Alzheimer's 
disease.117,168.192.275 
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Alzheimer's disease 
The prevalence of (Senile) Dementia of the Alzheimer Type in the elderly population has 
been estimated at 5-15%, making it the most frequent cause of dementia in the elderly. Its 
relative incidence in series of demented patients varies heavily, because the diagnosis is 
established "per exclusionem". 
In an early stage the disease is characterized by amnesia, disturbances of spatial orientation 
and lack of spontaneity.'" The male to female ratio is 1:2.,u76-"'The duration of this stage is 
approximately 2 - 4 years. In his own series of more than 150 pre-senile demented patients 
people20% had focal signs, predominantly dysphasia. Later, progressive dementia with typical 
focal features such as agnosia, apraxia and dysphasia, as well as urinary incontinence and gait 
difficulties develop. 
Table 22. Feature probabilities of four possible causes of dementia (Normal pressure hydrocephalus 
(NPH), intracranial space-occupying lesion (SOL), multi·infarct demenJia (MID) and PJziJeime(s disease 
(AD). Estimales that are based on (adjusted) data from the Ifterature are designated with', estimates that 
are based on semi-quantitative information (from reviews mostly) are designated with R, and estimates that 
are entirely subjective are designated with $. For sources see text. Figures are rounded to the nearest 5%. 
NPH SOL MID AD 
Male gender 5O%L 50%R SOO/oL 33%L 
Stepwise deterioration 1~IoR 30%$ 90%R 10%R 
Gait abnormalities 95%L 50%$ SO%,R 5%L 
Urinary incontinence 50%,L 20%$ 50%L 5%L 
Dysphasia 5%L 10%$ 25%R 25%L 
Extensor plantar responses 25%L 50%$ SO%L 5%R 
Pseuoo·bulbar signs 70%L 30%5 70%L 10%R 
Focal abnormalities 5%R 60%5 5OOioR 5%R 
Computed tomography 
The sensitivity and specificity of cr investigation for several causes of dementia are 
determined and used to compute the probability of a treatable lesion when the cr results are 
known, and the overall probability of finding any treatable lesion by cr. 
A diagnosis of probable Alzheimer type dementia is generally made after exclusion of other 
cerebral causes of dementia""" Intracranial space-occupying lesions will not be overlooked 
because they have to be rather large to cause global dementia. Artifacts are rare. Thus, both 
the sensitivity and specificity of cr for intracranial tumours that cause dementia will approach 
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100%. The aspect of the cr abnormalities seen in dementia ranges from mainly cortical atrophy 
to frank ventricular enlargemen~ as seen in NPH.'31 The sensitivity of cr for NPH (defined as 
the chance that cr indicates hydrocephalus when the patient really suffers from NPH) is about 
70% and the specificity (defined as 1 minus the chance that cr indicates hydrocephalus when 
the patient suffers from MID or AD) will be approximately 80%, when rigid criteria are applied. 
Tans' criteria for the cr-diagnosis of NPH in a study of 62 demented patients are based on 
LeMay's study: 1) absence of cortical atrophy, 2) and at least 2 of the following: a) frontal hom 
ratio> 0.50, b) width of third ventricle> 3.5 mm, c) width of fourth ventricle> 4.0 mm, d) 
periventricular lucencies, e) visibility of temporal horns. The final (gold standard) diagnosis 
was based on prolonged clinical observation."'",,1 
Shunting for normo.l pressure hydrocephalus 
Not even all patients with definite NPH respond favourably to shunting. This can be 
concluded from studies of patients with NPH secondary to subarachnoid hemorrhage, men-
ingitis, and intracranial surgery, in which diagnosis is beyond doubt 208 Consequently, if sec-
ondaryand idiopathic NPHhavea comparable response to treatment, a measure of the expected 
success rate when the diagnosis of NPH is uncertain can be derived by combining the 
probability ofNPH with the probability of successful shunting in patients with secondary NPH. 
The decision to shunt depends on the likelihood of normal pressure hydrocephalus, the 
chance of successful shunting, and the risk of complications from shunting.l0,157Decision theory 
will be used weigh these risks and benefits in order to identify which type of patient may be 
considered for shunting. The decision tree depicts the decision to shunt a patient with an 
uncertain diagnosis of NPH, based on history, physical examination and on the results of cr. 
Shunting carries a risk of mortality (P(M», resulting in death with a utility of O. When the 
patient suffers from NPH (with a probability P(NPH» and therapy is successful (P(S», there 
will be lasting improvement of cOgnition. This outcome has a utility of 1. When shunting is not 
successful, or when the patient's disease is not NPH, she will remain in a state of slowly pro-
gressivedementia, with a utility value U. The strategy do not shunt implies that the patient will 
remain in a state of slowly progressive dementia, also with a utility value U. Values of U close 
to 0 imply that in the perception of a patient or his representative a large improvement can be 
made after successful shunting, and thus, they are more in favour of 'shunting' than values 
close to 1. 
In decision theory utility isdefined as equal to the substitution probability p when a decision 
maker is indifferent between an uncertain outlook p . 1;(1-p). 0 with a chance p of the best 
outcome (lasting improvement of cOgnition and ambulation after shunting), valued 1, and a 
chance (l-p) of the worst outcome (death), valued 0, on the one hand, and on the other a certain 
outlook of slowly progressive dementia with utility U. There are several methods to elicit 
utilities.'''We will by-pass this aspect by investigating a large range of values for U. However, 
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even when utilities are not assessed directly, they have an inherent, intuitive meaning. When 
U = 0.75 for example, this means that the patient is willing to take a mortality risk up to 
1-0.75 = 0.25, or 25%, in order to be relieved from her dementia when operation is certainly 
suCCessful.393,396 
Improve 
NPH 
P(S) 
P(NPH) 
00 chang<> 
survive l.P(S) 
1·P(M) 
noNPH 
U 
1·P(NPH) 
shunt 
dk> 
0 
60-year-old woman P(M) 
NPH 
CT indicating NPH. P(NPH) 
noNPH 
U 
'.P(NPH) 
Figure 35. Decision tree for the shunting decision in patients whose CT indicates NPH. Square: decision node; Circles: 
chance node; rectangles: outcome node. Time flows from left to right. 
The chances of success after shunting in secondary NPH equal about 67% with a plausible 
range of 60%_75%.35.208 Thus, the likelihood of successful shunting (P(S) in our patient will 
amount to 0.67 times the chance ofNPH after a positive CT. in most recent studies, the mortality 
associated with shunting is 4%_9%,139,3S3,381,387 somewhat lower than in older studies. However, 
for the purpose of this analysis mortality of shunting P(M) is taken at 10%, in order to avoid 
the effects of publication bias.'" 
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8.2 Results 
Diagnostic probabilities 
The probability of NPH after history-taking and physical examination for the key patient 
amounts to 11 %, see Table 23. In profiles 1 and 3 the absence of gait abnormalities decreases 
the likelihood of NPH considerably. The diagnostic probability of an intracranial space-oc-
cupying lesion in the key patient is 9%, and it ranges from 2% to 14% for the different clinical 
profiles. The probabilities of NPH when this condition is and is not suggested by CT, and the 
probability that the patient harbours any neurosurgically treatable lesion (a space-occupying 
lesion or NPH) and the CT shows it (P(NPH v SOL,cr +», is also listed for each clinical profile. 
Table 23. Diagnostic probabilities for the four clinical profiles of the four causes of dementia based on history and physical 
examination, and the probability of NPH, when the Computer Tomogram indicates such a lesion (CT+), and when it does not 
(CT-). The last column gives /he probability that /he CT rightfully indicates any treatable lesion (space-occupying lesion or 
NPH) onCT. 
Diagnostic probabilities Probability of NPH after Probability of a treatable 
CT lesion on CT 
profile NPH SOL MID AD P(J{PH I C1' +) P(NPH J C1'-) P(NPH v SOL,C£ +) 
0.005 0.02 0.005 0.97 0,01 0.00 0.02 
2 0.11 0.09 0.02 0.78 0.33 0.05 0.17 
3 0.02 0.04 0.02 0.92 0.13 0.01 0.06 
4 0.40 0.14 0.07 0.39 0.75 0.25 0.47 
In Figure 36 an analysis of these results to plausible changes in the estimates is shown for 
the key patient. Changes in the prior probability of NPH and of gait abnormalities in Alz-
heimer's disease influence the diagnostic probability considerably. 
In order to make generalizations to otherdinical profiles~ we constructed a diagnostic chart, 
using the log-odds form of Bayes' theorem (Figure 37).' This cbart allows one to estimate the 
likelihood ofNPH in a certain patient, before and after CT. The effects of age on the diagnostic 
probabilities is also incorporated. In patients aged 75, the same ordering of the diagnostic 
probabilities as in profiles 1-4 emerges, but the probability of a treatable lesion is lower, and 
does not exceed 15%. 
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Figure 36. Analysis of /he sensi6vity of /he probabifity of NPH after history and physical examination and aUer a posi6ve CT 
to plausible changes in e86mates. This figure relates to the key pa6ent (profile 2). The basefine e86male is 0.11 and 0.33 
respectively. 
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Frgure 37. Algorithm for the probablli86c diagnosis of normal pressure hydrocephalus in demented pa6ents. When a sign is 
present, /he ro"esponding number indicated by /he left-hand table should be added to a total score. The right-hand table is 
used to ronvert this score (10 6mes /he'logoddS) via odds to probabilities. For every 10 points increase in total score, the 
odds for NPH double. To obtain the probability of NPH aUer a posi6ve or negalive CT, add 18 or -14 to /he total score, 
respac6vely. 
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Decision analysis of shunting for NPH 
In Figure 38 expected utilities of shunting and no shunting are computed for the key patient 
by "folding back" the decision tree. The difference between the two strategies is small, with a 
slight benefit for no shunting in the key patient. 
0.92 improve 
NPH 
P(S)..o.67 
~ P(NPH)-O.33 no change 
SUMV<> 1·P(Sr-o.33 
1·P(M)..o.90 
noNPH ~ 1·P(NPH)..o.67 shunt 
"" 
P(M)..o.10 
NPH 
P(NPH)..o.33 
Figure 38. Decision tree for thIJ shunYng decision in paUems whose CT indicates NPH. All probability· and uUlity·vaJues thlJl 
are applicable 10 paUenl2 have been inserted. Folding back thIJ tree results in an expaC/ed uUfity of 0.73 for shunUng, and 
0.75 for no shunUng. 
The decision tree is also evaluated using a threshold technique.'" Figure 39 shows which 
combinations of values for the mortality of shunting and the probability of success after 
shunting result in equal expected utilities for both treatment options. These threshold- or 
''break-even'' lines are plotted for various levels of U, see also the methods section. This figure 
illustrates which patients will and which patients will not benefit from shunting, according to 
the expected utility criterion. For patients with profile 1 and 3 finding evidence for NPH on 
cr should not lead to shunting, even when the utility U of dementia is taken at 0.5 of theutility 
of recovery. For the key patient (profile 2) a clear-cut preference does not seem to exist in the 
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present analysis, but when the utility of dementia equals 0.5, shunting is preferred (see also 
the methods section for the interpretation of utility values). But for someone with a profile like 
patient 4 shunting seems to be beneficial This conclusion is based on clinical information and 
cr results, but it may be modified by other prognostic test-results (e.g. conductance to outflow 
measurement, or external1umbar drainage).35,141,308A07 
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Figure 39. Break-even lines for the shunting decision in patients suspected of NPH. X-axis: probability of successful shunt-
ing in a patient whose CT indicates NPH. Y-axis: mortality of shunting. The lines depict the combinaffons of values that 
resun in equal expected utJ7iffes for the "do not shunt" and "shunt" deciSion, for various levels of the utJ7ity of dementia, U. 
Below each threshold line shunting is preferred, above each line no shunting. Clinical profiles of 60-year-old patients are 
indicated by black dots numbered 1-4, and clinical profiles of 75'year-old pailents by open dots numoored 1 '-4'. 
8.3 Discussion 
We estimated the likelihood of NPH and intracranial space-occupying lesion in demented 
patients with a typical clinical profile. Based on these estimates, the chance of successful 
shunting for NPH was assessed. Decision analysis was used to weigh the risks and benefits of 
shunting in each patient. 
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This paper is based on the scientific evidence that is currently available. Where information 
is sparse, conclusions of a decision analysis can only be tentative. This does not imply that a 
quantitative approach should be abandoned, but rather that the analysis has been useful in 
identifying areas of clinical knowledge that would (if expanded) contnoute much to better 
decision making in dementia. Particularly, estimates of the relative inddence of Alzheimer's 
disease and related disorders, and of the frequency of diagnostic signs and symptoms are 
seldom reported in the literature. The data in this analysis seemed reasonable estimates to the 
authors when they considered the scarce evidence. This means that the results of this study 
should be applied to other patients with skill and caution. 
The analysis has a normal cerebrospinal fluid pressure as a fixed assumption. This does not 
mean that patients are required to undergo a lumbar puncture before its results can be con-
sulted. On the contrary, our tables and figures help surveying the clinical situation that will 
exist in the-likely- event that the pressure is normaL In this way, they contribute to the decision 
whether or not a cr or any other major diagnostic procedure is worthwhile. 
Our method of analysis has its limitations: In the computations we used binary tests (in-
dicating absence or presence of a sign or symptom). We did not allow for intermediate 
observations. Also, diagnostic features do not occur independently. This will influence the 
retiability of the computed values, if no corrections are made. We have tried to overcome these 
problems by sensitivity analyses and by using a global association factor. It is clear that we 
have chosen for maximum simplicity. In our opinion, taking more diagnostic features into 
consideration would not add much to the usefulness of the model because these feature 
probabilities would even be harder to quantify and dependence between features would 
become a greater problem. For the same reason, we did not include entities as Binswanger's 
disease and demented patients with periventricular white matter hypodensity in the analysis. 
Our anaiysis helps in distinguishing between patients who are likely to benefit from 
shunting and those who are not. The threshold approach suggests that only a relatively young 
patient with dementia of recent onset, the full triad of symptoms and cr evidence of NPH 
should be considered for shunting, if no additional prognostic information is available. For a 
patient of older age with the full triad and for a 60-year-old patient with only gait abnormalities 
and dementia a toss-up situation exists. More prognostic information might be of importance 
for these patients. Obviously, for the other patients, the finding of ventricular enlargement on 
cr -suggesting NPH - should not have any consequences. 
Results of other prognostic tests may be of value, especially for patients with a profile like 
thekey patient When a patient improves in cognition orgaitafier a diagnostic lumbar puncture, 
the chances of successful shunting are high, but this phenomenon is rare, and when there is 
noc1inical effect successful shuntingisstillquite likely.300 Conductance to outflowmeasur ement 
may be of value. However, the results of the group of B0rgesen have not been reproduced by 
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others. """'Moreover, the additional prognostic value of this test over more easily obtainable 
clinical information is not dear. The same argument holds for externa1lumbar drainage and 
continous pressure monitoring. To our knowledge, the value of both tests has never been 
assessed in a prospective, independent study. SPEer scanning may render useful information, 
but its prognostic value is suggested in one study only,138 
Our general recommendations will not surprise those who have followed or participated 
in the discussion of the management of NPH in the literature. However, the recommendations 
from our decision model have a rational basis. The assumptions are easy to identify and are 
open for discussion. Estimates can be adjusted to personal insight and to the results of other 
prognostic tests, and the consequences of these changes can easily be assessed. Moreover, 
application of the model leads to a more individualized decision, which takes patient char-
acteristics into account in a controlled way. 
The analysis can be helpful in comparing the value of pieces of diagnostic information. For 
example, the absence of gait abnormalities in a demented patient is important; it makes normal 
pressure hydrocephalus an unlikely diagnosis. When interpreting a CT of a such patient one 
should be aware that NPH andsuccessfuI shunting remain unlikely, even when hydrocephalus 
appears to be present. 
Dietch observed that in dementia patients without special features the rate of treatable 
lesions is very small.51 Vanneste already emphasized the importance of clinical signs for the 
prognosis after shunting in NPH patients. In his retrospective follow-up study, the proportion 
of patients with permanent overall improvement in the categories with 'probable', 'possible' 
and 'improbable' normal pressure hydrocephalus according to a global dinlcal/CT scale was 
65%,15% and 13%, respectively.'" However, clinical and er criteria were informally weighed 
and lumped together in one scale, making more detailed conclusions impossible. 
In our opinion more information on thespedficityofclinical signs such as gaitabnormalities, 
urinary incontinence, slowness and apathy in Alzheimer's disease and related disorders is 
needed. 
In the diagnostic and therapeutic management of a dementia patient the clinician has to 
rely on experience and intuition to manage the large amount of information that arises from 
clinical findings, knowledge, and the literature. We do not suggest that our approach should 
be used instead of the approved methods of clinical reasoning. But we think that we have 
shown that a formal, quantitative approach is useful in the differential diagnosis and man-
agement of dementia patients. 
Notes 
a. This chapter is adapted tram; Dippel DW!, Habbema JDF. Probabilistic diagnosis of normal pressure hydro-
cephalus and other treatable cerebral lesions in dementia. J Neural Sci. In press. 
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h. Thesesubjectiveestimates were challenged by a senior researcher in clinical decision theory with special interest 
in the neurosciences, by a senior neurologist with long academic experience, and by an academically trained 
neurosurgeon. 
c. Because of rounding, and because we rook theweighted average of the diagnostic probabilities for the other causes 
of dementia, the results are accurate by approximately 5%. 
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Individualized prognosis in subarachnoid haemorrhageO 
Patients with subarachnoid haemorrhage have a poor prognosis. The three-month mortality 
after admission to hospital is about 40%/69 and varies with patient selection.256,293 Part of the 
mortality can be attributed to the initial haemorrhage, but rebleeding and cerebral infarction 
also take a heavy toll. 
Medical and surgical interventions have always aimed at prevention of the complications 
from subaracimoid haemorrhage. However, there is a lack of consensus about major aspects 
of the medical and surgical management Medical treatment options consist of antifibrinolytics 
(tranexamic add (TEA» to reduce the rate of rebleeding, and caldum antagonists (nimodipine) 
to prevent infarction. However, a favourable effect of tranexamic acid could not be demon~ 
strated in a controlled study,2l:r2 nor in a randomized controlled trial.389 The rate of rebleeding 
in thetranexamicadd branch of both studies was significantly reduced, but the rate of infarction 
was increased. The authors concluded that .... .for patients to benefit from antifibrinolytic 
therapy, the complications of treatment must be minimized while the ability to prevent 
rebleeding is preserved".'" Surgical treatment involves clipping of the aneurysm responsible 
for the haemorrhage. Early surgery will prevent most rebleeds, at the expense of a risk of 
surgical mortality. Delayingsurgeryuntil day 10-12 will decrease surgical mortality, but cannot 
prevent early rebleeds. 
All treatment options affect rebleeding and infarction risks. Patient-oriented dedsion 
making should thus depend on individualized estimates of the risks of rebleeding and 
infarction. We wili derive such estimates from a re-analysis of the da ta of the randomized 
clinical trial oftranexamic add against placebo.'" The effect of newer modifications of treatment 
(i.e. nimodipine307 and management of hyponatremia 159) on outcome will be assessed. 
In the next chapter, the results presented here will be used for a decision analysis of best 
combinations of medical and surgical strategies for subarachnoid haemorrhage patients, 
including the timing of surgery. 
9.1 Material and methods 
The original study was a randomized, placebo-controlled double blind clinical trial. Of the 
479 study-patients with subarachnoid haemorrhage that occurred within 72 hours, 210 were 
admitted to the Neurological Department of Dijkzigt Hospital Rotterdam, 23 to the Neurol-
ogical Department of the Academisch Medisch Centrum in Amsterdam, 217 to the Neuro-
surgical Department of the Southern General Hospital in Glasgow, and 29 to the Neurosurgical 
Department of the Royal Free Hospital in London. In total, 904 patients with subarachnoid 
haemorrhage were seen in the four centres during the study period, thus, 47% were excluded, 
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mainly because of a lapse of more than 72 hours between bleeding and admission (205 patients), 
a cause for subarachnoid haemorrhage obviously other than aneurysm (87 patients), death 
within a few hours in a moribund patient (55 patients), and (emergency) operation within 72 
hours from bleeding (51 patients). For a detailed description of the trial protocol see the original 
publication. 389 A few years after the conclusion of the trial and the publication ofits results, the 
er's made within 48 hours from admission were re-analyzed and graded according to the 
amount of subarachnoid blood, intraventricular blood and severity of hydrocephalus, because 
other studies had demonstrated the value of CT's in predicting infarction and poor outcom-
e?,119,171 
The er's of the 29 patients in the London branch of the trial were not available for 
re-analysis. Therefore, these patients are excluded, leaving 450 patients. In our analysis, only 
the patients with a er diagnosis of subarachnoid haemorrhage (blood visible in basal cis-
terns/fissures) or with a clinical diagnosis of subarachnoid haemorrhage with a positive 
angiogram within four days from admission are included. Forty-five patients did not fulfil 
these criteria of inclusion. Of the remaining 405 patients, 67 did not have their er re-analyzed, 
because further investigations did not reveal an aneurysm. This group is not excluded, but 
considered separately, because the present study has a pragmatic viewpoint, as it concerns 
prognosis and decision making at the time of admission ( ; inclusion in the study) in patients 
with possibly aneurysmal subarachnoid haemorrhage. 
Clinical variables 
As the results of this study should aid in decision making early after admission to the 
hospital, only the clinical information that is available at admission is considered. 
The medical history was taken with systematic recording of the time that had elapsed 
between the haemorrhage and admission to the hospital, complaints of headache and the 
occurrence of seizures or loss of consciousness at the time of the haemorrhage. A full neurol-
ogical examination was carried out on admission to hospital The level of consciousness at 
admission was classified according to the 14 point Glasgow Coma Scale.'" The presence of 
neck stiffness, urinary incontinence, speech abnormalities, retinal abnormalities (subhyaloid 
haemorrhage or papilledema), pupil abnormalities and limb weakness was noted. 
Hydrocephalus on er was defined as a bicaudate index greater than the 95'" percentile for 
age."" Patients were graded according to the amount of subarachnoid blood on er by aSSigning 
a score to each fissure or cistern according to its filling grade (0 ; no blood, 1 ; small, 2 ; 
moderate, and 3 = large amount of blood). A sumscore was created by adding up the scores 
for the cisterns. Cisterns that were not visible on cr were aSSigned the average value based on 
the other cisterns. Similarly, the amount of blood in each ventricle was also scored (0 ; no 
blood, 1 ; sedimentation, 2 ; partly, 3 ; completely filled with blood), and a sumscore was 
created. For a detailed description of the grading of the amount of blood on er see Hijdra.'1Il 
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For the present analysis, most clinical variables are recoded from three- or five-point scales 
to two-point (0=absent/1=present) scales: Age (55 or less; over 55), Hunt and Hess' score a,1I; 
Ill-V), Glasgow coma score (12-14; < 12), Amount of subarachnoid blood (0-9; 10 or more), Amount 
of intraventricular blood (0-2; 3 or more). Cut--off scores were determined by clinical usefulness 
and reproducibility,''''' but otherwise by the median. Absent (0) refers for all variables to the 
prognostically most favourable category. 
Events and health outcome 
Events such as death, rebleeding and infarction occurring within 1 month, and the health 
outcome at 3 months were recorded. Definite rebleeding was defined as sudden deterioration 
with increased haemorrhage, confirmed by CT or autopsy when compared to a previous CT, 
and possible rebleeding as sudden deterioration and death, without the possibility of proof by 
CT scan or autopsy. The diagnosis of definite infarction was made when the patient gradually 
developed focal signs or deteriorated in conscious level, with infarction confirmed by a CT 
scan or autopsy. Infarction was deemed possible when the patient gradually developed focal 
signs only, without CT confirmation. In our re-analysis, the "possible" and "definite" categories 
are combined. The health outcome after 3 months was classified according to the Glasgow 
Outcome Scale}93 consisting of the categories death or persistent vegetative state; severe dis-
ability; moderate disability; and full recovery. 
Statistical analysis 
The statistical analysis consisted of four steps. First, univariate analyses with one sided i 
significance tests are used to identify potential prognostic factors.'" One-sided significance 
tests are used, except for the variables sex, delay (of admission) and for the effect of treatment on 
three-month mortality, because in these cases the direction of the effect is not known before-
hand. Proportional hazards regression with stepwise forward selection assesses the impact of 
these variables on the occurrence of rebleeding, infarction and mortality from the initial 
haemorrhage in the presence of other prognostic factors.62;};OO;J261fl The selected variables are 
called prognostic factors. The risks of rebleeding, infarction and mortality in the 67 patients 
who did not have their CT analysed because another cause of the subarachnoid haemorrhage 
became evident during hospitalization, did not differ significantly from the base-line hazard. 
It is conceivable that these patients would have minor abnormalities on CT. Therefore, they 
were induded in the low risk group of the "CT-variables" in the regression analysis. 
Cox' proportional hazards model with stepwise forward selection of variables is used to 
assess the prognostic value of clinical variables in a multivariate framework over time. In this 
model the hazard rate (the instantaneous risk or incidence density at time t) of each event m 
(rebleeding, infarction, mortality from the initial haemorrhage and three-month mortality) for 
the nih individual, is expressed as a multivariate function (containing p variables x,.) of the 
base-line hazard function h.(t): 
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h •.• (I) = h.(I)· CX{t, ~ •. ,x...,) (26) 
Thus, for each individual or subgroup that is characterized by a unique combination of 
values for certain variables, the hazard rate h.,(t) is proportional to the base-line hazard 
h.(t).""'" The selection of variables for the regression equation is based on statistically 
significant changes in maximized partial likelihood (p <0.05, one sided) with and without the 
variable that is considered.57 The proportionality assumption is checked by stratifying the 
study-population by each variable and plotting In(-lnS.(I)) against time for mean values of 
the other covariates.2OO These plots are not presented here for reasons of space, but no gross 
violations of the proportionality assumption were encountered. 
Proportional hazards regression analysis can be used to estimate the relative risk RR (the 
ratio of incidence densities of the exposed and non-exposed with regard to event m) from a 
certain item of diagnostic information x ..... i' controlled for other prognostic factors; 
Rk - exp(~'.i . x.). (27) 
because the risk profile with x,.,.J = 0 is assigned to patients who are in the best prognostic 
category, this gives Rk = 1. Also, the parameters can be used to estimate for the n'" patient the 
cumulative probability p .. (t) of event m until day t, based on the available clinical information: 
~ _ _ - _ _ - ",(,~.'·· ..... ,l 
r •.• (I)-1 > •.• (1)-1 >.(1) . 
(28) 
in the third step, the event probabilities are brought in a competing risks model to compute 
the three-month mortality, which is expressed as a function of rebleeding and infarction risks 
and their lethality, and of mortality from the initial haemorrhage, and - indirectly - of treatment 
choice. The competing risks model combines mortalities from rebleeding, infarction and the 
initial haemorrhage. Data for rebleeding and infarction are obtained by multiplying by 
proportional hazards calculated probabilities with the lethality of rebleeding and infarction. 
Thelethality ofrebleedingandinfarctionare estimated usinga minimum i' -parameterization'" 
of the risks of mortality from the initial haemorrhage, from rebleeding and infarction and their 
lethality, that allows two independently occurring events and assumes that the lethalities are 
not affected by treatment with tranexamic acid. In this way, an individualized estimate of the 
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prognosis after subarachnoid haemorrhage is presented. Fmally, the impact of the prognostic 
factors on the difference in three-month-mortality is esthnated, and presented in a chart that 
is easy to use in a clinical setting. 
9.2 Results 
Table 24 lists the clinical characteristics of the study population. There are some imbalances 
between the two treatment groups. More patients in the placebo branch of the study had an 
angiogram showing an intracranial aneurysm and eventually underwent surgery. This table 
also shows the results of univariate analyses. For each variable it is indicated whether a stat-
istically significant relation exists with three-month mortality (0), mortality from the initial 
haemorrhage (M), and the occurrence of infarction (I) and rebleeding (R). All clinical variables 
are associated with three-month mortality, except headache, seizures at the ictus, neck stiffness, 
history of hypertension, and cardiovascular history. The signs and symptoms that are associated 
with infarction are generally not associated with rebleeding, but loss of consciousness at the ictus 
is an exception to this rule; it is the only variable that is related to rebleeding in the univariate 
analyses, apart from tranexamic acid. 
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Table 24. Clinical cIlatacteriSfjcs otthe study population by type of treatment, and their relaffon with three-month mortality, 
mortality from the iniffaJ haemonhage, and the occurrence of rebleeding and infarction. O. Overall (three-month) mortality, 
M. monaIity from the iniffaJ haemonhage, R = rebleed'mg, I = infarction (+ = staffsticaJly signifteant relation •• no staUSfjcaDy 
significant relation (p = 0.05, one sidedr)). t indicates a S/aIiSfjcaJly significant difference ({l<O.05 two sided X') between 
the placebo and Iranexamic acid group. 
P"cebo tranexarnic ace relation with 
(N=202) (N=203) outcome 
No perc. No perc. 0 M R 
Age + + 
<36 31 15% 31 15% 
36-45 38 19% 38 19% 
46-55 52 26'% 58 29% 
56-65 62 31% 40 20% 
>65 19 9% 36 17% 
Sex 
female 125 62% 122 60% 
modified Hunt & Hess score + + 
1-11 103 51% 116 57% 
III 63 31% 52 25% 
IV-V 36 18% 35 17% 
Glasgow coma score + + 
3-11 102 50% 110 54% 
12,13 62 31% 53 26% 
14 38 19% 40 20% 
Medical history 
History of hypertension 50 25% 33 16%t 
Cardiovascular hislOry 9 5% 21 10% + 
(To be continued on next page.) 
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(Continued.) Clinical characteristics of the study pllpuIation. 
Placebo tranexamic acid relation with 
(N=202) (N=203) outcome 
Signs and symptoms 
Loss of consciousness at the ictus 102 51% 97 48% + + + 
Seizures at the ictus 23 11% 20 10% 
Headache 176 87% 174 86% 
Incontinence 49 24% 51 25% + + 
Neck Stiffness (moderate-severe) 144 71% 150 74% 
Speech abnormalities 17 8% 9 4% + 
Retinal abnormalities 44 22% 43 21% + + 
Pupil abnormalities 13 6% 15 7% + + 
Umb weakness 32 16% 25 12% + + 
CompU1ed Tomography 
Subarachnoid blood + + + 
0-9 79 39% 62 31% 
10-19 56 29% 52 25% 
20-30 41 20% 46 23% 
missing values 24 12% 43 21% 
Intraventricular blood + + 
0-2 137 68% 111 55% 
3-12 41 20% 49 24% 
missing values 24 12% 43 21% 
Haematoma 51 26% 53 27% + + 
missing values 2 1% 3 2% 
Hydrocephalus 36 18% 36 18% + + 
missing values 27 13% 45 22% 
Angiography 
negative 14 7% 28 14%t 
intracranial aneurysm 149 74% 119 59% 
not done 39 19% 56 27010 
Surgery 106 53% 86 42%t 
Table 25 lists the results for each treatment group. Tranexamic acid reduces the risk of 
rebleeding by 13.8% (0.900=8.2%-19.4%) but it increases the risk of infarction by 8.3% (0.90 
0=1.5%-15.1 %). Thedifferencein three-month mortality (2.5%,0.95 0=-6.9%-12.1 %) is slightly 
infavour of tranexamic acid. It is larger when patients in perSistent vegeta tive state are included 
with the deaths (4.1 %,0.950 = -5.4% -13.4%). Fifty-two percent of the patients who had an 
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infarction, 84% of those who had a rebleeding, and only 23% of those who had neither event 
died. The lethality of rebleeding and infarction, and the mortality from the initial haemorrhage 
are all somewhat lower in the placebo group, but this is not statistically Significant. 
Table 25. Overall results in the placebo and the tranexamic acid group: rebleeding and infarction occurring within 1 month, 
and the three·month health outcome. 
Events 
Rebleeding (lethality) 
Infarction (lethality) 
Health outcome 
Persistent vegetative state 
Severe disability 
Moderate disability 
Well 
Mortality 
from rebleeding 
from infarction 
from the initial haemorrhage 
Mortality from any cause 
Prognostic factors 
Tranexamic acid 
(N=203) 
7.4% (86.7%) 
26.7% (53.7%) 
0.0% 
13.9% 
10.9% 
38.1% 
6.4% 
14.4% 
16.3% 
..ill..L± 
100.0% 
Placebo 
(N=202) 
21.3% (63.7%) 
18.3% (48.7%) 
1.5% 
9.9% 
9.4% 
39.6% 
17.8% 
8.9% 
12.9% 
a~6% ± 
100.0% 
Table 26 summarizes the results of the proportional hazards regresSion analysis with 
stepw:ise forward selection of prognostic factors. Tranexamic add is not only a prognostic factor 
for rebleeding and infarction, but it also increases the mortality from the initial haemorrhage. 
The relative risk (rate ratio) of rebleeding and infarction for patients treated with tranexamic 
acid,corrected for the effect of other Significant prognostic factors is 0.3 and 1.5, respectively. 
This is consistent with the observed risks in this trail, where the risk of rebleeding is reduced 
from 21.3% to 7.4%, for an uncorrected relative risk of 0.34. 
Figures 4Oa-c show the risks of infarction, rebleeding and the mortality from the initial 
haemorrhage for the minimum hazard patient and for a patient with values of 1 for loss of 
consciousness at the ictus (LCn and amount of subarachnoid blood >9 (SAB), who is treated with 
placebo or with tranexamic acid. Note how the favourable effect of tranexamic acid on 
rebleeding is counteracted by the risk of mortality from the initial haemorrhage and infarction. 
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Table 26. Proportional hazards model; Stepwise selection of variables and the associated rate ratio i.e. the ratio of the 
hazard with and without the symptom. Variables are listed in order of selection. 
Step Variable 
2 
3 
4 
5 
2 
3 
2 
3 
4 
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Infarction 
Amount of subarachnoid blood on CT >9 (SAB) 
Retinal abnormaUties (RE"!) 
Amount of intraventricular blood on CT >2 (IVB)) 
Treatment with tranexamic acid (TEA) 
Glasgow coma score <12 (GCS) 
Rebleeding 
Treatment with tranexamic acid (TEA) 
Loss of consciousness at the ictus (LCI) 
Amount of intraventricular blood on CT >2 (IVB) 
Mortality from the Initial haemorrhage 
Glasgow coma score < 12 (GCS) 
Amount of subarachnoid blood on CT >9 (SAB) 
Treatment with tranexamic acid (TEA) 
Age >55 (AGE) 
Rate Ratio (90% Confidence Interval) 
1.9 (1.3-2.8) 
1.9 (1.3-2.8) 
1.6 (1.0-2.4) 
1.5 (1.0-2.1) 
1.8 (1.2-2.8) 
0.3 (0.2{).5) 
2.1 (1.3-3.3) 
1.8 (1.2-2.8) 
5.3 (2.8-9.8) 
3.4 (1.7-7.2) 
2.1 (1.1-4.1) 
2.2 (1.2-4.2) 
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Fl9ure 40. Cumulative probabilities of rebfeeding, infarction and mortality from the initial haemorrhage for the minimum hazN 
aid paUent, not treated (curve 1-P) and for a paUent with loss of ccnsciousness at the ictus ana amount of subarachnoid 
blood >9, treated (ff-T) and not treated (I/-P) with traneXEmic acid_ Each graph has the number of days since admission on 
the X~is, and the cumulative probability on the Y·axis. 
Clinical profiles and treatment effects 
In order to get a better insight into the relation between overall mortality, clinical signs at 
admission and the complications from subarachnoid baemorrhage, we used the competing 
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risks model described in the methods section to compute the three-month mortality with and 
without tranexamic acid, as a function of the risks of rebleeding, infarction and mortality from 
the initial haemorrhage for each clinical profile. 
In order to find out if interaction between the effect of tranexamic acid on three-month 
mortality and the two main prognostic factors for rebleeding and infarction eJdsts, a separate 
proportional hazards regression model for overall mortality with four prognostic factors was 
constructed: GlasgllW coma score <12 (GCS, RR;2.5, 90% a 1.8-3.5),amount of subarachnoid blood 
on CT >9 ( SAB RR;1.7, 90% a 1.2-25), loss of corzscicusness at the ictus (LCI, RR;1.8, 90% a 
1.3-26), and Age >55 (AGE,RR;1.5, 90% a 1.0-20). Along with tranexamic add (TEA, RR;0.5, 
90% a 0.3-0.9) a factor TEA'SAB (RR 24, 90% a 1.2-4.8) could be induded. This interaction 
factor implies that for patients with a large amount of subarachnoid blood on cr (SAB;1) TEA 
increases the mortality risk, but for a patient with a small amount of subarachnoid blood on 
cr the mortality is decreased by tranexamic add. Adding a factor LO"TEA did not result in 
a statistically significant improvement of the model. 
Figure 41 shows the rebleeding and infarction chances and the estimated mortality 
according to the competing risks model for each clinical profile. A tree structure illustrates how 
the study population can be ordered according to the values for individual prognostic factors. 
The three-month mortality ranges from below 20% to over 80%. In order to approximate the 
natural history of subarachnoid haemorrhage, it is assumed that surgery does not take place. 
Infarction risks are adjusted for the effects of modern fluid management, see further below. 
The prognostic factors that make up the. clinical profiles were ranked according to the impact 
they have on the mortality difference between the treatment groups. The most common profiles 
(N) 10) have unfavourable values for not more than one prognostic factor. 
Table 27 shows the expected three-month mortality for the whole study population, when 
all individualized estimates of the competing risks model are averaged. When surgery does 
not take place (regime D, the risks of rebleeding will be higher than observed in the 
study-population. As a consequence, the three-month mortality will also be higher, and the 
mortality improvement due to tranexamic add will be greater. Without surgery, the expected 
three-month mortality with tranexamic acid is even smaller than was observed in the study 
population. However, surgery is used as a censoring varisble, and some patients have 
undergone emergency operation. 
In regime II the expected three-month mortality is computed as if 47.4% of the total study 
population (conform the observed proportion averaged for the two treatment groups) will 
undergo operation. This results in mortality differences between placebo and tranexamic add 
as observed in the study population, but the expected three-month mortalities are 5% lower, 
because surgical mortality (i.e. the risk of mortality of any kind after being operated) is not 
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Legend of Agure 41. Estimated risks of rebleeding (R). infarction (I) and /hree·mon/h mortafity (M) for each clinical profile, 
without tranexamic acid or surgical treatment but with adjustment for the effect of modem fluid management. The tree struc-
ture illustrates how clinical profiles are determined by absence (upper branches, 0) or presence (lower branches, 1) of each 
symptom. The number of patients wi/h each profile is /isted under (N). Bold text indicates more common (N)10) clinical 
profiles. For exampie, a patient wi/h clinical profile (H 1-->(H 1-->0 has a rebleeding and infarction risk of 29% and 37% 
respectively when treated wiIh placebo, and a 45% 3omonth mortality. 
taken into account. Taking the surgical mortality at 11 % (on average) for patients who are 
operated in both treatment groups results in the three-month mortality rates that are equal to 
those observed in the study population. 
Table 27. Competing risks model. Differences in three-month mortality between tranexamic acid and pfacebo for three clini-
cal management regimes: I no surgery at all, /I Surgery at day 10, and /1/ surgery atday 10 wi/h "modem management". For 
further expfanation see the Results section. 
Regime Assumptions tranexamic placebo Difference 
acid 
No surgery 
a "basefine" 34.3% 41.5% 7.2?/o 
b "modem fluid managemenr 33.2% 40.8% 7.6% 
Surgery 
a no surgical mortality 32.0% 34.4% 2.4% 
b surgical mortality. 11% 37.0% 39.4% 2.4% 
III Surgery and "modem managemenr 
a "modem fluid managemenr 35.9% 38.7% 2.8% 
b "modem fluid managemenr and nimodipine 34.2?/o 372% 3.0% 
Nimodipine reduces the rate of infarctions by approximately 34%."" In a recent study 
hypertension was treated only when the patient received prior medication, and fluid intake 
was not restricted, in order to prevent infarctions.l59,406 The rate of infarction was 10% instead 
of the expected 20%. However, this study had no experimental design. Moreover, in theplacebo 
branch of the British Nimodipine study, where no fluid restriction was employed, the rate of 
infarctions is even higher than in the placebo branch of the tranexamic add trial, and the rate 
of fatal infarctions is about equal."""" The effect of the changes in fluid-management and 
management of hypertension is incorporated by adjusting the regression estimates ofinfarction 
risk in model nob according to the weighted mean of HasanlS9 and our data. This implies a 
140 
Individualized prognosis in subarachnoid haemorrhage 
reduction in infarction rtsk by 1 - «I - .34) xO.81» = 46%, when the effects of nimodipine and 
hypertension and fluid management are independent The three-month mortality is decreased 
by 2.2% in the placebo group and by 2.8% in the tranexamic acid group, and the mortality 
difference is increased by 0.6% in favour of tranexamic acid (0.4% by modern fluid management 
and 0.2% by nimodipine). 
Figure 42 is a prognostic chart that depicts the impact of presence or absence of prognostic 
factors on the effect oftranexamic acid. It is assumed that each patient is scheduled fordelayed 
surgery as in regime IlL The estimates are based on a linear regression of the prognostic factors, 
where the difference in three-month mortality has to be predicted. The fit of the model is 
excellent (.-'=0.95, p<O.00OO5, standard deviation of residues 1.6%). 
Three-month mortality difference (TEA ~ placebo) 
for patients with subarachnoid hemorrhage 
admitted within 72 hrs and scheduled for surgery on day 10-12 
Loss of consciousness at the ictus ~ 8% 
Amount of subarachnoid blood on CT >9 + ?Ole> 
Retinal abnormalities + 1% 
Glasgow coma score <12 + 12<>/0 
Amount of intraventricular blood on CT >2 - 5% 
Age >55 + 4% 
Constant. - 7% 
Mortality difference (Add:) 
FJgure 42. Difference in three-month mortality be tween tranexamic acid and placebo determined by the presence or 
absence of prognostic veliables torrebleeding and infatClion. The paUent is scheduled for surgery on day 10-12 and 
receives modern medical management. ExEmpie 1: TmneX1llTlic acid treatment in paDent who saUsfies none of the crileria 
decreases the lisk of mortality affer subarachnoid haemorrhage by 7%. ExEmple 2: Treatment with lranexemle acid 
increases the mortality in a patient who has not lost consciousness at the ICtus, with a Glasgow coma score of 11 , no retinal 
abnormaJilies, and a substanlial amount of subarachnoid, but virtJJally no intraventriculat blood on CT, by 12'1.. 
9.3 Discussion 
We have used proportional hazards regression to investigate the effect ofc1inical variables 
on the risk of rebleeding, infarction and mortality from the initial haemorrhage. A competing 
risks model computes the three-month mortality as a function of the risks and lethality of 
rebleeding and infarction, and of the mortality from the inirial haemorrhage. Then, the effect 
of the prognostic factors for rebleeding, infarction and mortality from the inirial haemorrhage 
on the difference in mortality between placebo and tranexamic acid has been presented. 
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M.et/wd%gica/ aspects 
Our approach to modelling the clinical course of subarachnoid haemorrhage and the effect 
of tranexamic acid via prognostic factors for "intermediate events" is justified and clinically 
relevant~ becauseall treatments for subarachnoid haemorrhage act through modification of the 
risk of rebleeding and infarction. 
The results of any predictive model should be interpreted with care. An area of concern is 
the external validity of the study. The observations described here date from several years 
hence. cr scans have improved technically, but not to such an extent that this considerably 
influences the diagnosis of rebleeding or infarction after subarachnoid haemorrbage. The 
medical management of subarachnoid haemorrhage has changed, but adjustments for fluid 
management and treatment with nimodipine307 have been made. The regression models have 
not yet been tested on an independent sample. As is apparent from many reports, the base-line 
prognosis after subarachnoid haemorrhage differs from centre to centre. Beforeuse~ each centre 
would require to carefuily considerthenecessityofcalibratingthemodelsforthelocalsi tuation. 
Our study is not an ordinary retrospective subgroup analysis which scrutinizes the data 
for allkinds of modifications of the treatment effect. In this study we have tested the hypothesis 
that patients with a different risk profile for the complications of subarachnoid haemorrhage 
will be affected differently by tranexamic acid.'32 The highly variable prognosis of patients with 
subarachnoid haemorrhage was already recognized as an argument for such an effect-mo-
dification. Moreover~ the investigators who conducted the study already considered the 
possibility of effect modification, but they used less sensitive methods (i.e. logistic regression). 
Still, one requires caution in individualizing treatment effects within a 'negative' clinical trial."" 
However~ there were in this case ~ a priori~ clinical arguments for interaction between the tra-
nexamic add effect on mortality and predictors of rebleeding and infarction. A welcome side 
effect of the regression analysis is that it allows us to make consistent estimates of risks for 
clinical profiles that have not been observed in the trial. 
A side-issue is that we used the observed mortality difference (2.5%) as the best estimate 
of the treatment effect. In a classical statistical approach one might argue that the null-hypo-
thesis of "no treatment effect" is not rejected~ and that therefore a zero mortality difference 
should be assumed.'" However, the difference is small. 
Previous studies 
Other studies have also reported on the role of computed tomography in overall prognosis 
and in predicting infarctions in patients with aneurysmal SAH."'·171.372 These studies had a 
more explanatory than a pragmatic, decision-oriented character. For example, in the studies 
of Brouwers" and Hijdra,171 patients with a cause of the SAH other than a ruptured aneurysm 
were excluded from the analysis. In the latter study, clinical variables other than Hunt & Hess' 
grade and the Glasgow Coma score were not considered. 
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Our results confinn previous work identifying the amount of subarachnoid and intra-
ventricular blood as important predictors of infarction.'..,·16. Surprisingly, retinal abnormalities 
(comprising both subhyaloid haemorrhage and papilledema) also seem to be important 
independent predictors of infarction. Vanderlinden suggested a relationship between the 
occurrence of subhyaloid haemorrhage and sudden increased intracranial pressure in four 
cases of SAH, in whom these signs occurred after episodes of rebleeding.'" In an older series 
of 75 patients with SAH, the demonstration of subhyaloid haemorrhages seemed important 
prognostically, for 14 out of 23 patients with subhyaloid haemorrhage died, compared to 14 
out of 52 without this sign (p < O.D1, iJ.1Sl Re1inal abnormalities may relate to the severity 
and/or duration of the rise in intracranial pressure, occurring during aneurysm rupture and 
may represent a dynamic factor that is not covered by SAB and NB. 
In previous studies using a reliable definition of rebleeding, treatment with tranexamic add 
was the only prognostic factor assodated with rebleeding. Hasan found that patients with 
hydrocephalus who had extracranial drainage had a significantly higher risk of rebleeding. 
Theynoted that these patients underwent operation less often, but they did not adjust for longer 
exposure time.l60 We found two other factors related to the occurrence of rebleeding: loss of 
consciousness at the ictus and amount of intraventricular blood >2. Both may again indicate the 
dynamics oftheSAH, perhaps representing the size of the breach in the fundus of the aneurysm. 
Conclusions 
We conclude that the occurrence of rebleeding after subarachnoid haemorrhage relates to 
loss of consciousness at the ictus and to the presence of intraventricular blood. No other studies 
have demonstrated such a relationship. We have confirmed that the amount of subarachnoid 
and intraventricular blood on CT, and the Glasgow coma score are valuable, independent 
predictors of the occurrence of infarction. Other studies have already shown the reliabillty of 
these factorsY'O,406 Infarction also seems to be related to the presence of retinal abnormalities. 
This factor has not been considered in previous studies. 
Tranexamic add increases the mortality risks of patients with a large amount of sulr 
arachnoid blood on their initial CT, and it decreases the mortality risks of patients with a small 
load of blood and a high risk ofrebleeding. This conclusion is supported by clinical knowledge, 
the results of our competing risks model, and was confirmed by a statistically Significant 
interaction between amount of subarachnoid blood on CT and tranexamic add in theregression 
model for three-month mortality. The predictions from our competing risks model were 
condensed into a prognostic chart. 
Tranexamic add seems to relate to mortality from the initial haemorrhage in the propor-
tional hazards regresSion analysis, although this did not appear in the univariate analyses. 
Perhaps some of the mortality after the initial haemorrhage was in fact caused by ischaemia, 
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making our observation the result of difficulties with classification. Age is not a predictor of 
rebleeding or infarction, but it is associated with a higher mortality, thus representing a higher 
vulnerability of the elderly, see also Muizelaar.'" 
Our results can aid clinical practice. The prognostic factors are all easy to determine from 
clinical examination and from computed tomography. They can be used in assessingindividual 
prognosis. Moreover, if operation is not planned within the first few days, the information can 
indicate which patients should, and which should not be treated with tranexamic add. 
Further research 
We are aware that proof of the effects that are described in this analysis can only be obtained 
by conducting another experimental study, comparing modern subarachnoid haemorrhage 
management alone with modern subarachnoid haemorrhage management and tranexamic 
add. Our study may be helpful in identifying the right target population for such a triaL 
Interestingly, the type of patient that may benefit from treatment with tranexamic add is 
also likely to benefit from (early) surgical treatment. Surgery is primarily aimed at prevention 
of rebleeding, and its risks are, like treatment with tranexamic add, greater for patients who 
are at high risk of infarction. Only a very large randomized clinical trial may perhaps determine 
whether for certain patients a combination of medical therapies (probably including nimodi-
pine) with postponement of surgery to day 10-14, should be preferred over early surgical 
treatment. 
Oinical decision analysis'16 is an alternative approach to comparing many complicated 
management strategies, using sound estimates of risks and treatment effects. This study serves 
as a framework on which to base such an approach, integrating knowledge from different 
sources. The results of the decision analysis will be published in the next chapter. 
Notes 
a. This chapter is adapted from: Dippel DWJ, Van CrevelH, Lindsay KW,HijdraA, Habbema JDF. Management 
of subarachnoid hemorrhage: Individualized prognosis. Submitted for publication. 
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Chapter 10 
Management of subarachnoid haemorrhageO 
Subarachnoid hemorrhage is most often the result of rupture of an arterial intracranial 
aneurysm, close to the circle of Willis. Even when patients survive the initial hemorrhage and 
remain in good condition, the risk of deterioration from recurrent hemorrhage and brain 
ischemia or infarction is high. 
Surgical treatment is aimed at occluding the aneurysm from the drculation before 
rebleeding occurs. Early surgery on day 1-3 after subarachnoid hemorrhage has been advocated 
in order to minimize the rebleed risk Early surgery is more hazardous than delayed. surgery 
(on day 10-12), because the brain is tight and swollen, and the risk of vasospasm and infarction 
is increased.. Yet excellent management results have been reported by several authors.333,359 
Delayed surgeryis less effective than early surgery, because fewer patients will reach operation. 
Because of its relative safety, it is the treatment of choice among many neurosurgeons.204 
All medical treatment options act to decrease the potential complicationsfromsubarachnoid 
hemorrhage. Antifibrinolytics (tranexamic add or TEA) reduce the risk of rebleeding, but 
increase the risk of infarction.202,389 There is no empirical proof of a beneficial effect of antifi-
brinolytics on outcome after subarachnoid hemorrhage. We showed. in the previous chapter 
that antifibrinolytics may be used in selected patients with low infarction risks. It may be used 
as an alternative to operation in the first few months, or it may serve to bridge the dangerous 
period between admission to hospital and delayed surgery on day 10-12. Nimodipine,a caldum 
antagonist, reduces the risk of infarction both in pre- and post-operative patients with sub-
arachnoid hemorrhage, and it appears to remain free of major side-effects. 3fJ1 A high fluid intake 
and plasma volume expansion seems to be beneficial in patients at risk of ischemia.1S9 
Fludrocortisone acetate is commonly used to reduce salt wasting in patients with subarachnoid 
hemorrhage. Hyponatremia is associated with the occurrence of infarction, but a beneficial 
effect of fludrocortisone acetate on infarction risk or overall outcome has not been establi-
shed.158.406 
There is no consensus with regard to the use of antifibrinolytics and to the timing of 
aneurysm surgery after subarachnoid hemorrhage.122,21S,252,383,390,4Ol Moreover, it is unlikely that 
a single treatment strategy is best for all patients, with widely differing prognoses. Randomized 
trials comparing more than two medical regimes and/or different policies on the timing of 
surgery do not seem feasible. Only one large non-randomized comparative study has been 
carried out}ID..204 and one rather small randomized study}S9 both with inconclusive results. 
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A clinical decision analysis approach, using the best available, individualized estimates of 
risks and benefits of each treatment may be the best method to overcome the problems men-
tioned above. In the previous chapter, a re-analysis of a randomized clinical trial of tranexamic 
add, an antifibrinolytic agent, we described the risks of rebleeding, infarction and mortality 
from the initial hemorrhage as multivariste lime-dependent functions of clinical variables, 
using proportional hazards regression. These estimates will be used in the dedsion analysis 
that is presented in this paper. 
The following actions are considered in the analysis: Early surgery (on day 2) (ES), delayed 
surgery (on day 10) (oS), late elective surgery (after three months) (LS) and medication with 
nimodipine (N), and antifibrinolytics (AF). Reasonable combinations of these actions result in the 
following strategies: 
I No spedal actions. 
II Late elective surgery only (!.S). 
ID Nimodipine and late elective surgery (N, LS). 
N Nimodipine and antifibrinolytics and late elective surgery (N, AF, LS). 
V Early surgery, nimodipine and late elective surgery (ES, N, LS). 
VI Delayed surgery, nimodipine and late elective surgery (OS, N, LS). 
VII Delayed surgery, nimodipine, antifibrinolytics and late elective surgery (OS, N, AF, LS). 
The first two strategies in which no action is undertaken during the first three months are 
included for reference. The decision analysis model allows for other values for the day of 
surgery, but the discussion is focussed on day 2 and day 10. Late elective surgery is an option 
in strategies III-VII, because some patients will not be suitable candidates for surgery on the 
planned day, and surgery will have to be postponed. It is important to consider this option in 
the analysis, because it influences the attractiveness of non-surgical therapies compared to 
surgical strategies for the management of subarachnoid hemorrhage. Patients will of course 
receive optimum symptomatic treatment, including fluid intake of at least 3 litres, plasma 
volume expansion when there are signs of delayed cerebral ischemia and CSF drainage for 
treatment of hydrocephalus.159,160 
10.1 Material and methods 
Patients 
Five patients, who cover a wide range of clinical profiles will be considered in this analysis. 
Clinical profiles consist of combinations of prognostic factors for rebleeding, infarction and 
mortality from the initial hemorrhage, that have been identified in the previous chapter. Table 
28 lists the clinical characteristics of all five patients, and their risks of rebleeding, infarction 
and mortality. Patient 3 will serve as a key patient to illustrate the analysis. She is a 45-year-old 
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woman who has been admitted to hospital within 48 hours after the onset of a severe sudden 
headache. She did not lose consciousness at the time of the initial hemonnage. The patient 
scored 11 points on the 14-point Glasgow coma scale (E2 M5 V4)."'Neurological examination 
revealed no focal defidts and there were nO retinal abnormalities, but there was some nuchal 
rigidity. Computed tomography showed a rather large amount of subarachnoid blood in the 
hasal dsterns (>8 points) and virtually no intraventricular blood (<3 points), see also Hijdra.'''' 
According to the prognostic system described in our previous work, this patient would have 
a risk of rebleeding and infarction of 19% and 21 % respectively and a three-month mortality 
rate of 46%, if treated symptomatically. 
Table 28. Patient characteristics, one-month probabilities of rebleeding and infarction without further treat-
ment, and three-month mortality rates based on the re-analysis of the tTanexamic acid-trial. For each prognos-
tic factor letters indicate whether it is related to rebleeding (R), infarction (/) or mortality from the initial 
hemorrhage (M). '+' means factor present, '.' means factor absent 
Patient 
2 3 4 5 
Sex F F F F F 
Age(M) 45 45 45 45 65 
Glasgow Coma Score <12(IM) + + + 
Loss of consciousness at the ictus (R) + 
Retinal abnonnafities (I) + + 
SubarachnOid blood on CT >9 (1M) + + + 
Intraventricular blood on CT >2 (RI) + + 
One-month rate of rebleeding .25 .45 .19 .22 .19 
One-month rate of infarction .09 .08 21 .46 .41 
Three·month mortality rate .24 .41 .46 .60 .72 
Decision tree 
In a clinical decision analysis, alternative strategies consisting of one or more actions are 
considered. These were already listed in the introduction. The strategies can be illustrated by 
a dedsion tree (Figure 43). 
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The decision for surgiCill treatment (early or delayed) is represented in the upper part of the 
tree. Surgery will be carried out when the patient harbours an accessible aneurysm according 
to the cerebral angiogram and is in a stable clinical condition. For simplicity, the possibility of 
another cause for the subarachnoid hemorrhage than an aneurysm is excluded. Surgery will 
prevent any further rebleeding, but it is associated with mortality and morbidity. 
With medical treatment, there is a risk of death from the initial hemorrhage and risks of 
rebleeding and infarction. After surviving the first rebleed or infarct, there may be a second 
event. 
When the patient is still alive after three months, she will be in one of the health states Well, 
Moderate disability or Severe disability as described in the Glasgow Outcome Scale.''' The 
persistent vegetative state is not considered in view of its rarity after subarachnoid hemorr-
hage.""·16. The probabilities of these outcomes depend on the clinical state of the patient at the 
time of entry to hospital, the number of rebleeds and infarcts, and the occurrence of 
complications after surgery. After three months, the patient is assumed to remain in her health 
state for the rest of her life. It may be worthwhile to clip the aneurysm if surgery has not yet 
taken place, to prevent late rebleeding.'" Severely disabled patients have a reduced life 
expectancy~ and will not undergo late elective surgery. 
The decision tree is for illustrative purposes only. In the actual computational model 
(written in Pascal),"we first compute the one-month probabilities of rebleeding and infarction, 
the three-month mortality and probabilities of health states at three months. A life table 
approach with daily competing risks of rebleeding, infarction and mortality is used. This part 
of the analysis is directly based on the proportional hazards regression estimates from Chapter 
9. Confidence limits for the individualized estimates of rebleeding, infarction and mortality 
after subarachnoid hemorrhage are estimated according to Tsiatis'" with modifications by 
Christensen." The life expectancy and the time spent in each health state is computed for each 
treatment modality, using life table estimates and estimates of the long term risk of rebleeding. 
Preferences for health outcomes and time are considered by using discounted quality adjusted 
life expectancy (dQALE) as a proxy for the expected utility (see also the results section). The 
strategy with the highest dQALE should be considered as good advice. The robustness of the 
analysis is assessed by sensitivity analysis, i.e. by testing how sensitive the optimum decision 
is to changes in estimates within the plaUSible range. For a more detailed description of decision 
analysis techniques see.l 42.206.216.3% 
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Agure 43. Decision tree for the management of patients with subarachnoid hemorrhage. The upper part of the tree depicts 
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differ according to the chosen strategy. Letters at the end of a branch efKiing in a chance node refer to identical subtree 
struetures, The opUon of/ate elective surgery (strategy II, LS) is represented in the dotted rectangle, 
Available data and estimates 
In this section, we summarize data from a comprehensive review of the literature. Point 
values and plausible ranges with estimated 90% confidence bounds will be suggested in the 
text below, and are listed in Table 29. 
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Table 29. Probability estimates for the decision analysis of subarachnoid hemorrhage management For sources see ·Avai/~ 
able data and estimates'. 
Natural history of subarachnoid hemorrhage 
Severe disability after the inilial hemorrhage 
Moderate disability after the initial hemorrhage 
Le1l1a1ily of rebleeding 
Severe disability after non-fatal rebleeding 
Moderate disability after non-fatal rebleeding 
Lethality of infarction 
Severe disability after non-fatal infarction 
Moderate disability after non-fatal infarction 
Annual rale of rebleeding (1 st year) 
Annual rale of rebleeding (10111 year) 
Mortalily of late rebleeding 
Severe disability after non-fatal late rebleeding 
Annual excess mortality from severe disability 
Medical treatment 
RR of infarction with nimodipine 
RR of rebleeding with antifibrinolytics 
RR of infarction with antifibrinolytics 
RR of mortality from the initial hemorrhage wi1l1 antifibrinolytics 
Surgical treatment Patient 1 & 2 
Mortality 01 late elective surgery .02 .01-.04 
Morbidity of late elective surgery .06 .02-.10 
Mortalily 01 delayed surgery .05 .03-.07 
Morbidily 01 delayed surgery .09 .07-.11 
Mortalily of earty surgery .06 .04-.11 
Morbidity of early surgery .12 .09-.15 
RR of infarction after surgery 2.0 1.0-3.0 
Natural histlllY and medical treatment of subarachnoid hemorrhage 
Point value Plausible range 
.15 .10-20 
.17 .12-.22 
.75 .65-.65 
.53 22-.64 
.09 .00-25 
.32 .24-.40 
.16 .06-.30 
25 .11-.39 
.06 .04-.06 
.03 .02-.04 
.65 .50-.60 
.50 25-.75 
.05 .025-.1 
.66 .45-.87 
.30 .20-.50 
1.50 1.00-2.10 
2.10 1.60-7.00 
Patient 3 & 4 PatientS 
.02 .01-_04 .02 .01-.04 
.06 .02-.10 .06 .02-.10 
.07 .04-.10 .12 .07-.17 
.11 .06-.14 .16 .11-21 
.12 .06-.18 .22 .12-.32 
.16 .11-21 26 .16-.36 
2.0 1.0-3.0 2.0 1.0-3.0 
Causes of deterioration and death after subarachnoid hemorrhage have been divided into 
three categories: rebleeding, infarction and the effects of the initial hemorrhage (i.e_ acute 
ischaemic damage, late hydrocephalus and extracranialcomplications). The estimation of these 
risks from the data of the tranexamic add-trial has been described in the previous chapter. 
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The data from this trial suggest that approximately 80% of the patients who do not suffer 
a rebleeding or infarction~ survive. Of these, 15% and 17% remain severely and moderately 
disabled after three months. The lethality of rebleeding, adjusted for other causes of death, has 
been estimated at 75%. A large proportion of those who survive the recurrent hemorrhage, will 
remain severely disabled. The lethality of infarction is less than half that of rebleeding, and the 
risks of moderate and severe disability are also lower. 
Several years after the conclusion of the tranexamic acid-trial, the management of patients 
with subarachnoid hemorrhage has been modified from fluid restriction <Rotterdam) or no 
fluid expansion (Glasgow) to fluid expansion and to anti-hypertensive medication only on 
strict indication, i.e. only when the patient was already on treatment for hypertension before 
the subarachnoid hemorrhage occurred. The one-month rate of infarction in Rotterdam was 
considerably lower under the modified management regime.'SO In Chapter 9 we described how 
we adjusted the rate of infarction for this effect to 0.8 times the risk in the time that the antifi-
brinolytics trail was conducted. This adjustment is also used in the present study. 
The relative risk of rebleeding in patients on antifibrinolytics is 0.3 (0.2-{).5), adjusted for 
other significant prognostic factors in the proportional hazards regression model. This bene-
ficial effect of antifibrinolytics is counteracted by an increased risk of infarction; the relative 
risk is 1.5 (1.0-2.1). The effect of antifibrinolytics was further counteracted by an increase in 
mortality from the initial hemorrhage, with a relative risk of 2.1 (1.1-4.0). 
In the British nimodipine study"" a relative risk of fatal and non-fatal infarctions of 0.66 
(0.45-{).87) was observed in the nimodipine group. (In their article, the authors reported the 
effect of nimodipine as a rate difference of 34% (0.90 a: 13%-55%).) No modification of the 
effect of nimodipine by important risk factors for infarction was found. Others have reached 
similar conclusions.6•188,264..288,30S 
The long term risk of rebleeding was estimated from Winn,409.410 i.e. 6% annually in the first 
year after the subarachnoid hemorrhage, decreasing to 3% after nine years. The mortality of 
laterebleedingisestimatedat65%andtheriskofseveredisabilityafternon-fatallaterebleeding 
at 50%.409 
Long term survival was modelled according to the Dutch life tables of 1985." An annual 
excess mortality rate of 5% (0-10%) is assumed for patients in the state "severe disability". 
SUTgicol treatment 
Surgery has a strongly preventive effect on rebleeding. It will be preceded by angiography, 
for confirmation and localization of the aneurysm. In some patients, angiography will fail to 
reveal an aneurysm~ because the aneurysm is just not detected by the procedure, or an effective 
clot has sealed the remains of the aneurysm from the circulation. (Patients with perime-
sencephalic hemorrhage have already been excluded from the analysis.''') Of the 405 patients 
in the re-analysis of the tranexamic add-trial, 42 (10%) had a negative angiogram, and 
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angiography was not perfonned in 95 patients (23%), but 36 of these patients had an autopsy, 
revealing an aneurysm in 33. We estimate that of the patients like 1-4 who had not yet suffered 
a rebleed or infarction on the day of surgery, 75% (60%-90%) will actually undergo operation, 
compared to 50% (25%-75%) of the older patients like 5, who are more likely to deteriorate after 
the subarachnoid hemorrhage. 
Surgery carries a risk of mortality and morbidity. Some have reported excellent results of 
early surgery,333,35'''' but the non-randomized "Cooperative study on the timing of aneurysm 
surgery" suggests that there is no clear cut case for delayed or early surgery."" A statistically 
significant difference between the management mortalities for alert patients in the "early" and 
"delayed" surgery groups (11 % and 13% respectively) was not observed in this study, but the 
mortality rates in the 4-6 days-, and 7-10 days planned surgery intervals were higher (17% and 
15% respectively). Unfortunately, only combined rates of death and disability were reported. 
Events that caused disability before or after surgery were not distinguished. Moreover, esti-
mates of the mortality that is attributable to surgery have to rely on the classification of the 
authors, but no definitions or methods for classification are given. 
in the dinicalliterature the tenn surgical mortality is used to describe the probability of 
death from any cause after a certain time-period in operated patients. in this analysis, it is 
defined as the mortality that is attributable to surgery. This makes trade-offs between benefits 
and risks of surgery possible. 
In order to estimate the mortality and morbidity from acute aneurysm surgery, we used 
the multivariate prognostic model that is described in Chapter 9 to compute the expected 
mortality from the initial subarachnoid hemorrhage and from infarction in the 174 patients 
from the tranexamic acid~trial that had elective aneurysm surgery. The average time-span 
between admission and surgery was 10 days. The difference between the observed mortality 
(Kaplan Meier estimate) and the expected mortality (computed with proportional hazards 
regression estimates) amounts to 13.4%-7.8% = 5.6%. This is a good estimate of the mortality 
that is attributable to surgery in patients who are in good pre-operative condition. Of the 174 
subjects, 159 had a Glasgow coma score greater than 11 at admission. The risk of infarction 
after surgery was increased, but not statistically Significant. 
In the present analysis, surgical risks are broken down into those basic to the procedure 
itself (the basic surgical mortality) and those associated with technical difficulties related to 
the patient's condition, the amount of blood surrounding the aneurysm and the tightness of 
the brain (the excess surgical mortality). The basic surgical mortality is presumed equal to the 
risks of late elective surgery and to the risks of surgery of unruptured aneurysms,"" i.e. 0.02 
(0.01-0.04). The excess surgical mortality is taken at 0.03 (0.01-0.06) for delayed surgery in 
patients 1 & 2, and at 0.05 for delayed surgery in patients 3 & 4. These risks are taken two times 
(1.5 -3 times) higher for early surgery. The mortality from delayed surgery P(mds! is estimated 
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by adding the excess mortality P(em) to the basic mortality P(bm), i.e. P(mds) = P(bm) + P(em). 
The mortality from early surgery P(mes) is estimated by adding 2 (1.5-3) times the excess 
mortality to the basic mortality: P(mes) = P(bm) + 2 #. P(em). Thus, the mortality from early 
surgery relates to the mortality from delayed surgery as follows: P(mes) = P(bm) + 2 #. (P(mds) 
- P(bm». Delayed surgery for the key patient has a mortality risk of 0.07 (0.04-0.10) and early 
surgery has a risk of 0.12 (.07-.17). The relative risk of infarction after surgery is taken at 2 
(1_3).'" 
1 0.2 Results 
In this section, the results of the analysis for the key patient (nr 3) will be presented. Then, 
sensitivity analyses will be used to test the "robustness" of the results for the key patient against 
plausible changes in estimates. Next, the results for the other four patients will be ouilined. At 
last, early surgery will be considered in more detail 
Base-case analysis: key patient 
Table 30 summarizes the results for the key patient (patient 3). ·No specific treatment" 
would lead to lower rates of infarction than at the time of the tranexamic acid~trial, because 
the fluid management has since changed.'" The risk of rebleeding is slightly higher, because 
more patients remain at risk. Nimodipine treatment (III, N, LS) reduces the risk of infarction 
even more. The other treatment strategies lead to a reduced risk of rebleeding, with delayed 
surgery (strategy VI, OS, N, LS) as the least effective in this regard. These strategies also lead 
to an increased infarction risk Whether the increase in infarction risks is compensated by the 
reduced rebleeding risks, depends on the severity of both complications. Figure 44 shows how 
the cumulative rebleeding and infarctions risks are changed by surgical interventions. 
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Table 30. Results olthe decision analysis for the key paUent (patient 3). The cumu/aUve risks of rebleeding and infarction 
after one month (A), the cumulaUve three-month probabilities of being in different health states (8), the number of fife years 
spent without. with moderate, and with severe disebiOty (e) and the life expactancy proper (LE), with quality adjustment 
(OAL£) and quality adjustment and disooUOUng (dOAL£) (D). The best strategy and its ciosest contenders are underlined. 
Normal life expectancy for a Dutch woman of 45 equals 35.7 years, and the dOAL£ without morbidity and mortality from 
subarachnoid hemorrhage would be 15.8 years. 
Strategy 
II III IV V VI VII 
LS N,LS N.AF,LS ES,N,LS DS,N,LS DS.N,AF,LS 
A. Complicaflons 
Rebleeding .19 .19 .20 .05 .07 .14 .04 
Infarction .21 .21 .15 .20 22 .17 22 
B. Three-month health outcome 
Well .34 .34 .35 .29 .32 .33 .25 
Moderate Disability .09 .09 .09 .07 .08 .08 .07 
Severe Disebifity .11 .11 .11 .08 .16 .14 .11 
Death .46 .46 .45 .55 .44 .44 S7 
C. LHe years spent 
Well 72- 10.8 11.4 9.3 11.0 11.6 8.7 
Moderate disebility 1.9 2.9 2.8 2.4 2.9 2.9 2.3 
Severe disability 1.8 1.7 1.7 1.3 2.5 2.2 1.6 
D.Ufeexpectancy 
unadjusted LE 11.0 15.3 1M 13.0 1M .12& 12.7 
quality adjusted LE 10.4 14.8 1M 12.5 1U 1M 12.2 
discounted QALE 5.5 6.9 L2. 5.9 II II 5.7 
When the three month health outcome is considered, treatment with antifibrinolytics is 
assodated with a substantially higher mortality. However, the three month mortality in itself 
is not an adequate decision criterion, because the risks of severe and moderate disability after 
three months are different for each strategy. Therefore, we computed the probabilities of each 
health state after three months. For the key patient, the chance of being WELL is largest with 
conservative treatment without antifibrinolytics (strategy III, N, IS), but the mortality risk is 
lowest with early and delayed surgery (strategies V (ES, N, IS) and VI (OS, N, IS). Gearly, the 
utility of intermediate health states is important. Also, the remaining life expectancy is 
important because the long term risk of rebleeding depends on it. 
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Agure 44. Cumulative risks of rebleeding and infarction as a function of time (days from admission), for the key patient (nr 
3), wilh eany surgery (Slralegy V, ES,N,LS), delayed surgery wilhout (strategy VI, DS,N,LS) and wilh antifibrinolytics (strat-
egy VII DS,N,AF,LS). Ninety percent confidence intervals are indicated by vertical fines at !he end of each curve. 
The previous table also lists the expected number of life years lived in each health state for 
the key patient, per strategy. Added up, these figures give the total life expectancy for each 
strategy. Health status is taken into account by assigning utilities to each outcome, on a scale 
o (Death) to 1 (Well). Moderate disability is assigned a value of 0.95 (0.91-.99) and severe dis-
ability 0.75 (0.625-0.875). By multiplying the life years spent in each health state with their 
respective utility, a quality adjusted life expectancy (QALE) is computed. However, most 
people attach more value to nearby life years than to life years far away in the future. Therefore, 
5% (0%-10%) annually will be discounted.262 ln the remainder of this paper, outcomes will be 
given in discounted QALE (dQALE). 
When the key patient is treated only symptomatically (1), she would have a dQALE of 5.5 
years. Late elective surgery (IT) would increase this to 6.9 years. The reduction in rate of 
infarction by nimodipine (lU) adds another benefit of 0.6 life year, or 0.3 discounted quality 
adjusted life years. Adding antifibrinolytics (lV, VII) to the regimen is dearly not a good choice 
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for this patient. Early surgery M for patients in good condition reduces the risk of rebleedin~ 
but, because of the associated risks, the added benefit is no more than 0.2 discounted quality 
adjusted life years. For the key patient, delayed surgery when possible, with nimodipine M, 
DS,N,IS), offers a better balance between risks and benefits (0.1 discounted quality adjusted 
life year extra). 
Sensitivity analyses 
First we examined the effects of uncertainty in the estimates on the best strategies (i.e. early 
surgery 01, ES,N,IS) and delayed surgery M, DS,N,IS) for the key patient. Figure 45 shows 
parameters that have a relatively large effect on the difference in dQAL Y between strategy V 
(ES, N,IS) and V1 (D5, N, IS). The most important one is the excess mortality due to early 
surgery: when it is low, early surgery is preferred and when it is high, delayed surgery. Also, 
ahighriskofrebleedin~andalowriskofinfarctionaftersurgeryfavourearlysurgery. Plausible 
changes in some of the other estimates do not have a large effect on the difference between the 
strategies, although they may be quite uncertain or imprecise, because they appear in both 
strategies. 
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Difference between delayed surgery and early surgery in dQAlE 
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FJ9ure 45. SensiUvity analyses for the key paUent (nr 3). The effect of plausible changes in esUmated probabiliUes and 
paUent preferences on the differences in dQA1.£ between delayed surgery (strategy VI, DS,N,LS) and early surgery (strat-
egy If. ES,N,LS). The dotted Pne indicates a zero difference in discounted quality adjusted Iffe expectancy between the strat-
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indicated by a dashed One. When the difference is negative, early surgery is preferred. 
Other patients 
Table 31 shows the results of the analysis for all 5 patients, in discounted QALE. Forpatients 
1 and 2 strategies with antifibrinolytics yield a higherdQALE, because the inereasein mortality 
and infarction rate is relatively low, compared to the large effect on the rebleed rate_ For these 
patients the benefit of delayed surgery over late elective surgery is almost nil, because the risk 
of rebleeding with antifibrinolytics is very small For patient 4 either early or delayed surgery 
(without antifibrinolytics) has the largest benefit Patient 5 has the worst prognosis. For her, 
the highest dQALE is attained by strategies ill (N, IS) and VI (DS, N, IS). Planning surgery 
forsuch a patient does not affect the prognosis much-because the chance of actually undergoing 
surgery and surviving it, is only 0.09 (0.04-0.14) according to the decision model. However, 
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this analysis takes the time of admission as the decision point. The situation is different when 
patient 5 is alive and a reasonably good candidate for surgery on day 10. In that situation, 
surgery is indicated. 
Table 31. Resufts of the decision analysis for all five paUenlS in dQALE. The best strategy and its closest contenders are 
underlined. For a Dutch woman of 65 who did not suffer a subarachnoid hemorrhage, the unadjusted fife expectancy and 
tile discounted quality adjusted life expectancy would be 17.4 and 11.4 years, respectively. 
Strategy 
II 111 IV V VI VII 
LS N,LS N,AF,LS ES,N,LS DS,N,LS DS,N,AF,LS 
patient 1 7.9 9.9 10.0 ill ill 10.8 !.1.2 
patient 2 6.0 75 7.6 1M 1M 9.0 l.1.Q 
patientS 55 6.9 1.2 5.9 U U 5.7 
patient 4 4.0 5.0 
.M 4.6 g g 45 
patientS 22 2.6 g& 1.6 2.6 g& 1.5 
Early surgery 
Early surgery 01) is never the only best strategy in this analysis. Since our estimates of the 
mortalityandmorbidityfromearIysurgery-themostimportantfactor-areobtainedindirectly, 
they are quite imprecise. In order to determine when early surgery would be the best strategy, 
we varied the mortality from delayed surgery and early surgery by changing the surgical excess 
mortality and basic mortality~ (see also: Available data and estimates) for each patient over a wide 
range. Figure 46 shows how for patient 1 and 3-5 changes in the basic and excess surgical risks 
(reflected in the mortality and morbidity from delayed surgery) affect the choice of treatment. 
Plausible, low values of surgical mortality and morbidity aess than 0.05 and 0.09 respectively) 
change the best strategy to early surgery for patient 3 and 4, more clearly so when the excess 
mortality is only 1.5 times that of delayed surgery. For patient 1, intermediate and high surgical 
risks favour postponement of surgery, and treatment with tranexamic add, but when surgical 
risks are low, early surgery may be an option. Forpatient 2 (not in figure) early surgery is never 
the best choice. The high rebleeding risks favour treatment with tranexamic acid and delayed 
surgery. Forpatient5 there is moreuncertaintyabout the risks of early surgery and the preferred 
strategy. However, the dQALE of early surgery does not change much with surgical mortality 
and morbidity, because the chance of undergoing operation is quite small. 
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Patient 1 Risk 01 Patiant3 Risk of 
V VII IV 
eartysurgery 
V VI 
'" 
early surgery 
High : : : : : : ><~h 
V VII IV V VI 
'" : Intermediate Inlormad'late 
V VII IV V 
'" Low i Low 
0 .05 .10 .15 .20 Mortality 0 .05 .10 .15 .20 Mortality 
.04 .09 .1' .1' 24 Morbidity .04 .09 .1' .1' 24 Morbidity 
Risks 01 delayed surgory Risks 01 delayed surgory 
Patient 4 Risk of Patlon15 Risko! 
V VI 
'" 
early surgery 
V VI 
'" 
early surgery 
High High 
V VI 
'" 
V VI III 
Intermediate Intermediate 
V VI 
'" 
V VI 
'" Low 
. . . . : Low 
0 .05 .10 .15 .20 Mortality 0 .05 .10 .15 .20 MOrtality 
.04 .09 .1' .1' 24 Morbidity .04 .09 .1' .1' 24 MOtbidity 
Risks oj delayed surgery Risks of delayed surgery 
Rgure 46. Threshold analysis: the effect of changes in basic and excess surgicaJ on the mortality and morbidfty from 
delayed surgery and eany surgery, and /he preferred stralegy for paUents 1, 3, 4 and 5. (The case for paUenl2 (nol dis-
played) is trivial, because below a surgical mor/ality/morbidity of 0.095/0.135 delayed surgery wi/h TEA (VII, DS,N,AF,LS) is 
preferred, and above /his value nimodipine and TEA (sltalegy IV, N,AF,LS). Eany surgery is never preferred.) The shaded 
bar indicates which strategy has the highest expected utility, at a given level of surgical risks. When the surgicaJ risks are 
low, eany surgery (V, ES,N,LS) is preferred. But wilen /he risks of eany surgery are relaUvely high (uppar bat, 3 ,mes /he 
risks of delayed surgery), /he /hreshold for delayed surgery decreases, but wilen /hey are rela,vely low (lower bar, 1.5 ,mes 
/he risks of delayed surgery) /he /hreshold for delayed surgery increases. The plausible range for /he risks of delayed sur-
gery is indicaled for each paUenl. Very high surgical risks lavour nimodipine only, Sltalegy 1/1 (N, LS). 
10.3 Discussion 
This decision analysis synthesizes the available evidence on the risks and effects of surgical 
and medical treatment of patients withsubaraclmoid hemorrhage in one consistent framework 
and provides guide-Jines for their management Admittedly, the analysis does not permit 
completely certain and simple recommendations. But that has never been our aspiration, 
considering the complexity of the clinical problem and the still limited knowledge of sub-
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arachnoid hemorrhage and the effects of treatment As one would expect, most of our con-
clusions concur with current practice, However, we offer new recommendations with regard 
to the use of antifibrinolytics, and to the appropriateness of early surgery. 
Our analysis is largely based on data from a randomized clinical trial of tranexamic acid 
against placebo, conducted between 1979 and 1983. Arguments for using these particular data 
have been given in Chapter 9. Several aspects of the management of subarachnoid hemorrhage 
have changed since conducting this trial, but adjustments have been made to reflect the reduced 
rate of infarction that resulted from the changes in fluid management and from the use of 
nimodipine. 
The estimates of the risks of early surgery are based on extrapolation and on the literature, 
but not on new observations. Reliable data on the risks of surgery are scarce. We urge neuro-
surgical centres to publish their results, with an adequate description of the clinical char-
acteristics of the treated patients. 
Some centres that participated in the Cooperative Study had a 0% surgical mortality, 
suggesting that our estimates may be too high. However, thenumber of cases admitted to these 
centres was very small. When the occurrence of surgical mortality is considered. as a chan-
ce-process, it is not surprising that in a small group of patients no mortality occurs. Moreover, 
centres were selected on the basis of good surgical results.203 
Previous studies 
Two other decision analytic studies of the management of subarachnoid hemorrhage 
exist.123,2S They concern special cases, and no assumptions are made about the occurrence of 
infarction, nor about the effects of antifibrinolytics and nimodipine. General management 
guide-lines cannot be distiled from them. A more detailed discussion of these studies can be 
found in Chapter 3. 
The results of the Cooperative Study suggest a beneficial effect of early surgery compared 
to delayed surgery for North American centres only.''' These centres had better surgical results 
than the others. On the other hand, half of the patients in the delayed surgery group did not 
receive antifibrinolytics. in the study of Ohman,'" Hunt & Hess grade I-ill patients with recent 
subarachnoid hemorrhage were randomly allocated to surgery on day 0-3, day 4-7 or day 8 or 
later, there was no statistically Significant difference between the treatment groups. Moreover, 
antifibrinolytic therapy appears not to have been administered. Therefore, these results do not 
disagree with ours. 
Conclusions 
Our analysis suggests that for patients arriving at the hospital early after the subarachnoid 
hemorrhage in good clinical condition, delayed surgery and antifibrinolytics is the best option. 
For this category of patients, (i.e. Glasgow coma score more than 11, amount of subarachnoid 
blood less than 9, and age less than 55) treatment with antifibrinolytics is clearly advantageous. 
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Earlysurgery for these patients seems to offernoadditional benefitorno better overall outcome. 
But the differences in dQALE are small, thus, for centres with experience in early surgery, there 
is little reason to change their present practice. Moreover, if there is virtually no difference 
between early and delayed surgery in dQALE, the finaneal savings on bed usage may tip the 
balance. Patients in poor clinical condition, or with a heavy load of blood on the cr scan (like 
patients 3 and 4) should not receive antifibrinolytics. In these patients, early surgery leads to 
almost equal dQALE as delayed surgery without antifibrinolytics. 
We hope that our recommendations will contribute to the optimum care for future patients 
with subarachnoid hemorrhage. 
Notes 
a. This chapter is adapted from: Dippel DWI, Van Crevel H, Lindsay KW, Hijdra A, Habbema IDF. Management 
of subarachncrid hemorrhage: Decision analysis. Submitted for publication. 
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General discussion 
The aim of the studies in the preceding chapters is the synthesis of general clinical 
knowledge, empirical evidence and preferences for health outcomes in a decision analytical 
model of rational choice. Did we succeed? Are the results and our conclusions useful as clinical 
advice? Are the models and conclusions scientifically valid? The answer to the last question in 
particular is not straightforward. in this chapter, these matters will be discussed in general, 
and in relation to our studies. 
Theoretically, empirical validation of decision analytical studies is possible. But what 
should be the design of the study? One may envisage a clinical trial with random treatment 
allocation that corresponds to the main branches of the decision tree, when there is still rea-
sonable doubt about the best strategy. Another perhaps even more interesting approach would 
be to compare not clinical strategies, but clinical management without, and with decision 
analytical support. For patients with a recent transient ischaemic attack, the decision whether 
or not to undergo carotid angiography and perhaps endarterectomy, can be based on clinical 
insight and the literature, or the same decision can be based on the (yet to be updated) results 
of a decision analysis such as Matchar's study.'" With such a design it is possible to investigate 
whether a benefit can beattained by strictly adhering to themode!' sadvice, and as a by-product, 
the mode!'s predictions can be checked. It is of course not possible to establish the "general 
validity" of the decision analysis method itself.a Care should be taken that the model's advice 
does not influence decisions for patients allocated to management without decision analytic 
support. What should be the outcome measure of the trial? Certainly it must be the same 
attributes, weighted with an identical utility function (perhaps with individualized para-
meterization) as in the original decision analysis, because othenvise, the results of the 
experiment and of the model cannot be compared. 
Most decision analyses have been conducted because empirical studies were not feasible, 
thus, there are practical obstacles for such an evaluation. For example, in the unruptured 
aneurysm problems, empirical validation would require decades of follow-up per patient (the 
validity of analysis by means of patient-years of follow-up although useful by itself, in a large 
sample study with relatively short follow-up would meet criticism with respect to its gen-
eralisability). In subarachnoid haemorrhage, medical treatment options are theoretically easy 
to evaluate by randomized trial, but randomization for surgery was not considered feasible in 
the cooperative study of the timing of surgery in SAH,"" although this has been done in a 
smaller, but well designed study.289 However, the number of possible clinically relevant 
strategies is simply too high to be evaluated by trial. 
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Alternativel y,onemayexplore the construct validity of decision analytical studies. A sound 
approach is for thatrnatter to let potential decision makers, fellow decision-analysts and experts 
with clinical backgrounds formulate as much criticism as possible against a certain study, and 
consider the study valid~ as long as it can stand the critique, and the critique itself is valid, ie. 
aimed at the way the analysis was conducted, but not aimed at the problem itself. For example, 
the absence of empirical information regarding a crudal factor in a decision analysis is not a 
problem of the analysis, but belongs to the decision problem itself. Von Winterfeldt argues in 
this light that validation of the structure of a decision analysis is essentially inappropriate.'" 
In the next paragraphs we will summarize for each group of studies (i.e. unruptured 
intracranial aneurysms (Chapters 4-6), arteriovenous malformations (Chapter 7), dementia 
(Chapter 8) and subarachnoid haemorrhage (Chapters 9 and 10) the critique that was 
encountered during more than eight years of research and consultations and give our response. 
We will also mention useful clinical advice derived from each study's results, and give 
guide-lines for further research in these areas. The decision analytic literature on each subject 
was already discussed in Chapter 3, and the main conclusions of the studies are stated at the 
end of each chapter, and in the summary. These will not be repeated here. At the end of this 
chapter, the obstacles and opportunities for application of decision analysis will be given, in 
orderto contribute to a discussion about the role of decision analysis in neuro-scientificresearch, 
education, training and patient~management in the clinical neurosciences. 
11.1 Intracranial aneurysms and arteriovenous malformotions 
The decision analytic studies of the management ofunruptured intracranial aneurysms in 
this study were preceded by an application of Van Crevel,'" who described the management 
of a hypothetical patient, a 45-year-old woman with an unruptured 8 mm aneurysm of the left 
middle cerebral artery. The decision tree and utility function in this analysis form the basis for 
the analyses in Chapters 4-6 of this book, and for several consultations. Comments have been 
put forward by interested clinicians and investigators. The most important of these regarded 
the utility function; "when the patient knlJWS that he/she harbours an intracranial aneurysm, the 
uncertain outlook of the conservative management option will be harder to bear than when the patient 
does not knlJW of his condition or when the aneurysm has been clipped effectively, and therefore, telling 
the patient almost implies clipping the aneurysm". This psychological aspect is not included in the 
analysis. When patients have been informed it is questionable whether they would be willing 
to trade off survival against reduction in fear of aneurysm rupture; anyhow, it does at least not 
seem rational, because rupture and its consequences for health status and longevity have 
already been included in the tree. Therefore, analogously to our treatment of regret and dis-
appointment, improvement in psychological well-being is not included in the utility function, 
see Chapter 2, section 2.3. 
163 
Chapter 11 
Other criticisms regard specific estimates, and do not threaten the validity of the analysis. 
Some may argue that a decision analysis is "not possible" when empirical data are not available. 
But decisions will be made anyhow, as "dOing nothing" is also a decision. Then why not make 
it explicitly, and look at it in a scientific and consistent way? 
Our study concerning unruptured aneurysms in patients with TIA or familial aneurysms 
have demonstrated that some additional factors (such as the risk of treatment with acetyl-sa-
licylic add, or the risk of developing a new aneurysm) initialiy considered a strong factor 
against operation, were not that important. On the other hand, the lifetime risk of aneurysm 
rupture, determined by the life expectancy of the patient was a factor that tended to be 
underestimated in importance. Still, in spedfic cases a decision can be difficult, even with the 
guide-lines from the analyses. With the experience we have now, a treatment advice for spedal 
cases can be readily produced.b,c 
Several research recommendations can be made. For familial intracranial aneurysms a 
survey is currently conducted to investigate the occurrence of subarachnoid haemorrhage in 
fantily members of patients who presented with (aneurysmal) subarachnoid haemorrhage." 
With regard to the risk of rupture, large follow-up studies of unoperated patients will probably 
not be carried out anymore. Monitoring surgical results isa necessary, but nota very attractive 
type of research for clinicians. However, the analyses show that surgical results in the man-
agement of unruptured intracranial aneurysms, of arteriovenous malformations, and of sub--
arachnoid haemorrhage play a crucial role. Therefore, research in this area is strongly 
recommended. 
No comments spedfic to the analysis of the management of unruptured familial 
arteriovenous malfonnations were encountered. Apart from assumptions about the occurrence 
and risk of pulmonary arteriovenous malfonnations, our decision analysis does not differ from 
an analysis of non-familial arteriovenous malformations. We could therefore extend our con-
clusions quite readily to non-familial cases. 
11.2 Probabilistic diagnosis of normal pressure hydrocephalus 
The decision analysis of the management of patients suspected of normal pressure 
hydrocephalus has been criticized because of the many assumptions that had to bemade. Apart 
from thal;, there are two more fundamental difficulties. We modelled normal pressure 
hydrocephalus as if it was not a clinical syndrome, but a disease process, an entity that is 
identifiable independently of clinical Signs. Thus, the gold standard for prevalence (prior 
probability) estimation was based on neuropathological evidence, and the gold standard for 
diagnostic testing was prOlonged clinical observation. Botharequestionable entities, butsimply 
the best we have got The response to shunting asa Single diagnostic criterion was not sufficient 
in our opinion, because the possibility of a correct diagnosis in non-responding patients and 
the possibility of a transient response in non-NPH patients is ignored. Nevertheless, we think 
164 
General discussion 
we have shown that a large part of the variability in response to treatment can be explained 
by differences in ruagnostic accuracy. Therefore, it is important that research efforts are not 
only directed at prognostic factors in NPH (and clinical signs should not be forgotten), but also 
at the rate of occurrence of prognostic and ruagnostic factors (for NPH) in Alzheimer's disease. 
The second problematic point is the position of MID as a disease entity. The concept of MID 
now includes any demented patient with multiple infarcts, regardless of localization. 
Undoubtedly, the clinical picture differs between patients with small deep infarcts, white 
matter lesions or patients with large (sub)cortical infarcts. The clinical debate on this matter is 
just evolving,. and therefore, data are lacking. It is a matter of taste whether to include such a 
concept without data in the analysis. We decided not to, in order to maintain a certain level of 
clinical acceptability of the analysis. However, interesting analytic exercises could have been 
carried out. Perbaps part of the problem will be resolved by studies that compare information 
from clinical assessment, MRI and autopsy in demented patients with vascular (and other) 
lesions. 
11.3 Subarachnoid haemorrhage 
Theleading criticism of the prognostic model of subarachnoid haemorrhage is that it should 
have been validated on a independent sample of patients. This will be done in the near future. 
Especially with this study we received comments intended as severe criticism, like the fol-
lowing: "Most neurosurgeons will agree that only patients with a small amount o[blood on CT in good 
clinical condition should receive anti fibrinolytic therapy", and "most neurosurgeons will object to the 
idea that delayed surgery (with antifibrinolytictherapy! will lead to a better outcome than early surgery". 
This illustrates the sometimes difficult task of clinical decision analysts: when their recom-
menda tions are in line with current practice, the decision analysis is discarded as useless, but 
when the results are against intuition, the analysis is rejected also. Of course the opinion of an 
expert, at least partly based on intuition and implicit clinical reasoning (although valuable in 
itself), can never be an argument in favour or against the conclusions of an analysis. At the 
most, the non-coinciding of decision analytic advice with expert opinion can be reason to 
re-examine the model and the expert's reasoning for wrong assumptions. 
With regard to the management of subarachnoid hemorrhage, a rather complex decision 
analysis was carried out. Nevertheless, the structure of the analysis resembled closely the way 
experienced clinicians think about management of this condition (i.e. in terms of prevention 
of complications as rebleeds and ischaemia). Important insights from this analysis were that 
treatment of patients with antifibrinolytics on indication (determined by the amount of sub-
arachnoid blood on cr and the clinical condition at admission) has a place in modem SAH 
management Another interesting insight can be worded as follows: it does not matter very 
much when the patient is operated, as long as the surgical complication rate is low, and surgery 
takes place even when it is in the fonn of elective treatment after three months. 
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The most important question we had asked ourselves when carrying out the analysis was 
whether there would be a role for antifibrinolytics in combination with delayed surgery, now 
that management of SAH in itself has improved. This could be affirmed. The decision analysis 
pointed out that a benefit is likely for certain patients with SAH. A new randomized trial of 
antifibrinolytic therapy is now under way. 
11.4 The rOle of decision onalysis in the clinical neurosciences 
Obstacles 
Several circumstances have increased the need for decision analysis in the clinical neu~ 
rosciences. The development of powerful personal computers, the growing familiarity with 
clinical epidemiological techniques and the emergence of special centres for clinical decision 
sciences have facilitated the application of decision analysis to real clinical problems. However, 
decision~analytic applications have not found their way as easily into the clinic as once has 
been thought.'" 
Perhaps the main obstacle remains the reluctance of doctors to think in terms of prohability, 
in spite of omnipresent uncertainty.52 Data collected by history and physical examination or 
by the use of a test are treated as essentially perfect, so that uncertainties, which can be handled 
by probability calculus and statistical techniques, are ignored." It is perfectly normal and 
accepted for a physician in a clinical reasoning process to state (after the test has been carried 
out) that "test result X points at diagnosis Y, and "test result X is also compatible with not-Y". 
(probably this physician will order yet another test.) Regardlng prognosis doctors frequently 
state: "the prognosis is unknown", meaning that only probabilistic information is available. 
Some argue that frequentist data should not be applied to individual patients, not realizing 
that they thus negate the basis for their own research activities. Many tend to prefer vague 
terms as "unlikely" and uncommon" overpredsestatements asa probability ofO.OS, even when 
the information is available in that form. The use of quantitative estimates for probabilities 
gives in the eyes of some an air of exactness and "overprecision" to something they consider 
unmeasurable. Framing effects (overestimation of rare events, anchoring, etc.) may lead 
intuitively to other choices than decision analysis prescribes, which makes it even harder to 
accept the explicit advice." Add to this all the fact that the principal activities in patient care 
are non-numerate, making the absorption of quantitative techniques even more difficult 417 
A way out of the problematic situation sketched above leads via education. Future doctors 
should learn to think in terms of likelihood and probability, and should be shown how to use 
prohabilistic information when they think about the management of an individual patient. This 
requires an effort, especially from clinical teaChers.' In our opinion, probability theory provides 
the common language that would enhanceclinicaldlscussionsat thebedsideand duringdinica1 
rounds. Several text~books on clinical decision analysis exist,40.51,91,244,.3S2andsome popular books 
on biostatistics and clinical epidemiology try to merge the decision analysis approach with 
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other quantitative methods.187,328,397 Some medical textbooks already contain a chapter about 
decision analysis in general,C but decision analytic studies are not systematically referred to. 
(A decision-oriented textbook should have a 'signs and symptoms' or problem-oriented 
approach rather than a classic' disease and disorder' approach, but this is still a rarity.)'Perhaps 
an even greater impetus will be given when budget restrictions force the clinician to be more 
cost-effective in choosing between diagnostic and therapeutic possibilities on a more aggregate 
leve!. 
Decision making behaviour does not onJydepend on how and whata doctor thinks. Several 
other influences playa role, such as environmental, organisational, personal, finandal and 
economic aspects. A society that wants doctors to make rational decisions should not allow 
that a direct relation exists between ordering (obsolete) tests and finandal reward. Stated 
otherwise, doctors should be paid for thinking without doing, instead of being paid for doing 
without thinking. The comparison of the finandal structure of health systems in different 
European countries suggests however, that this latter is a necessary, but not a sufficient 
requirement for improvement.339 
Opportunities 
We will end with an optimistic view of the future of decision analysis. A paradigm of a 
decision~analytical application, not of its contents, but of the way it is organized and fits into 
everyday practice and education, and into a more general research effort targeted on a clinical 
problem in neurology, is presented. 
There is no consensus about the management of patients with a certain neurological 
condition. A research project is instigated by a group of clinical experts and investigators. 
Severalrounds of discussion follow ,structured with the he!p of a preliminary decision analysis, 
and an extensive (computerized) search of the literature is carried out. The bulletin boards of 
the major centres for clinical decision sciences and the clinical literature are searched for similar 
decision analytic applicatiOns. 
The available information from the literature and expert opinion are incorporated into a 
decision analysis model, together with estimates of secondary uncertainty.l42 The necessary 
computations are carried out, and at this point it should be determined by sensitivity analysis 
whether it is necessary to incorporate (and elidt) patient preferences for health outcomes. The 
end results of the decision analysis can then be presented as a distribution over the difference 
in expected utility between the strategies.'" This study is called the 'state of the art' decision 
analysis. Important, uncertain factors are identified: the reliability of diagnostic entities, the 
efficacy of treatment, prognOSis when untreated, the relation between clinical picture, diagnosis 
and prognosis, and risks of surgical or medical intervention. For certain (extreme) cases a 
management advice, based on the decision analysis can be given. However, a rather large' gray 
area', where there is no certainty about the best management, remains. The most important, 
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influential factor in the analysis seems to be the efficacy of treatment and its complications. It 
is decided to carry out a randomized trial in order to compare the outcome in treated and 
untreated groups. 
The randomized clinical trial is necessarily a pragmatic, intention-to-treat study. Care is 
taken that the "viewpoint" of the trial coincides with the viewpoint of the decision analysis. All 
cases with a clinical profile comparable to the key patient in the decision analysis are included. 
No cases with what turns out later to be aberrant diagnosis are excluded.'" The preliminary 
decision analysis has been helpful in determining the clinical profile of cases to be included in 
the trial, and to identify beforehand interesting sub-groups (cases that are less prone to adverse 
experiences, or at high risk of the primary outcome event). Kaplan Meyer estimates of survival 
with and without disability are made,302and presented as partitioned survival curves.l36 Resulfs 
are described in terms of (restricted) averages, not medians, because they do not combine.l15,l77 
Statistical significance is assessed as a function of the weight one may give to complications 
relative to benefits of treatment.176,343 Especially when a statistically significant overall effect of 
treatment has been found, an analysis of (predetennined) interactions between treatment 
effects and patients subsets is carried out, preferably by using multivariate techniques.'''' 
The results of the trial are used to update the' state of the art' decision analysis. The update 
is published as a letter to the editor in the same clinical journal as the original analysis, or as 
part of the discussion of the trial results. Amore technical paper, descnDing the decision analysis 
techniques and the link between the decision analysis and the trial should be available also.'" 
The recommendations of the updated 'state of the art' decision analysis may be distiled into a 
flow-chart or algorithm, for easy clinical use. Perhaps they will be used in a consensus paper, 
or in the fonnulation of practice guide-lines.'" It can also be used in education and training of 
residents. The state of the art analysis can also be used as a basis for decision consultation on 
behalf of difficult and special cases. As a welcome by-product, clinical observations and the 
relation between certain clinical factors and prognosis that may be discovered during the 
study,391 leads to the fonnulation of a new project of more fundamental biomedical research. 
Of the many tasks perfonned by physicians, the most pre-eminent is decision-making. 
Improving such a key taskshould improve the standard of patient care. We hope to have shown 
that work and research in the clinical neurosciences can be improved by formal decision 
support, in the form of decision analysis. We think improvement is necessary, because of the 
overwhelming growth of knowledge and the growth of diagnostic and therapeuticpossibilities, 
and the growing demands and criticism from the general public, that is entitled to rational, 
balanced and well-informed clinical decisiOns, based on excellent clinical judgment." 
Notes 
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a. One example of such a study has been described by De Domba/ (Brit Med 11972; 2: 957-964). He _ed the 
diagnostic perftmnance in real-time of a computer system using independent Bayes with that of a senror 
clinician in patients with acute abdominal pain, in a now classic study. The comparison concerned diagnosis 
only, not management decisions, and turned oul f_urably for the computer system. 
b. See Dippel DWl, Habbema IDF. Decision consultation far unruptured intracranial aneurysms. Arch Neurol 
1993. Submitted for publication. Draft available fram the aulhor. 
c. Note lhat such an advice need nol necessarily be extreme,. Some analyses, especitdlyanalyses of difficuIl cases 
result in a toss-up, leading to equivocal treatment advice. This is not due to insufficient analysis, but it can 
be inherent to the decisitJn situation. The eventual choice may then be based on additional (minor) con-
siderations. 
d. On the other hand, the modern clinician should not trade the old way of reasoning for a pocket calculator, that 
is used 10 endlessly multiply likelihood-ratios without considering local normal va/ues, prWrs, case-mix and 
clinical reality. 
e. See far example Goldman L Quantitative aspects of clinical reasoning. In: HIlTrison's Principles of internal 
medicine. Braunwald E, Isselbacher KI, Pelersdarff RG, Wilson ID, Martin IB, Fauci AS (eds.). 11" ed. 
McGraw-HilI, New Yark, 1987, pp 5-11. 
f. BUlseefarexampleFeniche1 GM. Clinicalpediatricneurology.Asignsandsymplarnsapproach,2""ed. Saunders, 
Philadelphia 1993. 
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Summary 
This thesis concerns the application of clinical decision analysis (a methodology for decision 
support, based on the theory of subjective expected utility, clinical epidemiology and bios-
tatistics) to several problems in the clinical neurosciences, where diagnosis, prognosis and 
therapeutic choice is not obvious. The aim of our studies is the synthesis of general clinical 
knowledge, empirical evidence and preferences for health outcome in a normative model of 
rational choice. 
In Chapter 2, the methodology of decision analysis is described. Uncertain events, test 
results and health outcomes are modelled in a decision tree with chance, decision and outcome 
nodes. General clinical knowledge and empirical evidence is condensed into explicit measures 
of uncertainty, using probability theory. Preferences for health outcome (utilities) are 
approximated on a quantitative scale. The expected utility for each strategy is computed by 
multiplying probabilities and utilities along paths in the decision tree. The effect of plausible 
changes in the assumptions and estimates is analysed by sensitivity analysis; i.e. by system-
atically varying a probability value over a plausible range, and examining the effect on the 
expected utility of each strategy. Related methods are described also, and the choice for decision 
analysis as a method for decision support in patient-oriented clinical decision making is 
argumented, as it is the only comprehensive, complete, theoretically well founded method-
ology. 
in Chapter 3, a search of the literature for all decision analyses published since 1975 that 
take on a clinical problem in the clinical neurosciences is described. These studies are reviewed 
and categOrized with respect to methodology (risk, ROC, risk-benefit, cost-effectiveness or 
cost-benefit, or utility analysis). Moreover, the applicability, extendibility and up-to-date-ness 
of the analyses is considered. 
Forty seven studies covering 28 different clinical problems in the neurosciences were 
identified. Twenty-seven studies lacked a case-description, and four studies did not even 
mention the clinical context of the problem. Almost all studies were complete, Le. covered the 
problem area adequately. Seventeen studies were dearly not up to date, either because new 
important evidence has been published, or because new technology has become available for 
clinical use. However, these studies coverten clinical problems, and fourcf these were followed 
by a new, up-to-date analysis. It is concluded that a wide spectrum of conditions in the clinical 
neurosciences is not yet adequately covered by decision analysis. 
In Chapter 4, three patients with transient ischaemic attacks, a stenotic or ulcerating carotid 
lesion and an unruptured aneurysm are discussed.. Decision analysis is used in comparing 
treatment strategies for each patient: clipping of the aneurysm, endarterectomy or both, with 
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or without platelet aggregation inlubitors. A full Bayesian analysis (probabilistic sensitivity 
analysis) with Monte Carlo simulation is used to estimate 95% confidence limits for the dif-
ference in discounted quality adjusted life expectancy between the treatment strategies. 
Platelet inhibiting therapy is indicated for all three patients, despite the increased risk of 
complications from subarachnoid hemorrhage. Carotid endarterectomy cannot be recom-
mended for any of the three patients. With regard to aneurysm surgery a toss-up exists in one 
patient, in another the aneurysm should be clipped, and in one the decision depends on the 
probability that the TINs originate from the aneurysm. For patients with TINs, a moderate 
carotidstenosis and an intracranial aneurysm that does not seem to be related to the symptoms, 
clipping of the aneurysm, nor endarterectomy can be recommended withconfidence, but when 
the aneurysm is just as likely the source of the TINs as not, clipping is recommended up to the 
age of 70, when the surgical risks are moderately high. 
In Chapter 5, clinical decision analysis is applied to the treatment decisions in four patients 
with an unruptured familial aneurysm. The surgical treatment was uneventful in all patients 
except for one patient with mild mixed aphasia and facial weakness postoperatively, which 
deficits disappeared in less than two weeks. In the decision-analysis, discounted quality 
adjusted life years are used as an outcome measure. Probability estimates are extracted from 
the literature when available. 
It is concluded that the decision to treat the aneurysm neurosurgically in three of the four 
patients was a correct one. In two of these three patients, the decision cannot be changed by 
plausible changes in estimated data. For the third patient, only the combination of a low 
probability of rupture, a high surgical mortality and morbidity and high discount favours 
conservative treatment. In the fourth patient a toss-up exists. 
More knowledge of the probability of rupture, the development of other aneurysms and 
the results of surgery of intact intracranial aneurysms would have made an analysis more 
accurate. Oinical research should address these issues. 
In Chapter 6 decision analysis is used to assess the decision to screen for unruptured 
intracranial aneurysms in two affected families, and to formulate guide-lines for similar 
decisions. Four strategies are compared: 'no screening', "screening directly' I 'screening twice' I 
and' screening later'. Intravenous and intra-arterial digital subtraction angiography techniques 
(iv-DSA, ia-DSA) are considered. Life years lived with and without disability are computed 
for each strategy. Loss of life expectancy with and without discounting and quality correction 
is used as an outcome measure. 'No screening' is the preferred strategy when population based 
estimates for the prevalence of IA's are used. Thus, the results of this analysis provide no 
justification for screening patients without a familial history. But a physician who thinks that 
the risk of an aneurysm is increased may rightly decide for screening, especially when the 
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patient is aged 40 to 60. Ia-DSA is preferable over iv-DSA. A scenario analysis suggests that 
screening with magnetic resonance angiography is only slightly better than with ia-DSA, 
because the complication rate o,f screening plays a minor role in the analysis. 
In Chapter 7 clinical decision analysis is applied to treatment decisions for three patients 
with unruptured familial intracranial arteriovenous malformations (A VM's) in association 
with hereditary haemorrhagic telangiectasia. The grades of the A VM's - according to Spetzler 
- were 1-0-{) (two patients aged 12 and 14) and 2-0-1 (one patient aged 43). The AVM in one 
patient (graded 1-0-0) was operated on without sequelae. In the decision analysis, life 
expectancy is used as an outcome measure, with and without quality of life adjustment and 
discounting for time preference. It is conduded that neurosurgical treatment is the best strategy 
for all three patients. Because no conclusive data are available concerning the natural history 
and neurosurgical treatment ofunruptured A VM' 5, we recommend the prospective application 
and testing of A VM grading systems. General treatment guide-lines balancing the lifetime risk 
of haemorrhage, risk of incomplete extirpation and surgical mortality and morbidity are 
presented. The analysis suggests tbat patients with low-graded A VM's which have not bled 
should be treated surgically, unless they are older than 60 years and have an increased risk of 
incomplete extirpation. 
In Chapter 8, clinical profiles of dementia patients, differing with respect to age, duration 
of dementia, presence of gait abnonnalities and urinary incontinence are discussed. Epide-
miological data, subjective probabilities and clinical reasoning are used to predict a treatable 
cerebral lesion, i.e. an intracranial space occupying lesion or nonnal pressure hydrocephalus 
(NPH). Our calculations make it possible to distinguish clinically between demented patients 
who are - and who are not -likely to benefit from cr investigation for treatable lesiOns, and 
eventually, from cerebrospinal fluld shunting for NPH. Utility calculations show that shunting 
can be recommended only for a patient with the full triad of symptoms, recent onset of dementi a 
and CT-evidence of NPH, when no other prognostic information is available. Future clinical 
research should address the long term prognosis of (treated) NPH patients, and the mortality 
of shunting, because these two factors are most critical to the shunting-decision. 
In Chapter 9 we present an individualized re-analysis of a randomized placebo-controlled 
study of the effect of tranexamic acid on outcome after subarachnoid hemorrhage. 
Individualized estimates of the risks of rebleeding, infarction, mortality from the initial 
hemorrhage, and of the effect of tranexamic acid were made using six prognostic factors, 
identified by proportional hazards regression with stepwise forward selection: age, Glasgow 
coma score, loss of consciousness at the ictus, retinal hemorrhage or edema, amount of sub-
arachnoid blood on cr, and amount of intraventricular blood on cr. Adjustments were made 
for the effect of nimodipine and plasma volume expansion on infarction risks. For each of 64 
clinical profiles the three-month mortality is computed by combining these risks. 
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The three-month mortality ranges from below 20% to over 80%, depending on the clinical 
profile. Types of patients who may and who may not benefit from tranexamicaddare identified, 
and the size of the effect is estimated for each clinical profile. 
Treatment with tranexamic add seems to be espectally harmful for patients with a large 
amount of subarachnoid blood on their initial CT~ and beneficial for patients with a low amount 
of subarachnoid blood and high risk of rebleeding. Ourresults can be useful in patient-oriented 
dedsion making and in designing further studies of the management of subarachnoid hem-
orrhage. 
In Chapterl0 the management of subarachnoid hemorrhage is studied by decision analysis. 
Optimal treatment strategies for individual patients, combining early surgery, delayed surgery, 
/ate elective surgery after three months, antifibrinolytics and nimodipine, are identified. 
Rebleeding, infarction and mortality risks as estimated by proportional hazards regression 
ina re-analysis of a randomized clinical trial of antifibrinolyticsagainst placebo, and data from 
the literature are used in a decision tree to compute the chances of good recovery~ moderate 
and severe disability and death after three months, and the (discounted quality adjusted) life 
expectancy for each treatment strategy. 
Treatment with nimodipine, and late elective surgery for patients with good outcome who 
have not yet been operated, are recommended. For patients in good clinical condition, antifi-
brinolytics and delayed surgery form the optimum treatment strategy. However, the benefits 
of early or delayed surgery are small compared to late elective surgery in this group, and 
therefore the surgical complication rate should be low. Patients with a heavy load of sub-
arachnoid blood on cr scan should be treated with (delayed) surgery, but not with antifibri-
nolytics, because of the increased risk of infarction. 
In Chapter 11 the validity of the dedsion analytic approach is discussed. It is concluded 
that because empirical validation is many times not possible, the construct validity of every 
analysis should be explored, by exposing the study to valid ctitidsm of potential dedsion 
makers, experts, clinical investigators and other decision analysts. For each study the critique 
is then summarized. It is concluded that the validity of the studies is not compromised, but the 
final dedsion is left to the reader. 
At last several obstacles to the acceptance of decision analysis in the clinical neurosciences 
are identified. A perspective on the future role of dedsion analysis in the clinical neurosdences 
is presented. 
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In dit proefschrift worden enkeIe toepassingen van besJissingsanalyse, een methode ter 
ondersteuning van medische besluitvOrming op het gebied van de klinische 
neurowetenschappen (neurologie en neurochirurgie) beschreven. Klinische besJissingsanalyse 
is gebaseerd op utiliteitstheorie en kansrekening, waarbij gebruik wordt gemaakt van 
technieken en methoden uit de klinische epidemiologie en biostaJistiek. 
In Hoofdstuk 2 wordt de methodologie van de besJissingsanalytische ondersteuning van 
klinische besluitvorming beschreven. Het beslissingsprobleem wordt weergegeven door 
middeI van een besJisboom, met daarin voor iedere mogelijke keuze de daaraan gereIateerde 
gebeurtenissen en uitkomsten, beschreven met behulp van met elkaarverbonden keuze-, kans-
en uitkomstknopen. Klinische kennis en empirische gegevens worden samengebracht in een 
explidete weergave van onzekerheden, door midde1 van subjectieve kanstheorie. 
Waarderingen van uitkomsten (utiliteiten) worden eveneens op een kwantitatieve wijze 
benaderd. De verwachte utiliteit van e1ke strategie wordt vervolgens berekend door kansen 
langs iedere tak van de boom en utiliteiten aan het eind van iedere tak met elkaar te 
vermenigvuldigen. De optie met de hoogste verwachte utiliteit wordt geadviseerd. Het effect 
van plausibele veranderingen in aannames wordt beoordeeId door middel van een 
sensitiviteits-, of gevoeIigheidsanalyse: Systematisch wordt de waarde van een bepaalde 
variabe1e gewijzigd, en de resulterende veranderingen in verwachte utiliteit van de 
verschillende strategieen worden met elkaar vergeleken. Verschillende andere methoden voor 
besluitvormingsondersteuning worden kort besproken, en de keuze voor beslissingsanalyse 
wordt gemotiveerd als zijnde de meest eenvoudige, complete methode met een goede 
theoretische basis. 
In Hoofdstuk 3 wordt een overzicht gegeven van sinds 1975 gepubliceerde 
besJissingsanalyses op het terrein van de neurowetenschappen. De studies worden kort 
besproken en gecategoriseerd naar de gehanteerde methode (risico-analyse, ROC analyse, 
cost-benefit of cost-effectiveness analyse, ofutiliteitsanalyse. De toepasbaarheid van de studies 
in de praktijk wordt onderzocht door systematisch enkele kenmerken na te gaan. Deze 
kenmerken zijn: de aanwezigheid van een casus- en contextbeschrijving, compleetheid, 
uitbreidbaarheid, en up-to-date zijn. 
Zevenenveertig studies betreffende 28 verschillende neurologische onderwerpen werden 
gevonden. Zevenentwintig studies ontbeerden een casus-beschrijving, en bij vier werd niet 
eens de context omschreven. Zeventien waren achterhaald, soms omdat belangrijke nieuwe 
empirische gegevens, en ongeveer even vaak omdat nieuwe diagnostische of therapeutische 
mogeIijkheden beschikbaar waren gekomen. Deze studies betreffen echter maar tien 
verschillende toepassingen, waarvan vier reeds door een nieuwe analyse waren behandeld. 
192 
Samenvatting 
In Hoofdstuk 4 worden drie patienten met "transient ischemic attacks", een carotisstenose 
en een ongeruptureerd aneurysma beschreven. Door middel van een beslissingsanalyse 
worden de behandelingsmogelijkheden vergeleken (aneurysma chirurgie, endarteriectomie, 
beide of geen van beide, en al of ruet plaatjes-aggregatierernmers). Een volledige Bayesiaanse 
analyse met een Monte Carlo simulatie wordt gebruikt om 95% betrouwbaarheidsintervallen 
te berekenen voor het verschil in verwachte utiliteit tussen de behandelingsopties. 
Plaatjes-aggregatierernmers blijken gei'ndiceerd te zijn voor alledrie de patiiinten, ondanks 
het verhoogde risico op complicaties van de eventuele subarachnoidale bloeding. Carotis 
endarteriectomie kan voor geen van de drie patienten worden aanbevolen. Wat betreft 
aneurysma chirurgie bestaat een "toss-up" voor een patient, voor de tweede kan operatie 
worden geadviseerd ... en voor een derde hangt de keuze tussen weI of met opereren vooral af 
van de kans dat het de TIA's ontstaan door thrombo-embolieen vanuit het aneurysma. Voor 
patienten met TIA's, een carotisstenose en een ongeruptureerd aneurysma kan 
endarteriectomie noch aneurysma chirurgie zonder meer met zekerheid worden aanbevolen. 
Maar als de patient jonger is dan 70, en het aneurysma is met even grote mate van 
waarschijn1ijkheid de bron van de TJA's als het aneurysma, dan kan aneurysma chirurgie wei 
worden geadviseerd ... ook al zijn de operatierisico's matig hoog. 
In Hoofdstuk 5 wordt beslissingsanalyse toegepast op de beslissing om vier patienten met 
een ongeruptureerd aneurysma te opereren. De opera tie verliep bij deze patienten 
ongecompliceerd, behalve bij een patient, bij wie post-operatief een geringe gemengde afasie 
en een lichte zwakte van de linker gelaatshelft werd opgemerkt, welke beide na twee weken 
waren verdwenen. 
Op grond van deanalysewordt geconcludeerd datde beslissing om depatienten te opereren 
correct was bij drie van de vier patienten. In twee van de drie gevallen was deze condusie niet 
gevoelig voor aannemelijke veranderingen in de kansschattingen. Voor de derde patient 
veranderde de conclusie aileen bij (onwaarschijnlijke) combinaties van een lage ruptuurkans, 
een hoogoperatierisico, en een hoge jaarlijkse "discount". Voor de vierde patient bestond een 
"toss-up". Meer kennis over het ruptuurrisico, het ontstaan van nieuwe aneurysmata bij deze 
patienten, en over de operatierisico's zou de analyse preciezer hebben kunnen deen zijn. 
In Hoofdstuk 6 wordt beslissingsanalyse gebruikt om het besluit twee families te screenen 
opde aanwezigheid van ongeruptureerde familiaire aneurysmata teevalueren. Tevens worden 
richtIijnen gegeven voor gelijksoortige, nieuwe beslissingen. Vier strategieen worden met 
elkaar vergeleken: 'niet screenen', inmiddelijk screenen, screenen na vijf jaar, en beide. 
Intraveneuze en intra-arteriele digitale substractieangiografie uv-DSA, respectievelijk iaDSA) 
worden beschouwd. De levensverwachting met en zonder ernstige handicap wordt berekend 
en de levensverwachting met en zonder kwaliteits"correctie" en "discount" wordt gebruikt als 
vergelijkingsmaat. 'Niet screenen' is de aanbevolen strategie als populatie schattingen van de 
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prevalentie van intracranHHe aneurysmata worden gebruikt. De resultaten van de analyse 
rechtvaardigen dus niet het screenen van wiUekeurige patienten zonder familiaire belasting. 
Maar een arts die denkt dat het risico op de aanwezigheid van een ongeruptureerd aneurysrna 
is verhoogd, kan goed onderbouwd kiezen voorscreenen, vooral wanneerdepatient eenleeftijd 
heeft tussen 40 en 60. IaDSA wordt geprefereerd boven iv-DSA. Eenscenarioanalysesuggereert 
dat screenen met rnagnetische resonantie angiografie slechts geringe winst oplevert, vooral 
omdat de complicaties van screenen slechts een ondergeschikte rol speIen in de analyse. 
In Hoofdstuk 7 wordt beslissingsanalyse toegepast op de behandelingskeuze bij drie 
patienten met een niet-gebloed-hebbende arterioveneuze malformatie in combinatie met 
hereditaire haemorrhagische telangiectasieen. De gradering van de A VM's - volgens Spetzler 
- bedroeg 1-0-0 (twee patienten van 12 en 14jaar), en 2-0-1 (een patient van 43jaar). Bij een van 
de drie patienten werd de arterioveneuze malformatie geopereerd zonder complicaties. In de 
beslissingsanalyse wordt weer levensverwachting met en zonder kwaliteitscorrectie en 
discount gebruikt om de strategieen te vergelijken. Opereren lijktde bestestrategie tezijn voor 
aUe drie de patienten. Omdat echter de literatuurgegevens betreffende operatieresultaten en 
natuurlijk beloop beperkt zijn, is het van belang dat in toekomstige studies graderingsystemen 
voor A VM: s prospectief worden toegepast. Algernene richtlijnen voor de behandelingskeuze 
worden gegeven, waarbij het cumulatieve risico op bloeding, de kans op onvoUedige extirpatie, 
en de complicaties van de opera tie tegen elkaar worden afgewogen. De analyse maakt 
aannernelijk dat patienten met laag-gradige A VM's die nog niet hebben gebloed dienen te 
worden geopereerd, behalve als zij ouder zijn dan 60 en een verhoogd risico op incomplete 
extirpatie lopen. 
In Hoofdstuk 8 worden klinische profielen van dementie patienten, verschiUend wat betreft 
leeftijd, aanwezigheid van loopstoornissen en urine-incontentie besproken. Epidemiologische 
gegevens, subjectieve kansschattingen en een klinisch redeneertrand worden tesamen gebruikt 
om een een behandelbare cerebrale laesie te voorspellen, n.L een ruimte-innemend proces of 
normal pressure hydrocephalus (NPH). Onze berekeningen rnaken het mogelijk om op 
klinische gronden een onderscheid te maken tussen dementie patienten die weI en niet 
waarschijnlijk voordeel behalen aan het ondergean van een cr schede1 in verhand met de 
cerebrale laesies en de mogelijkheid van het ondergean van een liquor-shunt. 
Utiliteitsberekeningen laten zien dat shunting aIleen kan worden aanbevolen voor een patient 
met de volledige trias van symptomen, en aanwijzingen op cr voor NPH, wanneer verder 
geen prognostische informatie beschikbaar is. Toekomstig klinisch onderzoek zou zich (ook) 
moeten richten op de operatiecomplicaties en op de lange terrnijn prognose bij deze patienten, 
omdat deze twee factoren in de beslissingsanalyse van het meeste belang bleken. 
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Samenvatting 
In Hoofdstuk 9 wordt een heranalyse van een gerandomiseerde placebogecontroleerde 
studie van het effect van tranexamInezuur op de gevolgen van een subarachnoidale bloeding 
beschreven. Gelndividualiseerde schattingen van de risico's van recidiefbloedingen, ischemie 
en de sterfte aan de bleeding zelf werden gebaseerd op 6 prognostische factoren, die werden 
gekozen met behulp van proportional hazards regressie met stapsgewijs voorwaartse selectie: 
leeftijd, Glasgow coma score, bewustzijnsverlies ten tijde van de eerste bloeding, preretinale 
bloedingen of papiloedeem, hoeveelheid subarachnoidaal bleed op de cr, en hoeveelheid 
intraventriculair bloed op de cr. De schattingen werden aangepast voor het effect van 
nimodipine en plasma volume expansie op het risico van ischemie. Voor elk van de 64 
patienten-profielen werd de drie-maands sterfte berekend door de drie risico's te combineren. 
De drie-maands sterfte varieert van 20% tot 80%, afuankelijk van het patienten-profiel. 
Types patienten die mogelijk weI en niet baat hebben bij behandeling met tranexamInezuur 
werden geldentificeerd, en de grootte van het effect werd geschat voor ieder patienten-profiel. 
Behandeling met tranexaminezuur lijkt vooral schadelijk te zijn voor patienten met een grote 
hoeveelheid subarachnoidaal bloed op de cr bij binnenkomst, en een gunstig effect te hebben 
voor patienten met een kleine hoeveelheid bloed en een hoog recidief-risico. Deze resultaten 
kunnen van belang zijn bij ge"individualiseerde besluitvorming, en bij het ontwerpen en 
plannen van verdere studies op het gebied van de behandeling van subarachnoidale 
bloedingen. 
In Hoofdstuk 10 wordt het beleid bij patienten met een subarachnoidale bloeding 
bestudeerd met behulp van een beslissingsanalyse. Optimale behandelingsstrategieen voor 
individuele patienten, bestaande uit combinaties van vroeg (op dag 2) vertraagd (op dag 10) 
opereren en laat--electief (na drie maanden) opereren, tranexaminezuur en nimodipine worden 
geYdentificeerd. 
De risico's van recidiefbloeding, ischemie en sterfte aan de bloeding zelf, zoals geschat met 
behulp van proportional hazards regression in een heranalyse van een gerandomiseerde studie 
van antifibrinolytica en placebo, en gegevens uit de literatuur worden gebruikt in een 
beslisboom om de kansen op goed herstel, matige en emstige invaliditeit en sterfte na drie 
maanden, en de "discounted quality adjusted life expectancy" voor iedere 
behandelingsstrategie te berekenen. 
Behandelingmet nimodipine, en late electieve operatie voor patienten met een goed herstel 
die nog niet zijn geopereerd kan zon~er meer worden aanbevolen. Voor patienten die in een 
goede toestand hetziekenhuis binnenkomen, vormenantifibrinolytica met vertraagde operatie 
de optimale behandelingsstrategie. De winst van vroeg of vertraagd opereren is klein in deze 
groep wanneer wordt vergeleken met laat-electief ingrijpen, en daarom dient de kans op 
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operatiecomplicaties laag te zijn. Patienten met een grote hoeveelheid bloed op de cr zouden 
moeten worden behandeld met (vertraagde) opera tie, maar nietmet antifibrinolytica, vanwege 
het verhoogde risico op cerebrale ischemie. 
In Hoofdstuk 11 wordt de validiteit van de beslissingsanalytische benaderIng van k1Inische 
besluitvorming besproken. De conclusie luidt dat empirische validerIng vaak niet mogelijkzal 
zijn, en dat daarom de construct-validiteit dient te worden geexploreerd, door de studie bloot 
te stellen aan valide kritiek van beslissers, experts, klinische onderzoekers en andere 
beslissingsanalytid. De mogelijke kritiek op iedere studie wordt dan samengevat en 
bediscussieerd. Een voorlopige conclusie is dat de validiteit van de studies niet in het gedrang 
is gekomen, maar de uiteinde1ijke beslissing wordt overgelaten aan de lezer. 
Tot slot worden be1emmeringen en mogelijkheden voor de verdere ontwikkeling van 
beslissingsanalyse in de k1inische neurowetenschappen geschelst. 
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